{
  "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
  "chunks": [
    {
      "text": "1 g ti efal enli bre ekr C-m il M ling edel ræf mu Medi g ved ebeh lig ik ft me utatio ici dr han kk ed on ir r. so ndl ke-d K n råd ot lin -sm KR de to ng m RA ets g a mac AS si af cel ib til lle B Bil Ans For Ans la sø rha sø ag increase gs n ndling ers e so not gsn end ov tat ti nota delig ver il Råd at fra ge an rsig det ved a Amgr nøg dr. sot ved ng ved torasib dr. sotorasib dr. sotorasib",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "",
        "start_page": 1,
        "end_page": 2,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Ballerup 26 August 2022 With Amgen's feedback on the draft assessment report for Sotorasib (Lumykras) second-line treatment of KRASG12C mutated non-small cell lung cancer. We want to highlight the significant innovation Sotorasib brings to patients with incurable non-small cell lung cancer with relapse after prior treatment. An innovation recognised by EMA, who awarded Sotorasib a conditional marketing authorisation due to the significant unmet need addressed by Sotorasib. We are therefore generally satisfied that the studies used reflect Danish clinical practice and that the methods used allow for a health economic evaluation. However, there are issues in this assessment report that Amgen wants to use the opportunity to comment on:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "For the Council of Medicinal Products",
        "start_page": 3,
        "end_page": 3,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "It is unclear why the Medical Council Secretariat has not included a review of undesirable side effects in the assessment of Sotorasib. This is despite the fact that comparative tables of these were prepared and attached to the application material, and that it is possible to include them in the health economic model. In this particular case it is difficult to assess whether adverse events are caused by Sotorasib in Codebreak 100, or whether they are caused by previous treatment lines, which is also commented on in the report. It could have been further clarified if there were also an opinion on undesirable side effects. Sotorasib caused fewer adverse effects of grade 3+ in Codebreak 100 (20.6%) compared to Docetaxel in SELECT-1 (30%) despite the fact that patients in Codebreak 100 were on active treatment for more than twice as long as in SELECT-1, had received several previous treatment lines, and patients in SELECT-1 have better performance scores than the patients in Codebreak 100. We are aware that a comparison of undesirable side effects can introduce a certain side effect, since this is investmentbed true to the same case.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "1. No inclusion of undesirable effects in the review",
        "start_page": 3,
        "end_page": 3,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In this case, it is considered that the reasoning is not consistent in the report. • The Medicin Board assesses, based on clinical experience, that the applicant's chosen extrapolation for docetaxel is too optimistic, as it is unlikely that approximately 4 percent of patients are still alive at docetaxel treatment after 5 years. Therefore, the Medical Board changes the extrapolation of OS for docetaxel to exponential distribution, see the orange curve in Figure 4. This is due to the fact that the exponential distribution has the best statistical fit (see AIC/BIC) of the three distributions (Weibull, Gompertz and exponential) that are considered clinically plausible. The Medical Board also extrapolates the OS for sotorasib with exponential distribution, since there are no clinical arguments that the paralegal distribution of patients should vary between the two treatment arms.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Example 1, change in extrapolation of survival.",
        "start_page": 3,
        "end_page": 4,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "• The Public Previously in the application, the Medical Board has submitted the following argument based on the Danish lung cancer register: • The experience of the overall patient group of 2015 is considered to be significant in patients with uters.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Example 1, change in extrapolation of survival.",
        "start_page": 3,
        "end_page": 4,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "If the medicine board is uncertain about the risk of double counting, as described here, it should be justified to reduce a charge of +15,000 kr on the basis of which it should include a charge of 150 kr per dose.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Example 2, change of cost estimates.",
        "start_page": 4,
        "end_page": 4,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Amgen, like other former applicants, wants to marvel at the medical council's practice of not presenting the results of the applicants' health economic analyses. Decision makers should take into account the analyses of both parties, as the true estimate must be assumed to be somewhere between the results of the two main analyses. In this particular case, Amgen's analysis gives a QALY gain of 0.63 against the Medical Council's 0.52 and an ICER of about DKK 550,000/QALY against the Medical Council's ICER of approximately 839,000 DKK/QALY. We look forward to the case to be resolved on 28 September, so that we can together ensure that G12C-muted NSCLC patients have access to an effective standard treatment in the second line.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "3. The Medical Council does not present the results of the applicant's main analysis.",
        "start_page": 4,
        "end_page": 4,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Tore von Würden Country Director Amgen, Danmark Public Amgros I/S Dampfærgevej 22 2100 København Ø Danmark T +45 88713000 F +45 88713008 Medicin@amgros.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Yours faithfully,",
        "start_page": 4,
        "end_page": 5,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "WHXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww\n\n...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "DBS, SNI",
        "start_page": 5,
        "end_page": 11,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "DBS, SNI",
        "start_page": 5,
        "end_page": 11,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "DBS, SNI",
        "start_page": 5,
        "end_page": 11,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 2
      }
    },
    {
      "text": "... ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "DBS, SNI",
        "start_page": 5,
        "end_page": 11,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 3
      }
    },
    {
      "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "DBS, SNI",
        "start_page": 5,
        "end_page": 11,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 4
      }
    },
    {
      "text": ".",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "DBS, SNI",
        "start_page": 5,
        "end_page": 11,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 5
      }
    },
    {
      "text": "Name Title Phone number Email Name Title Phone number Email Overview of the pharmaceutical Proprietary name Generic name Marketing authorization hol",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Contact information",
        "start_page": 12,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "ATC code Pharmacotherapeutic group Active substance(s) Pharmaceutical form(s) Mechanism of action Dosage regimenn Therapeutic indicationreleva assessment (as defined b European Medicines Agency, EM Other approved therapeutic",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Denmark",
        "start_page": 12,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "n Nicholas Sroczynski",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "indications",
        "start_page": 12,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "nsroczyn@amgen.com Jannick Burmester Health Economic Manager jburmest@amgen.com al LUMYKRAS Sotorasib",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Country Medical Lead, Denmark",
        "start_page": 12,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "L01XX73 KRAS G12C inhibitor Sotorasib Tablets for oral use Sotorasib is an inhibitor of KRAS G12C, a tumor-restricted, mutant-oncogenic form of the RAS GTPase, KRAS. Sotorasib forms an irreversible, covalent bond with the unique cysteine of KRAS G12C, locking the protein in an active state that predicts downstream oncogenic signaling and inhibitions cell growth. Sotorasib is administered orally at a dose of 960mg (8 x 120mg tablets) once daily until disease progression or unacceptable toxicity. ant for LUMYKRAS (sotorasib) as monotherapy is indicated for the treatment of adults by the with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and MA).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Ider in Amgen Denmark",
        "start_page": 12,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Combination therapy and",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Hospital?",
        "start_page": 13,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Packaging types, sizes/n",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "medication",
        "start_page": 13,
        "end_page": 13,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Orphan drug designation ceutical cted to d/or co-number of s n f Yes No Pack of 240 tab No Pa Confidentia bs of 120mg. The Commission shall, by means of implementing acts, adopt implementing acts laying down detailed rules for the application of this Regulation and laying down detailed rules for the application of this Regulation and laying down detailed rules for the application of this Regulation.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "units, and concentrations",
        "start_page": 13,
        "end_page": 17,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The study is a random placebo-controlled study. Further, CodeBreak 100 included patients with prior anti-PD-1 treatment, where there are no patients with prior PD-1 treatment, where there are no patients with prior PD-1 treatment included in SELECT-1. .....................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "3.1 Tables of tables",
        "start_page": 18,
        "end_page": 21,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "..................................................... ..................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "3.1 Tables of tables",
        "start_page": 18,
        "end_page": 21,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "3.1 Tables of tables",
        "start_page": 18,
        "end_page": 21,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 2
      }
    },
    {
      "text": "... ... ... ... ... ... ... ... ... ... ... ... ... ... Covariates Included in the Propensity Score Model Before and After ATT Adjustment • KRAS Table 86. Covariates Included in the Propensity Score Model Before and After ATT Adjustment • P.G12C-X ................................................................................................................................................................Bookmark not defined. Table 89. Goodness-of-fit Statistics for Jointly-Fitted OS Models for KRAS-mutant Patients (ATT)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "3.1 Tables of tables",
        "start_page": 18,
        "end_page": 21,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 3
      }
    },
    {
      "text": ".................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Figure 47.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "3.2 Table of figures",
        "start_page": 21,
        "end_page": 23,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Propensity Score Model 2. Balance of All Covariates. Flatiron KRAS G12C ................. Figure 49. Propensity Score Model 2. Balance of All Covariates. Flatiron KRAS Mutant .................. Figure 50. Propensity Score Model 3. Balance of All Covariates..................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "3.2 Table of figures",
        "start_page": 21,
        "end_page": 23,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "This means that there is a risk that the risk that the patient will be exposed to the risk that the patient will be exposed to the risk that the patient will be exposed to the risk that the patient will be exposed to the risk that the patient will be exposed to the risk that the patient will be exposed to the risk that the risk that the patient will be exposed to the risk that the patient will be exposed to the risk that the patient will be exposed to the risk that the patient will be exposed to the risk that the risk that the patient will be exposed to the risk that the patient will be exposed to the risk that the risk that the patient will be exposed to the risk that the risk that the patient will be exposed to the risk that the risk that the patient will be exposed to the risk that the risk that the patient will be exposed to the risk that the risk that the patient will be exposed to the risk that the risk that the patient will be exposed to the risk that the risk that the patient will be exposed to the risk.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "4. Summary",
        "start_page": 24,
        "end_page": 24,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The population of interest for this application is advanced NSCLC patients with KRAS G12C mutation who have received prior systemic therapy, in line with the EMA label of sotorasib. In Denmark, all patients diagnosed with NSCLC benefit from next-generation sequence (NGS) diagnostics, which includes genetic identification of the KRAS G12C mutation. The NSCLC population of interest will there already be identified in Denmark with the current SOC testing in all five regions of Denmark. Based on registry data and clinical expert validation, approximately 110-140 NSCLC patients with KRAS G12C mutation are expected to be viable for 2L treatment with sotorasib every year [2-5].",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Population",
        "start_page": 24,
        "end_page": 24,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Sotorasib is a novel, first-in-class, highly selective small-molecule inhibitor that covalently volumes to KRAS proteins harboring a G12C mutation. The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the grant of a marketing authorisation for sotorasib as for treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy. Sotorasib is administered orally and the recommended dose for adult patients is 960 mg (8x 120 mg tablets) once daily, at the same time each day.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Intervention",
        "start_page": 24,
        "end_page": 24,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "At the prescribed dose, treatment with sotorasib should be administered until disease progression or acceptable.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Intervention",
        "start_page": 24,
        "end_page": 24,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Other than sotorasib, no therapies exist specifically have received positive opinion by the CHMP for the treatment of KRAS G12C-mutated NSCLC. Doxetaxel is currently the standard 2L treatment for the majority of patients with advanced NSCLC in the current clinical treatment guideline from Danish Lung Cancer Group (DLCG)(6).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Comparator",
        "start_page": 24,
        "end_page": 24,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The CodeBreak 100 phase 2, single-arm trial provides the relevant efficiency and safety data for sotorasib in patients with KRAS G12C-mutated NSCLC. Evidence from CodeBreak 100 indicates that soorasib is highly effective when used in line with its indication as a second- or subsequent-line therapy. Median progression-free survival (PFS) was 6.8 months, and median overall survival (OS) was 12.5 months in the trial. There is a black of head-to-head trial data specifically considering KRAS G12C-mutated NSCLC. Howver, indirect treatment companies using robust data sources and methods available to exist. Sotorasib presents a loweroccurrence of grade 3 or worst treatment-related adverse events (TRAE) (20% vs 30%) and a lower numerical rate of treatment discrimination due to AEs (9% vs 14.5%). Patients with NSCLC generally report high symptomatic burn and impaired physical function and quality of life(8, 9). Health-related quality of life was investigated in CodeBreak 100 using the EORTC QLQ-C30 measure.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Clinical comparison",
        "start_page": 25,
        "end_page": 25,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Patients treated with soorasib generally maintained or improved compared with baseline. Sotorasib is expected to be safe and more viable compared to docetaxel, equalization with the clinical exposure of safety of a target the substance compatible to substances.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Clinical comparison",
        "start_page": 25,
        "end_page": 25,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "A horizontal-based partitioned survival model was developed in Microsoft Excel® to evaluate the cost effectiveness and safety data for sotorasib were taken from the CodeBreak 100 study. Relative effectiveness of sotorasib vs. docetaxel was estimated using a MAIC which used data from the SELECT-1 study. Health outcomes are extracted in terms of life-years and quality-adjusted life years (QALYs).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Health economic model",
        "start_page": 25,
        "end_page": 25,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the base-case where docetaxel is considered the comparator, the calculated incremental total life year gain of sotorasib versus docetaxel was Xyears. The assessed incremental costs of Xand incremental QAlys of Xresulted in an incremental cost-effectiveness ratio (ICER) of Xversus docetaxel. This would be cost-effective at a willingness-to-pay threshold of DKK 750,000 per QALY. The determinant sensitivity analysis demonstrated that the five parameters which had the largeest influence on the ICER were: (i) the hazard ratio (HR) to derived soorasib time to treatment discrimination; (ii) the administration cost of docetaxel; (iii) the relative dose intensity of the ICER were: (i) the risk ratio (HR) to derived soorasib time to treatment discrimination; (ii) the administration cost of docetaxel; (iii) the relative degree to loss; (iv) the objective factor;",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Outcome of health economic evaluation",
        "start_page": 26,
        "end_page": 26,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "It is therefore necessary to assess whether the risk of cancer is related to the risk that the risk is likely to arise in the future. Brain metastases are found in approximately 10% of patients with newly diagnosed NSCLC and 26% of patients with stage IV disease (16). Other common sites of metastases include the liver, adrenal glands, and bones. The distribution of types of lung cancer by hisology in Denmark is shown in Figure 1.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.1.1 Disease information",
        "start_page": 26,
        "end_page": 26,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "NSCLC SCLC Squamous Non-squamous Adenocarcinoma Others",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Lung Cancer",
        "start_page": 27,
        "end_page": 27,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "According to the case-law of the Court of Justice of the European Union, the Court of Justice of the European Union has consistently held that, in order to determine whether there is a likelihood of recurrence of injury to the Union industry, it is necessary to determine whether there is a likelihood of recurrence of injury to the Union industry and whether there is a likelihood of recurrence of injury to the Union industry, and whether there is a likelihood of recurrence of injury to the Union industry or to the Union industry, or whether there is a likelihood of recurrence of injury to the Union industry, or whether there is a likelihood of recurrence of injury to the Union industry, or whether there is a likelihood of recurrence of injury to the Union industry, or whether there is a likelihood of recurrence of injury to the Union industry, or whether there is a likelihood of recurrence of injury to the Union industry, or whether there is a likelihood of recurrence of injury to the Union industry, or whether there is a likelihood of injury to the Union industry.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.1.2 Molecular altars",
        "start_page": 27,
        "end_page": 27,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The KRAS consists of GTP and contains protein obtained in the cellular membrane which is important for intercellular signal transduction, and are found in active/inactive states depending on their binding with guanosine tri/diphosphate (GTP/GDP) (30). Mutations in KRAS genes can disrupt the processes involved in the proliferation and survival of tumor cells. Of the KRAS mutations, an estimated 80% occur at codon 12. The KRAS gene with a mutation resulting in a G12C amino acid substitution (KRAS G12C mutation) in codon 12 is a single guanine to thymine substitution that results in a glycine to cysteine substitution at amino acid position 12. This structural change in the protein results in a decision in the association of GTPase-activating proteins (GAPs), which results in a cysteine to cyste substitution at amino acid acid position 12.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.1.2.1 KRAS G12C mutation in NSCLC",
        "start_page": 27,
        "end_page": 28,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Lung cancer is diagnosed based on physical examination, presenting symptoms, medical history, and imaging (e.g., chest radiograph, compiled tomography [CT]/positron emission tomography [PET]-CT scan). If lung cancer is monitored, a tissue biopsy is obtained to make the pathological diagnosis, identification the histological subtype, and confirmation the stage of the disease (34). The stage at diagnosis helps undergo NGS-testing as part of the diagnostic trail to identify relevant targetable mutations including (EGFR, ERBB2, BRAF® throughout the patient's diagnosis with NSCLC undergo NGS-testing as part of the diagnostic trail to identify relevant targetable mutations (35).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.1.3 Diagnosis and stagnating",
        "start_page": 28,
        "end_page": 28,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The risk of cancer is often asymptomatic until the disease is advanced, making early diagnosis challenging (37). A diagnosis is generally not made until the tumor begins to obstruct the airway, resulting in dyspnea (shortness of breath), atelectasis (partial/complete lung collapse), pneumonia, bleeding from the airway mucosa, or pain due to pleural effusion (39), when curative treatment is not possible. Advanced NSCLC is highly symptomatic, with most patients experiencing symptoms related to the location and survival of the tumor.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.1.4 Clinical presentation",
        "start_page": 28,
        "end_page": 28,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "At present, no targeted therapy is available for patients with KRAS G12C-mutated NSCLC. Treatment options are limited for 2L+, and outcomes are suboptimal following progression with 1L treatment including an immune checkpoint inhibitor (ICI) with or without platinum-based chemotherapy (24, 49).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.1.4.1 Forecast of KRAS G12C-mutated NSCLC",
        "start_page": 28,
        "end_page": 28,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Real-world data from Danish national registers suggest that patients with the advanced XRAS G12C-mutated NSCLC have generally similar clients in terms of age, smoking history, and similar poor survival outcomes as other NSCLC patients (5). In this retrospective data analysis of intimately advanced NSCLC patients through the Danish national registers, including the Danish Lung Cancer Registry (DLCR), was conducted to determine incidence, molecular biomarkers, and treatment patterns with survival outcomes in patients diagnosed with advanced NSCLC(5). XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL = XL",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.1.4.1.1. Forecast of KRAS G12C-mutated NSCLC in Denmark",
        "start_page": 28,
        "end_page": 29,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The estimated incidence of the KRAS G12C mutation in X of non-squamous NSCLC patients (Data on file(5)). This equals to 292 KRAS G12C-mutated NSCLC cases within NSCLC in 2020.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.1.5 Epidemiology",
        "start_page": 29,
        "end_page": 30,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Sotorasib (LUMYKRASTM) is the first KRAS G12C inhibitor to be submitted for marketing authorisation. It is a once-daily oral therapy that is licensed by the European Medicines Agency (EMA)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.1.6 Patients population relevant for this application",
        "start_page": 30,
        "end_page": 30,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In line with the current treatment guidelines from the DLCG (6), clinical experts (2, 3) confirmed that increasing or increasing importance of patients in Denmark with NSCLC are not an option for patients with KRAS G12C mutation (58-61). With regard to the assessment of the risk of injury, the Commission considers that the risk of injury to the Union industry cannot be assessed in the light of the above considerations. The analysis is based on a basket of chemotherapy regimens, including platinum-based chemotherapy which is the most common regime in the basket (Table 60).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.2.1 Current treatment options",
        "start_page": 30,
        "end_page": 31,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "As described in section 5.2.1, docetaxel has been determined the appropriate comparator for this approach based on clinical guidelines by DLCG(6) and validation by two Danish clinical experts(2, 3).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.2.2 Choice of comparators (s)",
        "start_page": 32,
        "end_page": 32,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The recommended dose of docetaxel for adult patients is an initial dose of 75 mg/m2 as a one-hour intravenous infusion every three weeks.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.2.3 Description of the comparator (docetaxel)",
        "start_page": 32,
        "end_page": 32,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Generic name (ATC-code) Docetaxel (L01CD02) Mode of action Antineoplastic agent which acts by promoting the assembly of tubules into stable microtubes and inhibits their disassemblably which leads to a market decrease of free tubules. As microtubes do not resolve in the presence of docetaxel, they accumulate inside the cell and cause the initiation of apoptosis. Pharmaceutical form Concentrate and solvent for solution for infusion. Posology Docetaxel is administered as an I.V infusion. Should the pharmaceutical substance be Premedication to consist of an oral corticsteroid, such as hydrochlorothiazide 16 mg in monotherapy. Method of administration Docetaxel is given as an I.V infusion.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Subject",
        "start_page": 32,
        "end_page": 32,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Necessary monitoring, both during Hematological assessment of e.g. leukocytes, thrombocytes, and liver administration and during the treatment function through treatment. period In patients who experienced either febrile neutropenia, grade 3 or 4 stomatitis, neutrophil count < 500 cells/mm3 for more than one week, several or cumulative metabolic reactions or several peripheral neuropathy during docetaxel therapy, the dose of docetaxel should be reduced from 75 to 60 mg/m2 for all subsequent cycles. If the patient continues to experience these reactions at 60 mg/m2, the treatment should be discontinued.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Treatment:",
        "start_page": 32,
        "end_page": 32,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Need for diagnostic or other tests No diagnostic tests are required.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Treatment:",
        "start_page": 32,
        "end_page": 32,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "It is a once-daily oral therapy that is licensed by the EMA  •as monootherapy is identified for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have achieved after at least one prior line of systematic therapy as also described in the clinical direction by the DLCG (6). Sotorasib, is who are available for further treatment in 2L or subsequent-line the necessary necessary research in 2L. Sotorasib, is what is expected to be achieved in 2L or subsequent-line the necessary process in 2L. Sotorasibb i the CDLCG (6). With clinical evidence indicating significant improvements in PFS and OS, soorasib is highly innovative and provides a step-change in therapy for patients with KRAS G12C-mutated NSCLC who currently have no targeted therapy options available. A summary of soorasib is provided in Table 6 and further details can be found in Appendix C - Baseline characteristics of patients in studies used for the comparative analysis of effectiveness and safety. Table 6.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.3 Intervention",
        "start_page": 33,
        "end_page": 33,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Description of soorasib (LUMYKRASTM)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5.3 Intervention",
        "start_page": 33,
        "end_page": 33,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Generic name (ATC-code) Sotorasib (L01XX73) Mode of action Selective KRAS G12C inhibitor, which covalently and irreversible volumes to the unique cysteine of KRAS G12C. Inactivation of KRAS G12C by sotorasib blocks tumor cell signaling and survival, inhibitions cell growth, and promotes apoptosis selectively in tumors harboring KRAS G12C, an oncogenic driver of tumorigensis across multiple cancer types. Pharmaceutical form Immediate release, film-coated tablet. Posology Sotorasib is administered orally at a dose of 960mg (8 x 120mg tablets) once daily until disease progression or unacceptable toxicity. method of administration oral tablets",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Subject",
        "start_page": 33,
        "end_page": 33,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Treatment duration: per SmPC. Necessary monitoring, both during monitoring Monitor liver function tests (ALT, AST, and total bilirubin) prior to the start of administration and during the treatment every 3 weeks for the first 3 months of treatment, then once a month or as period clinically indicated. Monitor patients for new or changing pulmonary symptoms indicative of Interstitial Lung Disease / pneumonitis Needed for diagnostic or other tests The presence of a KRAS G12C mutation must be confirmed using a validated test prior to initiation of sotorasib therapy.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "administered with other medications",
        "start_page": 33,
        "end_page": 34,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In summary, a global systemic literature review (SLR) was used as the evidence base for this submission, and was locally adopted to fit the Scope of this application. This approach is considered to be the literature included in the global SLR to studies with either soorasib or docetaxel in adult patients with KRAS G12C-mutated advanced or metastatic NSCLC established in 2L+ study. The SLR search was initially conducted in June 2020 and an updated search was conducted on 26 January 2021. Additional sources of evidence have been added to support the application, as some results were not reported in the primary publications of the studies(71).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "6.1 Identification and selection of relevant studies",
        "start_page": 34,
        "end_page": 35,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "For full details on study characteristics of the included studies, please consult Appendix B - Main characteristics of included studies. Table 7. Relevant studies included in the assessment Reference Trial name NCT number Dates of study (title, author, journal, year) (start and expected completion date) Sotorasib for Lung Cancers with KRAS p.G12C Mutation. F. Skoulidis, et CodeBreak 27.08.2018 NCT03600883 Al. N Engl J Med. 2021. 384(25):2371-81. 100 28.12.2025 Selumetinib Plus Docetaxel Compared with Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced 25.09.2013 SELTECT-1 NCT019332 N21.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "6.2 List of relevant studies",
        "start_page": 35,
        "end_page": 35,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the absence of head-to-head studies, the two studies CodeBreak 100 and SELECT-1 examining the effectiveness and safety of soorasib, and docetaxel are presented in section 7.2.2. In section 7.2., an indirect treatment comparison of the relative efficacy is performed by soorasib and docetaxel using an unanchored MAIC. Safety outcomes were compared closely in section 7.2., as expected times were not feasible between soorasib and docetaxel. The study is based on the study design and baseline characteristics of the study population are specifically presented in Table 11 and Table 12. The study designs might affect the comparison of outcomes as CodeBreak 100 is an open-label single-arm study and SELECT-1 is a marginalised placebo-controlled study. This assumption is further validated as subgroup analysis from CodeBreak 100 shown median OS in patients that received only 1 prior line of therapy was 17.7 months (7.9, NE) (Ammen data on file) Table 8 patient subgroups by prior lines of therapy (Ammen data on file) N mOS Patient subgroups (OS) months (95% CI)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7. Efficacy and safety",
        "start_page": 35,
        "end_page": 36,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "For further assessment of comparability between the studies please consult the MAIC feasibility in Appendix K - MAIC.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 36,
        "end_page": 36,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In Table 9, relevant study outcomes are presented based on the data from March 2021 data cut for all outcomes except for the outcome EORTC QLQ-C30, which were based on the September 2020 data cut. The detailed results for both study arms in CodeBreak 100 are presented in Appendix D - Efficacy and safety results per study.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.1.2.1 CodeBreak 100 study",
        "start_page": 36,
        "end_page": 36,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Outcome Study arm N Result Reference Median PFS (CI) Sotorasib 126 6.8 months (5.1- (73) 8.2 months) Median OS (CI) Sotorasib 126 12.5 months (73) (10.0-NE months) Treatment interruptions due to Sotorasib 126 9 (7.1%) (73)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 9. CodeBreak 100 results",
        "start_page": 36,
        "end_page": 37,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "TRAEs grade 3+ - n (%) Sotorasib 126 26 (20.6%) (73) Treatment interruptions due to Sotorasib 126 11(8.7%), (73)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "TRAEs - n (%)",
        "start_page": 37,
        "end_page": 37,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "AEs grade 3+n (%) Sotorasib 126 77 (61%) (73) EORTC QLQ-C30 • mean change Sotorasib X X (71) from baseline (SD) Key: PFS, progression-free survival; OS, overall survival; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, TRAE, treatment-related adverse event. Study outcomes are presented based on the data from March 2021 data cut for all outcomes except for the outcome EORTC QLQ-C30, which was based on the September 2020 data cut.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "AEs-n (%)",
        "start_page": 37,
        "end_page": 37,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Median PFS was assessed according to RECIST, version 1.1 both by independent central review and by an investigator. Below graphs are plotd from analysis of data from independent central review. As of the data cut-off date, the median PFS was 6.8 (95% CI 5.1-82) months (Figure 2). The Kaplan-Meier estimate of survival was 52.2% (95% CI 42.6-60.9) at 6 months and 16.3% (95% CI 7.4-28.2) at 12 months. Seventy patients (56.5%) had experienced disease progression and 13 (10.5%) death events. A total of 41 patients (33.1%) were censored, and of those, 25 (20.2%) were on study without disease progression 7 (5.6%) started new anticancer therapy, 5 (4.0%) missed more than 2 cons.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Median progression free survival (PFS)",
        "start_page": 37,
        "end_page": 37,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "OS is defined as the time from the date of randomization until death due to any cause. Median OS was 12.5 (95% CI 10.0-NE) months (Figure 3). The Kaplan Meier estimate of survival was 75.5% (95% CI 66.8-82.2) at 6 months and 51.4% (95% CI 41.9-60.1) at 12 months. As of the data cut-off date, 59 (46.8%) patients had died. A total of 67 patients (53.2%) were censored, and of those, 56 (44.4%) were alive at the last follow-up and 9 (7.1%) contained (71).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Median overall survival (OS)",
        "start_page": 37,
        "end_page": 37,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Treatment-related adverse events (TREAs) were reported for a total of 88 patients (69.8%).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Description of the safety profile",
        "start_page": 38,
        "end_page": 38,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "HRQoL was expected to achieve a higher risk level for the EORTC QLQ-C30 measure in the CodeBreak 100 study. At baseline, subjects had a high risk level for EORTC QLQ-C30. Over time, mean global health status/QoL scores were generally maintained or improved compared with baseline, with mean change (for cycles 2 to 13 where there were > 5 patients) ranking from 1.9 (cycle 3) to -5.3 (cycle 11) (see Error! Reference source not found.). Results were similar for the other domain scores, e.g., physical functioning, role functioning, and cognitive functioning.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Health-related quality of life (HRQoL)",
        "start_page": 38,
        "end_page": 38,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": ") (i.e. if you are looking for a job, you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking for a job or if you are looking at a job or if you are looking for a job or if you are looking for a job.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "XThere are currently no known estimates of what constitutes a meaningful within-subject change in EORTC QLQ-",
        "start_page": 38,
        "end_page": 39,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In Table 10, relevant study outcomes are presented, based on the data cut-off in June 2016 (72). Only results for placebo plus docetaxel study arm are presented in the table, as the other study arm is not of interest for this assessment and the indirect comparison, which uses an unanchored MAIC due to the single-arm design of CodeBreak 100. The detailed results for both study arms in SELECT-1 are presented in Appendix D - Efficacy and safety results per study.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.1.2.2 SELECT-1 study",
        "start_page": 39,
        "end_page": 39,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Outcome Study arm N Results (IQR) References Median PFS Placebo + Docetaxel 256 2.8 (1.5-4.5) months (72) Median OS Placebo + Docetaxel 256 7.9 (3.8-20.1) months (72) Treatment interruptions due to AEs (%) Placebo + Docetaxel 256 37 (14.5%) (72) AEs grade 3+ (%) Placebo + Docetaxel 256 115 (45.0%) (72) EORTC QLQ-C30 NA NA NA NA Key: NA, not available; OS, overall survival; PFS, progression-free survival; TRAE, treatment-related adverse event. Data cut-off in June 2016 for all outcomes.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 10. SELECT-1 results",
        "start_page": 39,
        "end_page": 39,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Median PFS was assessed according to RECIST, version 1.1. As of the data cut-off date (June 7, 2016), the median PFS for patients receiving placebo plus docetaxel was 2.8 (IQR, 1.5-4.5) months (Figure 4) (72). Figure 4. Median PFS for patients receiving placebo plus docetaxel (patients of interest for treatment comparison) and selumetinib plus docetaxel. Key: HR, Hazard ratio; The dotted line indicators median survival.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Median progression free survival (PFS)",
        "start_page": 39,
        "end_page": 40,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "As of the data cut-off date (June 7, 2016), the median OS was 7.9 months (Interquartile range, 3.8-20.1) for patients receiving placebo plus docetaxel,corresponding to 170 events (Figure 5). Figure 5. Median OS for patients receiving placebo + docetaxel (patients of interest for treatment comparison) and selumetinib plus docetaxel. Key: HR, Hazard ratio; IQR, Interquartile range. The dotted line indicators median survival.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Median overall survival (OS)",
        "start_page": 40,
        "end_page": 41,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The most frequent adverse events reported as CTCAE grade 3 or higher were anemia (11 events, 4%), fatal (10 events, 4%), neutropenia (10 events, 4%), and (7 events, 3%).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Description of the safety profile",
        "start_page": 41,
        "end_page": 41,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "EORTC QLQ-C30 HRQoL outcomes were not investigated in SELECT-1 and there, no results are reported for HRQoL of patients treated with placebo plus docetaxel. No other instruments were used to measure HRQoL in SELECT-1 comparable to the patient's HRQoL in CodeBreak 100.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Health-related quality of life (HRQoL)",
        "start_page": 41,
        "end_page": 41,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "As regards the study of the data, the Commission considers that it is necessary to assess whether there is a risk of injury to the Union industry and whether there is a risk of injury to the Union industry and whether there is a risk of material injury to the Union industry or to the Union industry.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2 Comparative analyses of effectiveness and safety",
        "start_page": 41,
        "end_page": 42,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Data for the sole holder are derived from CodeBreak 100 study (75). CodeBreak 100 is an open-label phase II study which evaluated the safety, tolerability, and clinical effectiveness of sotorasib in (n = 126) subjects with NSCLC with KRAS G12C mutation. Docetaxel is a current standard of care for this patient group in Denmark and was there choosen as the comparator. A comparison of the CodeBreak 100 and SELECT-1 studies is presented in Table 11. In the absence of evidence, the Commission considers that the Commission's assessment of the existence of injury to the Union industry and the Union industry is based on the evidence available to the Commission that the injury suffered by the Union industry has been caused by the dumped imports from the countries concerned. Adjusting for all available variables would have resulted in a small bias, but also in a very low precision, with stochastic uncertainty causing results to be imprecise and accurate.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.1.1 MAIC overview",
        "start_page": 42,
        "end_page": 43,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Therefore, the number of variables adjustment for was restricted, keeping the variables that are most likely to remove bias. Variables that were considered less important in terms of bias, but would still increase stochastic uncertainty, were considered for removal. Variables identified as relevant prognostic variables were included for the base-case analysis. These are the variables that were identified as very important or somewhat important from the elicitation process.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.1.1 MAIC overview",
        "start_page": 42,
        "end_page": 43,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The companies of the patients who rely on patients in the CodeBreak in 100 and SELECT-1 studies are presented in Table 12. The distribution of patients between the two studies is similar in terms of age, with median ages of 63 and 61 years reported, specifically. Gender distribution is balanced in CodeBreak 100 and is slightly skewed towards goals in the SELECT-1 study. See also Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 1 of Table 2 of Table 2 of Table 1 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 1 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 1 of Table 2 of Table 1 of Table 2 of Table 1 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table 2 of Table of Table of Table 2 of Table 2 of Table 2 of Table of Table 2 of Table 2 of Table of Table of Table 2 of Table of Table of Table of Table of Table of Table of Table 2 of Table of Table",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.1.2 Population characteristics",
        "start_page": 43,
        "end_page": 44,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "A MAIC consists of several ways and means to achieve differences in OS and PFS between patients treated with sotorasib and docetaxel. Outcomes are reported in terms of HRs and corresponding 95% confidence interval (CI) for the different MAIC models. Parameter uncertainty was quantified based on robust standard errors. The starting list of candidacies was based on literature reviews and informed by discussion with experienced NSCLC professionals in the UK. These discussions involved separate interviews with physics experienced in treating attractive NSCLC patients who have a robust understanding of the current NSCLC management landscape. PD-L1 protein expression at baseline was included as it is only a relevant prognostic fact treatment.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.1.3 MAIC approach",
        "start_page": 44,
        "end_page": 45,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Very important risk-based approach (0, 1) * Presence of brain metastases (Y, N) Metastatic at baseline (Y, N) * PD-L1 protein expression (<5%, >5%) Presence of at least one of the following mutations/alterations: EGFR, ALK, BR Somewhat Age * important Smoking status (history of smoking vs. no history of smoking) * Body mass index Presence of liver metastases (Y, N) Presence of bone metastases (Y, N) Number of sites of metastasis (0, 1, 2, 3 or more) Number of superior lines of therapies (1, 2, 3) Type of therapies administered in superior lines Time from prior line initiation to the index date (<3 months, 3 - 6 months, >6 m Albumin at baseline LDH Lives operation (ALT, MRS);\n\nThe methods used to estimate weights in the MAIC are presented in Appendix K - MAIC.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Category Covariate",
        "start_page": 45,
        "end_page": 46,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "[...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...]\n\nApplicable to the highest risk of serious risks to health, risk of injury, risk of injury, risk of injury, risk of injury, risk of injury, risk of injury, risk of injury, risk of injury, risk of injury, risk of injury, injury, injury, injury, injury, injury, injury, injury, injury, injury, injury, injury, injury, injury, injury, injury, injury, injury, material injury, injury, injury, injury, injury, injury, injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, loss, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, material injury, injury, injury, material injury, injury, material injury, injury, injury, material injury, material injury, injury, injury, injury, injury, injury, injury, loss, material injury, material injury, material injury, material injury, material injury, injury, injury, material, material, material, material, material, material, material, material, material, material, material, material, material injury, material, material, material, material, material, material, material, material, material, material, material, material, material, material injury, material injury, material injury, material injury, material injury, material injury, material, material, material, injury, material, material, material, material, material, material, material, material, material, material, material, etc, etc, etc, etc, etc, etc, etc, etc, etc, etc, etc, etc, etc, etc, etc, etc, etc, etc, etc, etc, etc",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.1.4 MAIC Results",
        "start_page": 46,
        "end_page": 47,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "A plot comparing the MAIC-weighted KM OS curve for sotorasib (in blue) to the unadjusted docetaxel OS curve from SELECT-1 (in yellow) is shown in Error! Reference source not found., panel A. The comparison of the unadjusted KM OS curve for sotorasib from CodeBreak 100 (in blue) to the unadjusted docetaxel OS curve from SELECT-1 (in yellow) is shown in Error! Reference source not found., panel B. The MAIC-adjustment results in a light improvement in survival of patients treated with sotorasib compared to the unadjusted results.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.1.4.1 OS curve",
        "start_page": 47,
        "end_page": 47,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: KM, Kaplan-Meier; MAIC, matching-adjusted indirect comparison; OS, overall survival. A: adjuvanted sotorasib curve, B: unadjusted sotorasib curve. Note: Numbers at risk for adjuvanted KM is equivalent to sum of weights",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "A B",
        "start_page": 48,
        "end_page": 48,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Error! Reference source not found. panel A shows the base-case MAIC-weighted KM PFS curve for sotorasib (in blue) vs. the unadjusted KM PFS curve for docetaxel from SELECT-1 (in yellow). Error! Reference source not found. panel B shows the unadjusted KM PFS curve for sotorasib from CodeBreak 100 (in blue) vs. the unadjusted KM PFS curve for docetaxel from SELECT-1 (in yellow).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.1.4.2 PFS curve",
        "start_page": 48,
        "end_page": 48,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Two sets of covariates were selected for inclusion. The sets included (i) all covariates pre-specified as important (SET 1) and (ii) all covariates available for adjustment (SET 2). Patients with missing values for included covariates were not adjusted for in the MAIC analyses; no imputation was performed. Within the different MAIC analyses, three patients with no smoking status and 28 patients with no PD-L1 expression level information were excluded from the analyses. The results of unadjusted and adjuvanted HRs contained using the weighted Cox models worked to the different MAIC-adjusted KM datasets are presented in error!",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.1.4.3 PFS and OS results",
        "start_page": 48,
        "end_page": 48,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Reference source not found. The results represent a significant increase in the HRs compared to the HRs compared to the previous year.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.1.4.3 PFS and OS results",
        "start_page": 48,
        "end_page": 48,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "In a comparison using the most plausible indirect method possible given the data limits (MAIC), sotorasib",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.1.5 Conclusion on MAIC analysis sotorasib vs. docetaxel",
        "start_page": 49,
        "end_page": 49,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "comparator docetaxel monotherapy, exceeding the minimal clinically important difference of 3-month median PFS, previously defined by the lung cancer expert committee at DMC(7).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "adjustment indicated that sotorasib provided a X-month gain in median PFS compared with the primary",
        "start_page": 49,
        "end_page": 49,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "monotherapy, exceeding the minimal clinically important difference of 3 months median OS, previously defined by the lung cancer expert committee at DMC(7). Corresponding Kaplan-Meier plots for OS are presented in Error! Reference source not found., and in Error! Reference source not found. for PFS. The estimated hazard",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "that sotorasib provided a Xmonth gain in median OS compared with the primary comparator docetaxel",
        "start_page": 49,
        "end_page": 49,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "MAIC analysis based on reliable estimates of prognostic import, and the matching presented an effective sample size of over 106 patients. This reported a small loss of data compared with the pre-adjusted sample size. Sensitivity analysis, and the fact that the analyses could not be adjusted for the greater negative prognostic factors in the sotorasib trial population, suggested these estimates may be conservative. Given the phase 2 single-arm trial data currently available in support of sotorasib, and the black of data for the relevant comparators specifically in KRAS G12C-mutated NSCLC, every effort has been made to achieve the most robust possible outcomes.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "ratios for OS and PFS were similar between the unadjusted analysis and base-case MAIC analysis (X).",
        "start_page": 49,
        "end_page": 49,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "A formal statistical comparison between the two studies on safety outcomes was deemed impossible due to differences in follow-up times and the study design, as this is grounds for high uncertainty in a comparison. Treatment differences due to either adverse events or grade 3-5 adverse events more specifically, were not included in the MAIC. The safety comparison of these between sotorasib and docetaxel will there be narrative. Grade 3-4 is not presented in this section, as it was not possible to conduct any narrative comparison to SELECT-1, where only grade 3+ has been reported. Please refer to Table 43 for reporting of degree 3-4 adverse events for sotorasib from Code100.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.2 Safety",
        "start_page": 49,
        "end_page": 49,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The median duration of treatment was 5.5 months (range: 0.2-17.8) for soorasib (73), and 2.4 months (range: 0.1-27.4) for docetaxel (72) (approximately 2.4 months). The proportion of patients discontinuing treatment due to adverse events were lower for soorasib (8.7%) and docetaxel (14.5%), docetaxel showed a higher discontinuation rate. The absolute difference between the median duration of treatment corresponds to approximately 3.1 months, which compares the comparison of the two treatments. (0.8) NA NA Dyspnea 2 (1.6) 1 (0.8) 1 (0.8) 1 (0.8) NA NA NA Neutropenia 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 8 (3) 4 (2) Hepatotoxic event 1 (0.6) 1 (0.6) 1 (0.0) 1 (0.0) 1 (0.8) NA Lymphopenia 1 (0.0) 1 (0.0) 1 (0.6) 1 (0.0) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 8 (2) Hepatotoxic event 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.) 1 (0.) 1 (0.) 1 (2) Heptotoxic event 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.8) 1 (0.)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.2.1 Discontinuations due to adverse events",
        "start_page": 49,
        "end_page": 51,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "According to the Court of Justice, the Court of Justice considers that the Court of First Instance's judgment in Case C-47/01 Commission v Italy [2008] ECR I-7197, as amended by the Court of Justice of the European Union [2008] ECR I-7197, that the Court of Justice of the European Union [2008] has consistently held that the Court of Justice of the European Union [2008] has failed to fulfil its obligations under the Treaty on the Functioning of the European Union [2008], in so far as it has failed to fulfil its obligations under the Treaty on the Functioning of the European Union [2008], in so far as it has failed to fulfil its obligations under the Treaty on the Functioning of the European Union [2008], in so far as it has failed to fulfil its obligations under the Treaty on the Functioning of the European Union [2008], the Court of Justice of Justice of the European Union [2008].",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "7.2.3 Conclusion for comparative analyses between sotorasib and docetaxel",
        "start_page": 51,
        "end_page": 51,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The risk-benefit analysis was used in the progression-free state and were at risk of progression of disease or death. Transitions to the death-free from either the progression-free or advanced disease health states. In the light of the above, the Commission considers that the Commission's assessment of the compatibility of the aid with the internal market does not lead to any distortion of competition within the meaning of Article 107 (3) (c) of the Treaty. The model uses a 7-day cycle length, with a half-cycle correction applied and a time horizontal of 20 years. This compares with the maximum life expected of the cohort preferred by parametric survival analysis and was considered appropriate by clinically experts given that it is highly unlikely for patients with NSCLC with the KRAS G12C mutation with advanced or metastatic disease to monitor beyond this time point. The impact of the selection of the time horizon on results is estimated in a sensitivity analysis. A discount rate of 3.5% per year was applied for costs and outcomes.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.1 Model",
        "start_page": 52,
        "end_page": 53,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The model is based on effectiveness and safety data from the clinical trials, CodeBreak 100 and SELECT-1. A MAIC has been conducted to establish the relative effectiveness estimates between sotorasib and docetaxel, as described in the clinical section of the dossier, section 7.2.1. The adverse events rates are directly derived from CodeBreak 100 and SELECT-1, as described in section 8.2.2.5. Health state utilities have been estimated using the Danish tariff set(86) and the EQ-5D-5L data from CodeBreak 100, described in section 8.4. 8.2.2 Relationship between the clinical documentation, data used in the model and Danish clinical practice",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.2.1 Presentation of input data used in the model and how they were obtained",
        "start_page": 53,
        "end_page": 54,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The patient population for this economic assessment is NSCLC patients with KRAS G12C mutation in 2nd line, in line with the EMA label of soorasib. Sotorasib provides a treatment for 2nd line NSCLC patients, where no targeted treatment is currently available, and chemotherapy would be the only available treatment for the patients. The effectiveness and safety of soorasib and docetaxel in 2nd line for KRAS G12C mutation NSCLC patients were investigated in CodeBreak 100 and SELECT-1. There, to fit the scop of this assessment, data from CodeBreak 100 trial is included in the model. In Table 19, data on the patient population from the clinical trial is represented, as well as the results for the model.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.2.2.1 Patient population",
        "start_page": 54,
        "end_page": 54,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Patient population Clinical documentation / Used in the model Danish clinical practice indirect comparison etc. (including source) Important baseline characteristics Age (mean) 62.9 62.9 Danish patients are expected to be lightly older. (2, 3.5) (see Table 1) Gender (% female) 50.0% 50.0% More women are expected in Danish clinical practice (2, 3.5) (see Table 1) Weight (kg) 71.08 71.08 Expected to be similar(2, 3) Body surface area (m2) 1.81 Expected to be similar(2, 3)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 19.",
        "start_page": 54,
        "end_page": 54,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Sotorasib (LUMYKRASTM) is the first KRAS G12C inhibitor to be submitted for marketing authorisation. It is a once-daily oral therapy licensed by the EMA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.2.2.2 Sotorasib",
        "start_page": 54,
        "end_page": 54,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Intervention Clinical documentation Used in the model Expected Danish clinical (including source) (number/value including practice (including source source) if known) Posology 960 mg (8x 120 mg tablets) Same as clinical Same as clinical once-daily oral documentation documentation Treatment duration / Treat until disease progression Treat until disease Same as clinical Criteria for end of or unacceptable toxicity progression or documentation unacceptable toxicity treatment: • Dose reduction as per SmPC Dose reduction captured using RDI from CodeBreak 100 in the model.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 20. Intervention",
        "start_page": 55,
        "end_page": 55,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Docetaxel is selected as a comparator for the application, please consult section 5.2 for full details on docetaxel. The recommended dose of docetaxel for adult patients is an initial dose of 75 mg/m2 as a one-hour infusion every three weeks. Treatment is continued based on an individual assessment of clinical tolerance and effectiveness in consideration of several adverse events, which may prompt either dose reduction or complete treatment interruption. Patients will rarely have more than 6 cycles.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.2.2.3 Comparators",
        "start_page": 55,
        "end_page": 55,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Comparator Clinical documentation Used in the model Expected Danish clinical (including source) (number/value including practice (including source) source) Posology Docetaxel is administered as a Same as clinical same as clinical one-hour i.v. infusion every documentation documentation three weeks. Docetaxel is given at 75 mg/m2 in monotherapy Treatment duration / Treat until disease progression Treat until disease Same as clinical criteria for end of or unacceptable toxicity progression or documentation unacceptable toxicity treatment: Dose reduction captured using RDI from SELECT-1 in the model",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 21. Comparator",
        "start_page": 55,
        "end_page": 55,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The relative effectiveness outcomes have been described in section 8.3. A MAIC analysis has been conducted to establish the relative effectiveness between sotorasib and docetaxel. Results of the MAIC analysis have been described in section 8.3.1. Description of overall survival has been provided in section 8.3.3.2, description of progression-free survival has been provided in section 8.3.3. and description of treatment duration have been provided in section 8.3.5",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.2.2.4 Relative effectiveness outcomes",
        "start_page": 55,
        "end_page": 55,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Grade 3 or above TRAEs with an incidence of ≥ 0.5% in any of the comparator arms (sotorasib and docetaxel) are included in the model. Sotorasib adverse events are induced by the CodeBreak 100 Clinical Study Report for the March 2021 data cut (87). Docetaxel adverse events are induced by the SELECT-1(72). A table of the adverse events and incidence used in the model is shown in Table 22. In the base-case analysis TRAEs are utilized for the sotorasib and docetaxel treatment arms. TRAEs were preferred to minimal bias biases given the absence of randomized data and the fact that some AEs may be driven by the underlying disease.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.2.2.5 Advertise reaction outcomes",
        "start_page": 56,
        "end_page": 56,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Advertise reaction outcome Sotorasiba Docetaxelb",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 22.",
        "start_page": 56,
        "end_page": 56,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Neutropenia 0.8% 1.6% Note: a, CodeBreak 100 phase 2 NSCLCcohort, TRAEs reported. March 1, 2021 data cut-off (87) bJanne 2017 eTable 1 Most Frequently Reported Advertise Events Causally Related to Treatment(72)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Increased aspartate aminotransferase 5.6% 0.0%",
        "start_page": 56,
        "end_page": 56,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "As defined in paragraph 7.2.1,CadeBreak 100 is a single-arm clinical trial, no direct head-to-head evidence to compare the clinical efficacy between the two comparators. The extrapolations were assessed for visual match between the parametric fittings and the KM data, goodness-of-fit statistics and the clinical plausibility of long-term outcomes, in line with NICE DSU guidance (TSD 14) (88). In addition to the MAIC vs. SELECT-1, the Flatiron real-world data were used for sensitivity analysis. Here, a real-world chemotherapy-basket served as a proxy for docetaxel treatment. The rationale for this confirmatory analysis was first, that the SELECT-1 population was anti PD-(L)1 naïve. Second, as CodeBreak 100 is a single-arm trial, this alternative approach was applied to demonstrate the robustness of the results.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.3 Extrapolation of relative effectiveness",
        "start_page": 56,
        "end_page": 57,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Two sets of X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, X, varia were selected for inclusion in the model.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.3.1 MAIC results",
        "start_page": 57,
        "end_page": 57,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "A plot comparing the MAIC-weighted KM OS curve for sotorasib (in blue) to the unadjusted docetaxel OS curve from SELECT-1 (in yellow) is shown in Error! Reference source not found. panel A. The comparison of the unadjusted KM OS curve for sotorasib from CodeBreak 100 (in blue) to the unadjusted docetaxel OS curve from SELECT-1 (in yellow) is shown in Error! Reference source not found. panel B. The MAIC-adjustment results in a light improvement in survival.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.3.2 Overall survival",
        "start_page": 57,
        "end_page": 57,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This means that it is not possible to determine whether there is a difference between the price of the goods and the price of the goods and the price of the goods and services in question.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "A B",
        "start_page": 57,
        "end_page": 58,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Glossary-of-fit statistics using Akaike information criteria (AIC), and Bayesian information criteria (BIC) are presented for jointly fixed and restricted and independent models (Table 23). According to the Court of Justice of the European Union, the Court of Justice of the European Union and the Court of Justice of the European Union have consistently held that the Commission's assessment of the compatibility of the aid with the internal market does not constitute State aid within the meaning of Article 107 (3) (c) of the Treaty. Given the log-normal distribution, the goodness-of-fit statistics pointed to the restricted model, rather than the irregular one.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Statistical goodness-of-fit",
        "start_page": 58,
        "end_page": 61,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Therefore, the approach taken to modeling OS was the jointly limited restricted log-normal model, considering a treatment effect for sotorasib.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Statistical goodness-of-fit",
        "start_page": 58,
        "end_page": 61,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "A plot of jointly produced parametric distribution produced to the MAIC-adjusted KM curves for sotorasib and docetaxel is shown below (Error! Reference source not found.). Visual inspection of the plots indicated that extracted data matched the KM plots well (Error! Reference source not found.). All extrapolations for sotorasib indicated OS of sotorasib compared to docetaxel. Visual inspection of the docetaxel plot confirm that the log-normal distribution is giving the best fit. In terms of other distributional assumptions, the plot indicated that the Weibull and Gompertz distribution overestimated OS in the first 14 months but were very conservative the KM plot (Eror! reference source not found.).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Visual inspection of observed data",
        "start_page": 61,
        "end_page": 61,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: KM, Kaplan-Meier; MAIC, matching-adjusted indirect comparison; OS, overall survival.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 61,
        "end_page": 61,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Exp Gompertz Weibull GG Log-logistic Log-normal Sotorasib 2 months 91.3% 91.0% 92.9% 95.8% 94.7% 95.5% 6 months 76.0% 75.6% 77.7% 76.9% 78.0% 77.4% 12 months 57.8% 57.7% 57.9% 55.7% 56.0% 56.1% Docetaxel 2 months 85.8% 85.5% 88.3% 89.1% 89.2% 89.3% 6 months 63.3% 62.7% 65.5% 65.7% 62.7% 61.0% 61.6% 12 months 40.0% 39.9% 39.9% 38.2% 37.0% 38.1% 38.1% Key: Exp, exponential; GG, Generalized gamma; OS, overall survival.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "XX",
        "start_page": 61,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In summary, the goodness-of-fit statistics indicated that the log-normal approach to OS extrapolation was the best statistically fitting distribution, with the Weibull, Exponential and Gompertz performing relativelypoorly. There was some evidence to suggest that the proportional hazard assumption did not hold true and, there, the application of a HR to estimate a treatment effect was not considered appropriate. Howver, the QQ diagnostic plot clearly demonstrated that an accelerated failure time model was valid, which was supported by the performance of these restricted models and the visual inspection versus the observed data.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Base-case parametric survival curve selection",
        "start_page": 62,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The clinical plausibility of the long-term extrapolations used in the economic analysis was evaluated by considering the prescribed OS landmark results at timepoints of 1-year, 5-years, and 10-years, and the shape of the underlying hazard function was assessed. The OS predictions for the joint fitting (restricted) models at landmark time points are presented in Error! Reference source not found..",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Clinical plausibility of long-term extrapolations",
        "start_page": 62,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Clinical experts consulted by Amgen considered docetaxel survival predictions at 5-years of approximately 5% to be reasonable in this population and would expect a small proportion of patients to remain at the 10-year landmark. Though it was acknowledged that patients in clinical practice could perform lightly worst, the more pessimistic curves presented (exponential, Gompertz and Weibull) were considered to underestimate the long-term survival and did not reflect clinical experience. The base-case log-normal model was determined to provide clinically valid projections of docetaxel and was",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 62,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In view of the above, the Commission considers that the measure in question is compatible with the internal market within the meaning of Article 107 (3) (c) of the Treaty.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "sotorasib at 5-years (X and 10-years (X were considered reasonable given the observed response rate, duration",
        "start_page": 63,
        "end_page": 63,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Error! Reference source not found. panel A shows the base-case MAIC-adjusted KM PFS curve for sotorasib (in blue) vs. the unadjusted KM PFS curve for docetaxel from SELECT-1 (in yellow). Error! Reference source not found. panel B shows the unadjusted KM PFS curve for sotorasib from CodeBreak 100 (in blue) vs. the unadjusted KM PFS curve for docetaxel from SELECT-1 (in yellow).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.3.3 Progression-free survival",
        "start_page": 63,
        "end_page": 63,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: KM, Kaplan-Meier; MAIC, matching-adjusted indirect comparison; PFS, progression-free survival. A: adjuvanted curves, B: unadjusted curves. Subsequently, parametric model fitting was carried out for docetaxel and MAIC-weighted time-to-event data for sotorasib, in line with the methods detailed in NICE DSU TSD 14 (88). Standard parametric distribution were independently and jointly (with unlimited and restricted models) obtained using the statistical software R (ver. 4.0.3) and the flexible distribution package. The parametric distribution modeled included experimental, Weibull, Gompertz, generalised gamma, log-normal and log-logical distribution (Table 24).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "A B",
        "start_page": 63,
        "end_page": 63,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "For the purposes of this Regulation, the following definitions shall apply:\n\n16,5 11,5 116,6 116,7 11,9 1729,0 1726,9 Gompertz 561,8 567,7 1616.9 1174.0 1728,6 1616,7 1716,0 1716,0 171717171729,0 1737.9 1736.9 1716,9 1616,9 1116,0 1728,6 1728,6 1728,6 1724,4 1731,9 1724,4 1731,9 1724,7 1731,9 1742.7 1731,9 1722.7 1617,7 1717,4 1731,9 1727,7 Weibull 558,4 564,4 564,0 1160,6 1667.7 1167.7 118.9 1734,7 1717,8 1729,0 1729,0 1729,9 1726,9 1726,9 1729,9 Gömpertz 561,8 562,3 562,7 109,5 1110.1 1651 1651 1627,7 1729,5 16,7 1729,0 Lig-normal 55,1 1110.1 1616,8 16,8 16 6 6 16,6 16,7.S in KKKKKKKKKKK toiiK 5 5 5 55 in 552 552 552 552 55, 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6.SSSS right.S right.S right.S right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right of right of right of right of right of right of right of right right right of\n\nSchoe Key: MAIC, match cum hing-enfe hing- mulative ha -adjusted in eld residua -adjusted in azards plot for PFS using Bas direct comparison; PFS, progress als plot for PFS using base-c direct comparison; PFS, progress Pa Confidenti se-case MAIC ssion-free survival. case MAIC ssion-free survival.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Statistical goodness-of-fit",
        "start_page": 64,
        "end_page": 65,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "age 59 of 237 ial General Business",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Statistical goodness-of-fit",
        "start_page": 64,
        "end_page": 65,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Key: MAIC, matching-adjusted indirect comparison; PFS, progression-free survival. In summary, there was evidence to suggest the proportional hazard assessment was not valid. The accelerated failure time assumption, however, appeared appropriately valid. In terms of the selected distribution function, consistent with the approach taken in OS, the restricted log-normal model has been applied for treatment extrapolation.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 12. QQ plot for PFS using base-case MAIC",
        "start_page": 66,
        "end_page": 66,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "A plot of mixed parametric distribution produced to the MAIC-adjusted PFS KM curve for sotorasib and the unadjusted PFS KM curve for docetaxel is shown below (Error! Reference source not found.). Visual inspection of the plots indicated that the extrapolated data based on the log-normal distribution matched the KM plots well (Error! Reference source not found.).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Visual inspection of observed data",
        "start_page": 66,
        "end_page": 66,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: KM, Kaplan-Meier; MAIC, matching-adjusted indirect comparison; PFS, progression-free survival.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 67,
        "end_page": 67,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "As explained above, it is reasonablely selling the most appropriate distribution to model PFS was less clear than OS, the goodness-of-fit statistics indicated that the log-normal approach to PFS extraction was the best statistically fitting distribution, with the Weibull, Exponential and Gompertz performing relatively relatively poorly.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Base-case parametric survival curve selection",
        "start_page": 67,
        "end_page": 68,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The clinical plausibility of the long-term extrapolations used in the economic analysis was evaluated by considering the predicted PFS landmark results at timepoints of 1-year, 3-years, and 5-years, and the shape of the underlying hazard function was assessed. Clinical experts consulted by Amgen considered docetaxel and sotorasib projections based on the selected log-normal distribution to be appropriate, clinically valid and reflect the expected survival of the population under consideration. Furthermore, similar to the conclusions on the hazard function shape for OS, the clinical experts considered a non-monotonic hazard function was appropriate to model long-term PFS.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Clinical plausibility of long-term extrapolations",
        "start_page": 68,
        "end_page": 68,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The additional analyses included using alternative MAIC models, independent parametric matching models, applying the unused analyses (no MAIC), application of a single HR (as the proportional hazard assumption was unclear), and use of KM currencies before extraction. These are detailed as follows: • Use a limited best-fitting distribution for both PFS and OS, the second best-fitting distribution (still based on the log-normal assumption) for PFS • Parametric fit based on unadjusted analyses (restricted model).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.3.4 Scenario analysis for survival outcomes",
        "start_page": 68,
        "end_page": 68,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Sotorasib treatment duration was modeled using an HR applied to PFS. The HR was estimated from CodeBreak 100 (75) using a Cox model with the effect estimated between time to treatment discrimination (TTD) and PFS (X The HR applied only depends on CodeBreak 100 data and methodologywise is a valid approach for any option of modeling OS and PFS.. Additionally, it was considered that it was intended to transform nature of sotorasib. Error! Reference source not found.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.3.5.1 Sotorasib",
        "start_page": 68,
        "end_page": 69,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The modeling of TTD by applying a HR to the PFS curve was validated by comparing the obtained TTD curve to the actual TTD KM curve from the soorasib arm in CodeBreaK 100: the modelled TTD shown good compliance with the KM curve (Error! Reference source not found.). To account for the expected important correlation between PFS and TTD, clusters based on subject ID were introduced in the Cox model. Cluster's are used to take into account correlation in the observations, and also triggers the compilation of a robust variation for the model. The R code used to estimate the HR of TTD vs PFS is provided below.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "TTD is modelled applying a HR of X) to the modelled PFS curve.",
        "start_page": 69,
        "end_page": 69,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This approach to estimate treatment measurement. This approach, above, compared to the HR approach, is compared to the HR approach, is compared to the HR approach, is compared to the HR approach, is more complex but less integrated: The HR approach is based on a single parameter from a single trial. Adding MAIC Weight, where measured to the HR approach, where time-to-even data of two tals are being combined, for TTD SELEC-1 based KMcurves do not exist. Adding MAIC weight gains across costs would be added to the complexity but not achieved. For example: • In NSCLC it is common to sume TTD=PFS if this is in-line with the licence and SmPC wording or otherwise linked TTD to PFS by either applying a HR or adding a mean number of cycles of treatment at progression in the model (i.e. if TTD is lightly higher than PFS).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 69,
        "end_page": 69,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "There was no robust data to inform treatment duration for docetaxel.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.3.5.2 Docetaxel",
        "start_page": 69,
        "end_page": 70,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: PFS, progression-free survival; TTD, time to treatment interruption.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 70,
        "end_page": 70,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Please refer to sections 8.3.2, 8.3.3, and 8.3.5 for information on time to event data.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.3.6 Time to event data • summarized:",
        "start_page": 70,
        "end_page": 70,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "HRQoL data were collected in CodeBreak 100 using the EQ-5D-5L questionnaire before any clinical assessments and before receiving study medication. The questionnaires were advised at the beginning of each three-week treatment cycle for the first seven cycles, and every six weeks subsequently for as long as the patient remained on treatment. The EQ-5D-5L questionnaire was also advised at end of the treatment visit as well as on the safety follow-up visit (~ 30 days after the last dose of sotorasib).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.4.1 Overview of health state utility values (HSUV)",
        "start_page": 70,
        "end_page": 70,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Description statistics by visit are provided for the mean EQ-5D utility index score by visiting the Danish tariff (Error! Reference source not found.).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.4.1.1 Description analysis of CodeBreak 100 EQ-5D-5L",
        "start_page": 70,
        "end_page": 71,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: Danish EQ-5D-5L index (86). Note: Analysis based on CodeBreak 100 reported EQ-5D-5L from 15MAR2021 data cut.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 71,
        "end_page": 71,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: Danish EQ-5D-5L index (86) Note: Analysis based on CodeBreak 100 reported EQ-5D-5L from 15MAR2021 data cut.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 71,
        "end_page": 71,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "MMRMs were used to assess the change of utility from baseline with Reference source not found.. Denmark Utility Index scores (Error! Ref or! Referen icating staff hout covariaference so nce source not found..",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.4.1.2 Mixed models for repeated measures analysis",
        "start_page": 71,
        "end_page": 71,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Index MID threshold (0.080), except for Cycle 17, Cycle 19, and Cycle 21. LS mean change from Baseline estimates was not significantly different from zero across all visits (as indicated by the 95% Cis). Available subject observations out of the EQ-5D-5L analysis population had decreased by over half at Cycle 4.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "stable across timepoints, decreasing X. This did not change meaningfully and remained within the Denmark",
        "start_page": 72,
        "end_page": 72,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "For the base-case, utilities based on health state accumulation was used, as it both reflects the health status of patients following the structure of the clinical trial and the partitioned survival model. Health state utilities by progression status are presented using the Danish EQ-5D-5L value set(86) (Error! Reference source not found.), Utilities are age-adjusted in the model according to the DMC guidelines. For the Danish EQ-5D-5L value set(86), the progression health state utility was lower than pre-progress and was",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.4.2.1 Base case (health state utilities)",
        "start_page": 72,
        "end_page": 72,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Utilities by time to death using the Danish EQ-5D-5L value set (86) are presented in Error! Reference source not found.. For the Danish EQ-5D-5L value set, time to death at 3 to 6 months was lower than more than 6 months",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.4.2.2 Time to death utilities",
        "start_page": 72,
        "end_page": 72,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "utilities have been expanded in scenario analyses.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Were lower and statistically significant (X (Error! Reference source not found.).",
        "start_page": 73,
        "end_page": 73,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In this regard, the Commission considers that it is appropriate to take into account the fact that, in the present case, it is not possible to determine whether there is a difference in treatment between the two. Market-wide neutropenia 0.047 (0.016, 0.077) Nafees 2008(91) Fatigue a 0.073 (0.037, 0.110) Nafees 2008(92) Increased ALT a 0.050 (0.040, 0.060) NICE TA 347, 520, and 484 [assumption] (82, 90, 91) Increased AST a 0.000 NICE TA484 [assumption](90) Neutropenia a 0.090 (0.059, 0.120) Nafees 2008(93) Increased white blood cell count 0.050 (0.0040, 0.060) Assumption, value used in NICE TA 347, 520, and Dyspnea 0.050 (0.026, 0.074) Doyle 2008 (8) Febrile neutropenia 0.90 (06) Market-free neutropenia 0.050 (06, 0.050) Market-wide thrombosis",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.4.3 Advertise reactions and treatment modality disutility",
        "start_page": 73,
        "end_page": 74,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The drug acquisition cost per treatment is presented in Table 26 below, with the unit costs for comparators sourced from Medicinspriser.dk (94). The sotorasib dose of 960mg per day is included in the licensing and the dose regime in CodeBreak 100 (73, 95, 96).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.5.1 Intervention and counterpart costs and resource use",
        "start_page": 74,
        "end_page": 75,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The costs of treatment administration for sotorasib and docetaxel are shown in Table 27. As sotorasib is an oral drug, it is assued that the patients receive training on how to manage the drug, and there no administration costs have been assumed for these visits. According to the SmPC, the time required per administration of docetaxel is 60 minutes every 3 weeks(92). Following consultation with two Danish clinical experts, it was confirmed that administration of docetaxel at their partements was coded using the DRG code, 27 pp.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.5.2.1 Administration costs",
        "start_page": 75,
        "end_page": 75,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Given the limited published literature that explores the resource use associated with previously treated locally advanced or metastatic NSCLC, monitoring and disease management costs are largely associated with assumptions used and accepted in previous DMC submissions and validated with Danish clinical experts. Disease monitoring and management costs were combined with the model structure and response resource utilisation in both progression-free and post-progress health states. A summary of the blood sample cost used in the economic model is presented in Table 28, and the unit cost of other disease management is presented in Table 29. A summary of the risks and cost per cycle used in the economic model is presented in Table 28, and the unit cost of other disease management is presented in Table 29.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.5.2.2 Monitoring and disease management costs",
        "start_page": 75,
        "end_page": 75,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "L+D (DIFFMAS) 90 Creatine 24 Calcium 24 Albumin 24 Liver (ALT) 24 Liver (AST) 24",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Hb 31",
        "start_page": 76,
        "end_page": 76,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Units Cost per unit (DKK) Source Outpatient consultation 1.732 DRG 2021, 04MA98: MDC04 1-day group, pat. At least 7 years, Diagnosis: DC349: lung cancer UNS(98). CT scan 2,007 DRG 2021, 30PR06: CT scan, complicated, Diagnosis: DC349: lung cancer UNS Procedure: UXCC00 CT scanning of chest(98). Blood samples 241 See Table 28. Table 30. Disease management costs per model cycle Health states First cycle • Progression-free • Unites progression-free downstream cycles Post-progress (frequency per cycle) (frequency per cycle) (frequency per cycle) (frequency per cycle) Outpatient consultation 1.00 0.25 0.25 CT-scan 1.00.00 0.08 Blood sample 3.25 0.25 Total cost (DKKKK)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 29.",
        "start_page": 76,
        "end_page": 76,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Currently, no standard treatment is defined for 3L treatment of NSCLC patients (2, 6). Based on clinical expert input, patients with ECOG PS 0 or 1 will often be referred to a phase 1 or 2 trial investigating an experimental treatment(2). It is considered that no cost associated with experimental treatment will be successfully by the hospital, there necessary treatment cost has been distributed from this health economic analysis.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.5.2.3 Subsequent treatment cost",
        "start_page": 76,
        "end_page": 76,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "As described in section 5.3, KRAS testing is part of the current NGS panel for NSCLC patients in Denmark and no additional tests beyond those used in the routine diagnostic workup and management of patients with NSCLC are required. This has been confirmed by two Danish clinical experts(2, 3).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.5.2.4 Biomarks testing",
        "start_page": 76,
        "end_page": 76,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "DIDID, DID, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DID, DIG, DIG, DIG, DIG, DIG, DIG, DIG, DIM, DIM, DIM, D G G G I D D D D D I D D D D D D I D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D I D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.5.2.5 Adverse response unit costs and resource use",
        "start_page": 77,
        "end_page": 77,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The unit cost per patient hour is estimated to be DKK 179 and the transportation cost per visit was assumed to be DKK 100 in line with the DMC guidelines(99) (see Table 32). Patient and transportation costs were applied to every visit to the hospital, e.g., training for administration of sotorasib, IV administration and disease management. To estimate patient costs, time usage was assumed, see Table 33. Table 32. Unit cost for estimation of patient cost and transportation cost Unit cost Resource (DKK) Source average daily week 179 Medicinal product board",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.5.2.6 Patient and transport cost",
        "start_page": 77,
        "end_page": 78,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Patient time associated with 90 Based on SmPC for docetaxel, 90 mins. Is administration of docetaxel assumed for IV administration of docetaxel(92) Patient time associated with outpatient 60 60 mins. assumed",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "administration with sotorasib",
        "start_page": 78,
        "end_page": 78,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Patient time associated with CT-scan 60 mins. assumed Patient time associated with blood 30 mins. assumed",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "consultation",
        "start_page": 78,
        "end_page": 78,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The structure is typical of NSCLC and oncology modelling and has been used in several previous DMC assessments.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.6.1 Base-case overview",
        "start_page": 78,
        "end_page": 78,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Docetaxel: Assumed to be equal to PFS MAIC source MAIC Adjusted: •all variables of prognostic alternative option not feasible due to low effective",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "TTD",
        "start_page": 78,
        "end_page": 78,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "With regard to risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ that that that that that that that that that that that that that that that that that that that that that that that that that that that that that that that that that that that that that‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐\n\nKey: 2L, second-line; DMC, Danish medications council; HRQoL, health-related quality of life; IV, intravenous; MAIC, matching-adjusted indirect comparison; NSCLC, non-small-cell lung cancer; PFS, progression-free survival; OS, overall survival; SAF, safety analysis set; TTD, time to treatment interruption; TRAE, treatment-related adverse event",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Importation· (SET 1) samples size.",
        "start_page": 79,
        "end_page": 79,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the model base-case where docetaxel is considered the comparator, counted results are presented in Error! Reference source not found.. Using a 20-year time horizon, the incremental total life-year gain of sotorasib versus docetaxel was X years. The counted incremental costs of X DKK and incremental QALYs of X resulted in an incremental cost-effectiveness ratio (ICER) of X DKK/QALY versus docetaxel. This would be cost-effective at a willingness-to-pay threeshold of DKK 750,000 per QALY. XX",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.6.2 Base-case results",
        "start_page": 80,
        "end_page": 80,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: AE, adverse event; ICER, incremental cost-effect ratio; LY, life-years; NMB, net monetary benefit; WTP, willingness-to-pay; QALY, quality-adjusted life years.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X",
        "start_page": 80,
        "end_page": 80,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The results of the DSA comparing sotorasib with docetaxel are presented as tornado plot in Error! Reference source not found.. The plot demonstrate the top 10 parameters that had the largest effect on the ICER determined as the difference in the lower and upper bound parameter values. The five parameters which had the largest influence on the ICER were (i) the hazard ratio to deive sotorasib time to treatment interruption, (ii) the administration cost of docetaxel, (iii) the relative dose intensity of sotorasib, (iv) the health state utility of progression-free and (v) the hazard ratio to resulting docetaxel time to treatment metabolism.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.7.1 Deterministic sensitivity analyses",
        "start_page": 80,
        "end_page": 80,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: Admin, administration; AE, adverse event; HR, hazard ratio; IV, intravenous; PFS, progression-intensity; TTD, time-to-treatment-discontinuation.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 81,
        "end_page": 81,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Sceneario 100 analyses were found to exist in the market-based alternative solutions of alternative inputs on the model results. Table 35 summary analyses the scenarios considered. Table 35. Description of scenario analyses No. Scenario Base-case Assumption Use 2nd best fitting OS and PFS distribution, generalised gamma. Use 3rd best fitting OS and PFS distribution, log-log-log-log-log-logical. Restricted model using log-normal distri 3 Unrestricted log-normal distribution for PFS. -free ameter intervention. urvival; RDI, relative dose rs, settings, or assumptions Rational Effect of choosing the second-best and third-best fitting Jointly produced parametric fits using the restricted model. This is the time to death usage status using time to death uses Effect of reducing time 12 15-year time horizon.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.7.2 Scenario analysis",
        "start_page": 81,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "20-year time horizon. Horizon by 5 years. Drug wastage is exceptionally 13 Including drug wastage. No drug wastage is assumed. included. Patients are assumed. Patients are assumed to relative dose intensity of drug is taken from 14 Exclude RDI. receive 100% of the drug clinical trials dose. Key: AE, adverse event; ATT, average factor effect of drug is taken from 14 Exclude RDI. receive 100% of the drug clinical trial dose.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.7.2 Scenario analysis",
        "start_page": 81,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The total cost and QALYs were recorded for each iteration and averaged. PSA results for the comparison to docetaxel are presented in Error!",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "8.7.3 Probabilistic sensitivity analyses",
        "start_page": 83,
        "end_page": 83,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: ICER, incremental cost-effectiveness ratio; Incr., incremental; QALY, quality-adjusted life year. Error! Reference source not found. representatives the scatter plot of the incremental costs and QALYs from the PSA results based on 1,000 iterations. As shown in the cost-effectiveness acceptance curve (Error! Reference",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 83,
        "end_page": 83,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "750,000 WTP threshold.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "source not found.), sotorasib has a X% probability of being cost-effective versus docetaxel considering the DKK",
        "start_page": 83,
        "end_page": 83,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: QALY, qu duality y-ad djust ted life year; WT TP, willngness-to Conf o-pay.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 84,
        "end_page": 84,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: QALY, quality-adjusted life year; WTP, willingness-to-pay.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 85,
        "end_page": 85,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The budget expected budget impact of reducing sotorasib as a possible standard treatment in Denmark. The budget impact was estimated per year for the first 5 years after the introduction of sotorasib in Denmark. The budget impact model was definitely next within the cost-effectiveness model, and there any changes in the settings of the cost-effectiveness model would affect the results of the BIM. The budget impact result is representative of the population in the cost-effectiveness model and the survival outcome of this population The analysis was developed by compating the costs for the Danish regions per year over the five years in the scenario where there exists",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "9. Budget impact analysis",
        "start_page": 85,
        "end_page": 85,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "If you want to earn more money than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want. If you want to earn more than you want to earn more than you want, you have to pay more than you want to earn more than you want. If you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "9.1 Number of patients and market uptake",
        "start_page": 85,
        "end_page": 86,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "If you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn more than you want to earn than you want.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "9.1 Number of patients and market uptake",
        "start_page": 85,
        "end_page": 86,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Based on the base-case settings, the estimated budget impact of recommending sotorasib as default",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "9.2 Budget impact",
        "start_page": 86,
        "end_page": 86,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "To test impact of the patient number estimate on the budget impact of reporting sotorasib, scenario analyses have been conducted on two scenarios: - Scenario 1, where 110 patients are eligible for 2nd line treatment each year. - Scenario 2, where 140 patients are eligible for 2nd line treatment each year. The budget impact results of reporting sotorasib for scenario 1 has been reported in Error! Reference source not found. and for scenario 2 in Error! Reference source not found..",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "9.3 Scenario analysis",
        "start_page": 86,
        "end_page": 86,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Thus, the Commission considers that there is no reason to believe that the Commission's assessment of the compatibility of the aid with the internal market does not lead to a distortion of competition between Member States.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "10. Discussion on the submitted documentation",
        "start_page": 87,
        "end_page": 87,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The clinical value of sotorasib compared to docetaxel is demonstrated by the survival outcome measures, PFS",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Clinical outcomes",
        "start_page": 87,
        "end_page": 87,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "PFS(7). For the primary comparator docetaxel monotherapy (X), exceeding the minimal clinically important difference of 3 months in median OS(7). Safety outcomes were compared narratively and were limited by incomparable exposure times between sotorasib and docetaxel evidence. The median duration of treatment varied from 5.5 months for sotorasib to 2.4 months for docetaxel. Sotorasib presented a lower rate of treatment interruptions due to AEs (8.7% vs. 14.5%), and loweroccurrence of grade 3 or worst TRAEs (20.6% vs. 30.0%).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "with docetaxel monotherapy (X]), exceeding the minimal clinically important difference of 3 months in median",
        "start_page": 88,
        "end_page": 88,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The CodeBreak 100 trial provides an early indication of the effectiveness and safety of targeted therapy with sotorasib. The trial recovered patients who are reflecting of those in Danish clinical practice (as observed in the retrospective registry study described in section 5.1.5) and assessed relevant outcomes using the dose regimen applied by the EMA. Results from indirect comparison using the most plausible method available to detect relative effectiveness estimates between sotorasib and docetaxel was used. In the context of a disease with no other targeted agents, high and urgent unless needed, and with limited available data, the evidence in support of sotorasib is compatible.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Strengths",
        "start_page": 88,
        "end_page": 88,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "With regard to the risk of injury, the Commission considers that there is a risk that the risk of injury will be reduced to the level of the injury suffered by the Union industry as a whole.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Limitations",
        "start_page": 88,
        "end_page": 88,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "With regard to the analysis of the risk-benefit analysis, the Commission considers that the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis of the risk-benefit analysis. The ICER extended the willness-to-pay threshold of DKK 750,000 per QALY in only one scenario.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Health economics",
        "start_page": 88,
        "end_page": 89,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In the sense above above, CodeBreak 100 means that soorasib is a highly effective and affordable phenomenon for NSCLC patients with KRAS G12C mutation.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Conclusion",
        "start_page": 89,
        "end_page": 90,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "25. LUNGEVITY 95. Drugs Brought for lung cancer. Available from: cabivers/lung cancer-101/treatment options/targeted-therapy. Last updated: 16 April,. 2021. 48. Wood R, Taylor-Stokes G, Smith F, Chaib C. The humanistic ben of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and carerather should. Qual Life Res. 2019;28(7):1849-70. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised tests. Trials. 2010;11(1):1-8. 71. Amgen Inc. Data on file: Clinical Study Report: CodeBreaK100 The sector sector sector risk. Levels of risk-based risk-based risk-based risk-based risk-based risk-based risk-based risk-based approach to risk-based risk-based risk-based risk-based approach to risk-based risk-mitigation measures, including risk-based risk-based risk-mitigation measures, including risk-based risk-based risk-mitigation measures, and risk-based risk-mitigation measures;\n\nThe SLR conformed to published guidelines issued by the Cochrane Collaboration (1) and the Centre for Reviews & Dissection (CRD; York, UK) and followed the methodological requirements of the National Institute for Health and Care Excellence (NICE), UK, the Preferred Reporting Items for Systematic Reviews and Meta-Analysiss (66), and the Consolidated Standards of Reporting Trials (CONSORT) and statements (66-70). The SLR search was conducted in June 2020.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12. References",
        "start_page": 92,
        "end_page": 98,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "An updated search was conducted on 26 January 2021. Searches were conducted in Embase, Medline and The Cochrane Central Register of Controlled Trials (CENTRAL), for the original and updated searches.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12. References",
        "start_page": 92,
        "end_page": 98,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "This means that it is not possible to assess the impact of the aid on competition and trade between Member States, but rather to assess whether the aid is compatible with the internal market and whether the aid is compatible with the internal market and whether it is compatible with the internal market within the meaning of Article 107 (3) (c) of the Treaty on the Functioning of the European Union, and whether it is compatible with the internal market within the meaning of Article 107 (3) (c) of the Treaty on the Functioning of the European Union, and whether it is compatible with the internal market, and whether it is compatible with the internal market, and whether it is compatible with the internal market, and whether it is compatible with the internal market within the meaning of Article 107 (3) (c) of the Treaty on the Functioning of the European Union, and whether it is compatible with the internal market, and whether it is compatible with the internal market within the meaning of Article 107 (3) (c) of the Treaty on the Functioning of the European Union.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Search Strategies",
        "start_page": 98,
        "end_page": 98,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In this case, the Commission considers that the Commission's decision to initiate the procedure laid down in Article 108 (2) of the Treaty on the Functioning of the European Union to initiate the procedure laid down in Article 108 (3) of the Treaty on the Functioning of the European Union (hereinafter referred to as \"the EEA Agreement') constitutes State aid within the meaning of Article 108 (1) of the Treaty on the Functioning of the European Union. 10 square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square thousand square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square or square square square square or square square square square square or square square square square square square or square square square square square square square square square or square square square square or square square square square square square square square or square square square square square square or square square square square square square square or square square square square square square or square square square square square square square square square square square square square square square square square square square square square square square square square or square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square or square or square or square or square or square square square square square square square square square square square square square square square square square square square or square or square or square square square square square square square square square square square square square square square square square square square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or square or",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Embase • original search",
        "start_page": 99,
        "end_page": 102,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "20* $2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2 $2$2 $2 $2 $2 $2 $2 $2 $2 $2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2$2\n\n7 1 or 2 or 3 or 3 or (4 and 5 and 6 and 6) means of crossover procedure/ or double-blind procedure/ or random 8 single-blind procedure/ (random$ or equivalent or factorial$ or crossover$ or cross-over$ or cross-over$ or cross-ov 9 adj blind$) or (singl$ adj blind$ or (singl$ adj blind$) or (singl$ or allocat$ or volun 10 8 or 9 11 (animal$ not human$).shhh,hw. 12 10 11 11 13 7 and 12 14 (2020 Sep* or 2020 Oct* or 2020 Nov* or 2020 Dec* or 2021 J 15 13 and 14 16 16 13 to ed=20200901-2020-2021126 17 15 or 16 Confidential $ not human$).shhw. 12 10 10 11 13 7 and 12 20 20 20 20 20 20 00 blind$ or 2020 blind$ or 2020) or song$ or otherwise $ or otherwise $ or otherwise $ or otherwise $ or otherwise $ or otherwise $ or otherwise $ or otherwise $ or at $ or 9 11 or 11 or 9 11 11 11 or 9 11 or otherwise'.'.'.'.'..) means of.) shall c b b b b b b b b b b, and. organisations, b b b b.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Embase - 2021 update",
        "start_page": 102,
        "end_page": 106,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "organisations, and. The Court of Justice of the European Union (hereinafter referred to as the Court of Justice of the European Union) has consistently held that, in the present case, the Court of Justice of the European Union has failed to fulfil its obligations under the Treaty on the Functioning of the European Union (hereinafter referred to as the Court of Justice of the European Union) and that the Court of Justice of the European Union (hereinafter referred to as the Court of Justice of the European Union) has failed to fulfil its obligations under the Treaty on the Functioning of the European Union (hereinafter referred to as the Court of Justice of the European Union (hereinafter referred to as the Court of Justice of the European Union) and has failed to fulfil its obligations under the Treaty on the Functioning of the European Union (hereinafter referred to as the Court of Justice of the European Union) (hereinafter referred to as the Court of Justice of Justice of Justice of the European Union) (hereinafter referred to as the Court of Justice of Justice of Justice of the European Union) (hereinafter referred to as the Court of Justice of Justice of Justice).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Embase - 2021 update",
        "start_page": 102,
        "end_page": 106,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Reference lists of included publications and relevant SLRs/NMAs were scanned.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "• Reference lists",
        "start_page": 106,
        "end_page": 106,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "• Corporate Corporate Corporate Corporate (CBR) Limited (CBR) Corporate Corporate (CBR) Corporate Corporate (CBR) Corporate Corporate (CBR) Relates below were originally searched for the World Single Arm Trials in patients with KRAS G12C-mutated NSCLC on 24 July 2019. These searches were updated 10 March 2021 to identify single arm trials in patients with KRAS mutant NSCLC in the period 2019 to 2021.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Search strategies for single-arm trials",
        "start_page": 106,
        "end_page": 107,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "5 exp colon cancer/ or exp rectum cancer/ or colorectal tumor/ 301 005 6 ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosign$ or bowl$ or 323 534 anal or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or metastas$ or meta-sta$ or sarcoma$ or adenom$ or lesion$)).ti,ab.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "4 limit 3 to yr=\"2014 -Current' 71 463",
        "start_page": 107,
        "end_page": 107,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "25 and 25 years and 25 years and 25 years).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "10 k ras oncogene/ 9909",
        "start_page": 108,
        "end_page": 109,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "5 exp colon cancer/ or exp rectum cancer/ or colorectal tumor/ 184 107 6 ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosign$ or bowl$ or 224 916 anal or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or metastas$ or meta-sta$ or sarcoma$ or adenom$ or lesion$)).ti,ab.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "4 limit 3 to yr=\"2014 -Current' 29 081",
        "start_page": 109,
        "end_page": 109,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "((k ras or k-ras or k-k-ras or ki-14 621 ras or ki ras or Kras1 or Kras2 or KRAS1P or RASK or RASK1 or RASK2 or RASK2 or or Kirsten RAS) adj5 (mutation$ or mutant$ or mutated or status or exon or gene$ or translocation$ or arrangement$ or oncogene$ or fusion$ or expression$ or over?expression$ or amplification$ or inversion$ or deletion$)).ti,ab. 12 10 or 11 13 epidemiology/ or epidemiology.ti, 14 incidence/or accident.ti,ab. 15prevalence/orprevalence.ti,ab,kw 16 Sunday. 3 1 or 2 4 limit 3 to yr=\"2014 -Current.$ (Limit not valid in DARE; records were established] 5 exp colon or or exp rectum cancer/ or relative tumor/ 6 ((colorect$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosign$ or bo anal or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo$ or carc or adenocarcinoma$ or meta$ or meta-sta$ or sarcoma$ or adenom$ or lesion$) 7 5 or 6 8 limit 7 to yr=\"2009 -Current\" [Limit not valid in DARE; records were or lost] 9 4 or 8 10 k ras oncgene/ 11 ((k ras or kras or k-ras or v. 29 27 not 28 30 limit 29 to English language [Limit not valid in ACP Journal Club was established] 31 limit 30 to (editorial or review) [Limit not Club,CDSR,DARE,CLEED,CLHTA,CLCMR; records were established] 32 systematic review/or \"systematic review (topic)\"/or syste analysis/or \"meta analysis (topic).\"mp.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "10 k ras oncogene/ 12 293",
        "start_page": 109,
        "end_page": 112,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "or meta-analysis.mp. 33 31 not 32 34 30 not 33 35 remove duplicates from 34",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "10 k ras oncogene/ 12 293",
        "start_page": 109,
        "end_page": 112,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ $$$ $$$$$ $$$$$$$$ $$$$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $\n\n29 27 not 28 30 limit 29 to English language c-k-ra en RA oratio ressio survi val).ti, as or ki-31465 AS) adj5 on$ or on$ or ival* or 523163 ,ab,kw. 132750 31 limit 30 to (editorial or erratum or letter or note or patent or reports or \"review\" or short 104 survey or tombstone) 32 systematic review/ or \"systematic review (topic)\"/ or systematic review.mp.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "• Embase • updated search: 10 March 2021",
        "start_page": 112,
        "end_page": 114,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "or meta-511387 analysis/ or \"meta analysis (topic).\"mp. or meta-analysis.mp. or meta-analysis.mp.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "• Embase • updated search: 10 March 2021",
        "start_page": 112,
        "end_page": 114,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "5 exp colon cancer/ or exp rectum cancer/ or colorectal tumor/ 199364 6 ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosign$ or bowl$ or 251120 anal or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or metasta$ or meta-sta$ or sarcoma$ or adenom$ or lesion$)).ti,ab.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "4 limit 3 to yr=\"2019 -Current' 15154",
        "start_page": 114,
        "end_page": 114,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "($$ovreish anvs or kras or uk-ras or ki-16640 ras or ki ras or ki or kras1 or kras2 or kras1 or kras2 or kras1P or RACK or or RACK1 or or RACK2 or or or RACK2 or or or RACK2) adj5 (mutation$ or mutant$ or mutated or status or exon or gene$ or translocation$ or oncogene$ or fusion$ or expression$ or over?expression$ or amplification$ or inversion$ or deletion$)).ti,ab. 12 10 or 11 13 epidemiology.ti,kw.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "10 k ras oncogene/ 12466",
        "start_page": 114,
        "end_page": 116,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "$Searches 1 exp Carcinoma 11 or or more 12 or more, Non-Small-Cell retail price $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ or $$$$$$$$$$$$$$$$$$$$ or $$ or $$ or $$ or $$ or $$ or $$ or $$ or $$ or $$ or $$ or $$ or $$ or $$ or $$ or $$) $$ or $$) $$) $$ or $ or $ or $) $$) $$) $$) or $) or $ or $ or $ or $ or $ or $ or $ or $ or $ or $ or $ or $ or $ or $) or $) or $) or $) or $) or $ or £) or £) or £) or $ or $ or $ or £) or $ or $ or $ or ( $ ( $ ( or $ or $ or / / / / / / / / / / / / / / / / / / / / / / / / / / / / /\n\n29 27 not 28 30 limit 29 to English language [Limit not valid in ACP Journal Club,CD was established] 31 limit 30 to (editorial or review) [Limit not va Club,CDSR,DARE,CLEED,CLHTA,CLCMR; records were established] 32 systematic review/or \"systematic review (topic)\"/or systema analysis/or \"meta analysis (topic).\"mp. or meta analysis.mp.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Cochrane updated search: 10 March 2021",
        "start_page": 116,
        "end_page": 117,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "or meta analysis.mp. 33 31 not 32 val* or overallsion-free surviv DSR,DARE,CLCM aid in AC atic review.mp survival* or 105477 val).ti,ab,kw. 25533 MR; records 66 CP Journal 1 p. or meta-33812",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Cochrane updated search: 10 March 2021",
        "start_page": 116,
        "end_page": 117,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "This is the only way to ensure that the costs incurred by the company are taken into account in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company in the calculation of the costs incurred by the company. • Detailed risk assessment for patients Intervention/comparator Any therapies licensed in the United States Treatments specifically or European Union for the second or later targeting EGFR/ALK or ROS 1 line treatment of patients with NSCLC mutations Or other targetable Treatment with Immuno-oncology mutation therapies will be considered as is in Scope even if not a specified treatment post progression on an anti PD-(L)1 Efficacy Outcomes Non-clinical outcomes • Time to progression (TTP)§ • Time to next treatment (TTNT) • Event-free survival (PFS)§ • Progression after next line of therapy (PFS2) § • Time to progression (TTP)§ • Time to next treatment (TTNT) • Event-free survival§ CRITERia Study design/setting",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "35 remove duplicates from 34 65",
        "start_page": 118,
        "end_page": 119,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "• All-grade treatment-only AEs • Treatment related grade 3 or 4 AEs • Treatment related SAEs • Tolerability: dose reduction and intervention, discrimination (any reason), discrimination (due to AEs) Phase II • IV randomd controlled trials • Trials with a phase I component only • Non-randomized clinical trials • Studies with < 10 participants n English language publications (English Non-English language languages abstracts of foreign language publications without an publications will be considered for English abstract. inclusion.) For the applied researches, full papers • Studies published prior publication or after 2015/93\n\nHowever, if HRQoL data from SAT studies were identified in the NSCLC SLR Update and SLR Recreen, data will be included n Only single-arm trials Exclu (experimental/interventional, not studio observational) 1) SLR Update: Published since 2019 Congress abstract searches limited to the past 3 year and clinical trials (to cover KRASm)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Safety and tolerability:",
        "start_page": 119,
        "end_page": 120,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Published from 2014 to 2019 (to cover KRASm) English language usage Criteria or types other than NS otherapy or surger vant comparator arm) out animal/in vitro ies and case reports SCLC reputation (u studio unless ies, cs a case Publication type All publication types, except editorials and reviews, but including systematic reviews* Country Not restricted",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "2. SLR Screen:",
        "start_page": 120,
        "end_page": 121,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Results of the studies conducted in the SLR of RCTs The PRISMA flow chart illustration the number of studies meeting the inclusion criteria, and the exclusion of irrelevant RCTs, is provided in Appendix Figure 1. The electronic database search identified 13,752 quotes, of which 5,488 were identified as duplicates and excluded. The remaining 8,264 quotes were screened on the basis of title and abstract, and 7,818 were then excluded leaving 446 quotes to be screened on the basis of the full publications. During full text screening, 431 publications were subsequently excluded resulting in 18 included publications related to 17 unique studies reported on a KRAS population or subgroup.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Results of the SLRs",
        "start_page": 121,
        "end_page": 121,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In this respect, the Commission considers that the analysis is based in the 2015 updated research, superiored a comparison in the original research, revealed as a result of studies are less than the total of the original and updated research.The list of the 17 studies meeting the broad reliability criteria is provided in Appendix Table 3. Of these 17 studies meeting the broad inclusion criteria, 7 were conducted specifically in KRAS mutant NSCLC patients (see Appendix Table 3). Of these, 5 out of these data typically in patients has the KRAS G12C mutation (see Appendix Table Table 4). The SLR confirmed there are currently no published RCs of soorasib or another KRAS G12C mutation (see Appendix Table 4). The SSLR confirmed there are currently no published in RTs of soorasib or another KRASG12Cs can be identified. The results of the studies are based on the results obtained and the results obtained are based on the results obtained.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix Figure 1. Study flow of included and excluded RCTs",
        "start_page": 122,
        "end_page": 122,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Trials offer marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplace marketplacemarketplacemarketplacemarketplacemarketplacemarketmarketplacemarketmarketplacemarketmarketplacemarketplacemarketmarketplacemarketmarketplacemarketplacemarketmarketplacemarketmarketmarketplacemarketmarketplacemarketmarketmarketplacemarketmarketplacemarketmarketmarketmarketplacemarketmarketmarketplacemarketmarketmarketplacemarketmarketplacemarketmarketmarketmarketmarketmarketmarketplacemarketmarketmarketmarketmarketmarketplacemarketmarketmarketmarketmarketmarketmarketplacemarketmarketmarketplacemarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarketmarket\n\nThe patients who eat arms, and therefore the body body Uniting of recovered >2 previous function erlotinib 100 mg system of therapies were 2) Treated brain orally once daily + excluded metastas were shown >2 previous function erlotinib 100 mg system of therapies were 2) Treated brain orally once daily + excluded metastas were soldinib 150 mg allowed if not required orally once daily steroid or antiepileptic (n=30) medications. Gerber et al 2018 (104) USA study Erlot, 150 mg 1) Patients had received 1) Patients in 1) Patients with knowledge 1°: PFS performed orally once daily in at least one previous line of inoperable locally acting EGFR mutations NCT01395758 2°: OS, radiat bam between July combination with chemotheraday added or metastatic in that one previous line of efficient one previous line of inoper one previous line of inoper one previous line of inoperable locally acting EGF EGFR mutation (s nCT smoking), NCT NT013957 58 2°: OS, radiograph b between July composition Close murder In accordance or met or met or metastatic wear wear wear wear wear wear wear wear were were carried carried were carried carried carried carried carried carried carried carried performed. answer.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria",
        "start_page": 123,
        "end_page": 135,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "to answer. answer. answer. answer. answer. answer to answer to answer to answer to answer to answer Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase Phase 2,. ECOG PS 0°2) Investigator's choice chemotherapy (gemcitabine 1250 mg/m2 days 1 and 8 every 21 days, docetaxel 75 mg/m2 day 1 every 21 days, or pemetrexed 500 mg/m2 day 1 every 21 days) (n=45) Goldman et al 2020 (105) International Abemacib 200 mg 1) Patients who 1) Patients with 1) studied PO twice a day progressed after metastatic (stage IV) unstable NCT02152631 in October 2011 platinum-based NSCLC with detectable metastas (n=270) Phase 3 (still active at chemotherapy (orwith or mutations in codons 12 time of writing\n\nFor example, in this case, the patients who or had agents or 14 days for established market risk, market risk, market risk, market risk, market risk, market risk, market risk, market risk, market risk, market risk, market risk, market risk, market risk and tolerabies Patients with e/untreated brain ses Patients with e/untreated brainses Patients with 1°: OS e/untreated brain 2 °: PFS, ORRR, ses safety and tolerabi and Included in Danish nt submission and reason and independence Excluded No relevant intervention Trial name, NCT ID, Study d Study names, study Janne et al 2017 NCT01933932 SELECT-1 Phase 3 Papadimitrakop BATTLE-2 Phase 2 Dates of study, Interventions Prior therapy Inclusion crieria Exclusioncriteria Primary an design, Study location or places or places where retail shop shop shop shop shop shop shop shop of region Number of patients prior CDK4 and CDC 6D6 means of business business risk, businesses should arise arise 1 1 or places to selling selling selling risk, customers 1 1 day 1 day 1 or 1 day business risk risk risk risk risk; P retail business business business business business business business business risk, market market market market market market market market market market, market market market market market, market, market, market market, market, market, market market market, market, market, market, market market market market, market market, market, market, market, market, market market, market, market, market, market, market, market market, market, market, market, market, market, market market market, market, market, market market market market market market market market market market market market market market market, market market market market market market, market, market market market, market, market, market, market market market market market, market market market market market market market, market, market, market market, market, market market market market market market, market.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria",
        "start_page": 123,
        "end_page": 135,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "(n=254) 1 patiently or only if the risk of premature anticancer drug therapy and TBRA-mutant prior treatment with an plus docetaxel tumor MEK inhibitor or any (same schedule) docetaxel-containing 3) With WHO (n=256) regimenn was excluded performance status of 0 or 1 poulo et al US study Arm 1, erlotinib 150 1) Patients reflexory to 1) Patients aged ≥ 18 1) Subjects whose tumor 1°: 8-week diseas mg once daily more than one prior years with harbours the EML4-ALK control rate (n=22) those who were randomly pathological fusion gene (unless the 2°: OS, PFS, ORR an approved, limited by\n\nIn this case, the Commission shall also consider the best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best established brain expression level Hong Kong, every 3 weeks with immune-stimulatory 2) Patients with known metastas Hungary, Italy, Mexico, Norway, (n=290) antitumour agents EGFR mutation or ALK including checkpoint-location could Peru, Poland, target agents, and target agents, and previous reception of or Switzerland), Switzerland, Switzerland, Switzerland use of serum, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, we are an additional line of TKI Federation, excluding check-location could, and a Singapore, Spain, Singapore, Spain, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland, Switzerland use to maintenance to maintenance to maintenance we an maintenance to maintenance the maintenance the chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain chain labour labour work business business business business business business business business, business, business business business business business, business business business business business, business, business, business business, business, business business, business, business, business, business business, business, business, business, business, business, business, business, business, business, business, business, business, business, business, business. In the absence of any comments, the Commission will examine whether the measures at issue in the main proceedings constitute State aid within the meaning of Article 107 (1) of the Treaty and Article 108 (1) of the Treaty. Hops of end point TTP and Included in Danish t commission and reason Excluded Population with no relevant mutation Trial name, Dates of study, Interventions Prior therapy Inclusion crieria Exclusion crieria Primary and included in Danish NCT ID, Study design, Study location or details, secondary endpoint submission and Study names, Phase of region Number of patients reasonable study Pillai et al 2020 (110) International Gatespib 150 1) Patients who had 1) Patients with stage 1 °: PFS, OS in patients between April and 1°: OS study considered mg/m2 IV on days 1 submitted following IIIB or IV brain metases NCT01798485 2°: PFS, OS in patients between April and 15 + DoCetumumumumumum ofum ofum ofum ofum ofum ofum ofum ofum ofum ofum ofum of square square square square square with elevated GALAXYKX or IV brain metases NCT NCT 79 8798485 2: PF, US II II II II II II II II II II II II I W W W W W respectively IV, W respectively IV, W respectively IV, W respectively D D D I I I I I I I I I I I I 1 1 year 2 and 1 year year 2 S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S\n\nHopefully harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder than harder. If the risk of non-squamous or history of cardioc disease, MRT01244191 2°: PFS and safety and Russia, the Tivantinib 360 mg system anticancer IV non-squamous or history of cardioc disease, MARQUEE United States, twice only orally applicable, including superior NSCLC, ECOG PS, PSQ1 uncontrollable IV non-squamous or history of cardioc disease, NCT01244191 2°: PFS and safety and safety and russia, the Tivantinib 360 mg systemic anticancer IV non-squamous or history of cardioc disease, MRT01244191 2°: PFS and safety and safety as well as RUSIA, the Tivantinib 360 mg systemic cancer IV non-squamous or history of cardiovascular disease, MRT0124491 United States, or otherwise only orally applicable, including risk management NSCLC, ECOG PS of 0.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria",
        "start_page": 123,
        "end_page": 135,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 2
      }
    },
    {
      "text": "In this case, patients who had MET positive with ECOG 2) Patients with interstitial 2013). 150 mg (n=2 active active progressive disease Place IV + infection, uncontrolled GI of an EGF, patients who had MET positive with ECOG 2) patients with interstitial with ECOG 2) patients with interstitial 2013). 150 mg (n=250) patients with interstitial 2013). 150 mg (n=250) patients with interstitial 2013). 150 mg (n=250) patients with interstitial 2013.). < 150 mg/dL and 2) Patients with disease + erlotinib 43 mg adequate progression at the time of for 21 days (n=103) hematopoietic, study entry hepatic and renal function atary endpoiin ORR, CR, and included in nt submission reason PR, Excluded No intervention Danish and relevant Appendix Table 4. Baseline characteristics from 5 RCTs that provided data in patients with KRAS G12C-mutated NSCLC Trial name, Treatment arm Age, Male, n (%) PD-L1 KRAS e ) c s ua Included in DMC on expression, [ 95% CI] s u o m m m a u n u n gs lle , n (%) PD-L1 KRAS e ) c u r)\n\nCarter et al 2016 Sélumetinib 64 a 4 (36) Current: 0 (0) 0 (0) - - KRASm: 11 (100) (n=11) (50 / 83) Former: 11 KRASmG12C: 4 (36) NCT01229150; (100) Excluded CTEP: 8444 Not relevant Phase 2 Erlotinib+ 66 14 (47) Current: 9 (30) 0 (0) - - - - KRASm: 30 (100) comparators selumetinib (58-82) Former: 21 (70) KRASmG12C: 8 (27) (n=30) Gerber et al 2018 Erlotinib + 64 18 (35) Current: 3 (6) - - - - - - KRASm: 51 (100) (104) tivantinib (n=51) (IQR, 55) Former: 43 (84) KRASmG12C: 26 (51) Excluded NCT013957 70) Not relevant Phud 2 stocks\n\nThe results of the studies are based on the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out and the results of the studies carried out.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria",
        "start_page": 123,
        "end_page": 135,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 3
      }
    },
    {
      "text": "Only the publication by Skoulidis 2021 qualified for inclusion concerning sotorasib as monotherapy in the correct population with the latest data-cut of as of 15 March 2021. Included and excluded publications from electronic searches. KARMASR Sm001B_N SAT_FTSRCLC Decisions_19 May 2021_For Report_updated_June_2021.xlsx Appendix Figure 2.Student flow of included and excluded single-arm trials Appendix Table 5. Summary of 44 included single-arm studies\n\nWithin 28 DCR, PFSighter 3;\n\nIn the absence of evidence, the Commission considers that the measures in question constitute State aid within the meaning of Article 107 (1) of the Treaty on the Functioning of the European Union (TFEU) and Article 107 (1) of the Treaty on the Functioning of the European Union (TFEU) and Article 108 (3) of the Treaty on the Functioning of the European Union (TFEU) and Article 108 (3) of the Treaty on the Functioning of the European Union (TFEU) and Article 108 (3) of the Treaty on the Functioning of the European Union (TFEU) and Article 108 (3) of the Treaty on the Functioning of the European Union (TFEU) and Article 108 (3) of the Treaty on the Functioning of the European Union (TFEU) and Article 108 (3) of the Treaty on the Functioning of the European Union (TFEU) and Article 108 (3) of the Treaty on the Functioning of the European Union (TFEU) and Article 108 (3) of the Treaty on the Functioning of the European Union (TFEU) and Article 108 (3) of the Treaty on the Functioning of the European Union (TFEU) and Article 108 (3) of the Treaty on the Functioning of the Functioning of the European Union (TFEU), the Treaty on the Functioning of the Functioning of the European Union and of the European Union (TFEU). b ≥ 3: 20 (100) Advanced or N CHT: 20 (100) metastatic solid BEV: 10 (50) tumors; standard of Nivolumab: 1 (5) care infective or TKI: 19 (95) inapropiate; Crizotinib: 1 (5) ≥ 20 years old; ECOG Erlotinib: 10 (50) PS ≤ 2; no significant Gefitinib: 13 (65) comorbidity: 1 (20) NSCLC expansion: pathologically or cytologically confirmed NSCLC (IIIb or IV); Measurable disease per RECIST v1.0; one of the following: EGFR mutation (plus prior treatment with an EGFR inhibitor); KRASm; gene fusion of RET, ROS1, or ALK (prior treatment with an ALK inhibitor) Key Ex Crit R xclusion teria Key Primary and Summary MTRPs and 1\n\nLowercase of Country NCT0264/01 United States Gandara, 201 USA NCT ID, Study Dates Intervention Prior therapy Key Inclusion or Criteria Key Exclusive and Name, Phase of Number of Criteria Secondary Study Patients with LoT Median (Range), Endpoints/Objectives NSCLC in Total Number or n (%) 42 NCT0264204 18 Jul Docetaxel and 1:16 (29.6) KRASm and known NR Primary: ORR in all KRASm 2016 to trametinib 2: 38 (70.4) KRASm subtype; NSCLC Secondary: ORR, OS, and Phase 2 15 May 54 KRASG12C IV or recover; PFS in KRASG12C and 2019 1: 6 (31.6) Measurable disease KRASm Non-G12C; grade 2 (68.4) GREIG; UK 1 (31.6)\n\nIlli== home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home house home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home\n\nNCTPLEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LE-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-LEI-I-LEI-LEI-LEI-LEI-LEI-LEI-I-LEI-LEI-LEI-I-I-I-I-I-I-I-I-I-LEI-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I-I\n\nDisease and ophthalmopathy Froesch, 2020 NCT02964689 Enrollme Binimetinib, NR Stage III - IV NSCLC NR NR Switzerland nt: May pemetrexed and unsuitable for curative Phase 1b 2017 to cisplatin treatment; PS 0 to 1, Dec 2019 18 KRASm; no prior systemic therapy Desai, 2020 NR Conduct Liquidafenib All cancers: ≥ 3 (inc.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Local adaptation",
        "start_page": 135,
        "end_page": 153,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Histologically or Untreated Primary during dose Australia & ed: 20 19 (9 dose B-RAF inhibitor cytologically confirmed Leptomeningeal or escalation: safety and New Zealand Phase 1 Nov 2013 escalation + 10 treatment) 50% advanced/metastatic brain metastases; tolerability, including DLT to 19 Oct dose expansion) prior surgery ≥ 75% solid tumours;\n\nIn the absence of evidence, the Commission will assess whether there is a risk of serious injury to the Union industry and to the Union industry. Level of risk of risk of loss of risk of loss of equity risk of loss of equity risk of loss of equity risk of loss of equity risk of loss of equity risk of loss of equity risk of loss of equity risk of loss of equity risk of loss of equity risk of loss of equity risk of loss of equity risk of loss of equity risk of equity risk of loss of equity risk of loss of equity risk of equity risk of loss of equity risk of equity risk of loss of equity risk of equity risk of loss of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of equity risk of risk of risk of risk of risk of risk of risk of equity risk of equity risk of equity risk of risk of equity risk of equity risk of equity risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of risk of\n\nICIs NCT02031458 NR Atezolizumab None BIRCH 204 Phase 2 NCT01988896 27 Dec Atezolizumab 3 (0-11) ECOG PS 0 or 1; Knowledge or active Primary: safety and 2013 to 9 and cobimetinib sensitive disease untreated CNS tolerability l Phase 1b May 28 per RECIST v1.1.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Local adaptation",
        "start_page": 135,
        "end_page": 153,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Levels of measures; Secondary: 76 overall 2016 autoimmune response; DoR, PFS, OS disease; Prior therapy with T-cell-modulating agents; Prior intolerance to a MEK inhibitor 20 NCT02779751 14 Nov to Abematiclib and Cohort A: CHT-naïve Cohort A CHT-naïve NR Primary: number of 3 Feb pembrolizumab Cohort B: 68% 1 prior with ≥ 1% TC PD-L1 participants with SAEs Phase 1b 2020 50 line of CHT sustaining, KRASm non- and non-SAEs (estimate squamous NSCLC Secondary: ORR, DCR, d Cohor B squamous DoR, PFS, OS, PK completi subtype; ≤ 1 prior on: 29 platinum-containing Oct CHT regime 2021)\n\nCryptoShhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh\n\nThese included 5 records that related to the CodeBreak 100 trial of sotorasib and 1 that related to another adadrasib, which is another KRASG12C inhibitor that is in development but not yet licensed for use. The other records related to therapies that are not comparators for sotorasib, and so do not inform this address of sotorasib.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Local adaptation",
        "start_page": 135,
        "end_page": 153,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 2
      }
    },
    {
      "text": "The global study SLR for single-arm systems included 44 references, and in the local adaptation 43 references were included market red in Appendix table 3. The global SLR for evidence was added to support the application as some results were not reported in the primary publications of the studies (71). Eligibility Inclusion Criteria Exclusive Criteria Population Patients with NSCLC (any stage, any line of Tumor types other than NSCLC treatment) carrying a KRAS G12C mutation or any other KRAS mutation Note and other KRASm)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Local adaptation:",
        "start_page": 153,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "According to the Commission's assessment, the Commission considers that the Commission's assessment of the compatibility of the aid with the internal market is not sufficient to assess the compatibility of the aid with the internal market. Ø +45 70 10 36 00 medikraadet@medicinraadet.dk Yes Med anne, dicrinrå NCT01 SELEC Internal stu ydet Dampfae 19339 con nect CT-1, bet nationale een udy Oct ber and Jan ry Ærgevej 27-29, Amgen Proprietary - For Internal Use Only platinum-2 weeks based on before combination initiation of therapy, soorasib targeted therapy, therapyes, or myocardial both infarction within 6 months and 75 mg of 1) Patients 18 1) Mixed 1°: PF ned selumetin years or small cell had 2°: tw ib older DOR, with and non-",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Conclusion of the global SLRs and the local adaptation",
        "start_page": 154,
        "end_page": 156,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The literature search added to the highest standards for conducting and reporting. The SLR was re-fitted for the purpose of the assessment in Denmark using the same methodology.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Quality assessment",
        "start_page": 156,
        "end_page": 156,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The data-on file from CodeBreak 100 trial use for this submission were in full study report and were developed to support regulatory submission to EMA/FDA. The data analysis thereunders to the most stringent quality criteria. Table 38 Ongoing studies that may inform the evidence base for sotorasib and comparators Page 150/237 Medicinsrat Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medicraadet@medicinraadet.dk Appendix B - Table 39: Main study Trial name: CodeBre Objective Publications\n\n• An ECOG performance score of 0 to 1 (on a scale from 0 to 5). • Measureable disease according to RECIST, version 1.1.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Unpublished data",
        "start_page": 156,
        "end_page": 159,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Exclusion: • Active unlimited brain metastases. • The receive of more than three previous lines of therapy. • The receive of systemic anticancer therapy within 28 days before the initiation of soorasib therapy. • The receive of therapeutic or palliative radiation within 2 months before the initiation of soorasib therapy. • Previous treatment with a direct KRASG12C inhibitor. • Myocardial infection within 6 months of study day 1. • Gastrointestinal disease causing the inability to take oral medication. • Level of risk-benefit analysis: • Level of risk-benefit analysis: • Level of risk-benefit analysis: • Level of risk-benefit analysis:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Unpublished data",
        "start_page": 156,
        "end_page": 159,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "This is the case for patients with severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease infection disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease\n\nDK-2100 København Ø +45 70 10 36 00 medicinraadet@medicinraadet.dk Trial na Main in exclusive Interven Compar Medicinrae ame: SE inclusio on criteria rator(s kadet D ELECT-on and eria s) Steamfa Ærgevej Amgen Proprietary - For Internal Use Only NCT number: NCT01933932 Main inclusion: • Provision of signed, written, and dated informed prior to any study specific procedures • Male or female, aged 18 years or older • Hisological or cytological confirmation of locally advanced or metastatic NSCLC (IIIB-IV) • KRAS mutation positive tumor sample as determined by the designed testing laboratory • Failure of 1st line anti-cancer disease the treatment to radiologic NSCLC (IIIB-IV)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 40: SELECT-1 • Study Characteristics",
        "start_page": 159,
        "end_page": 160,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "• Medium-sized small cell and non-small tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue tissue\n\n• Matched placebo in combination with 75 mg/m2 of docetaxel intravenously on day 1 of every 21-day cycle All patients received granulocyte stimulating factor (G-CSF) or, where available, pegylated G-CSF (pegfilgrastim) starting within 24 hours following each docetaxel administration and not within 14 days before the next docetaxel dose. Patients received study treatment until objective disease progression, intolerant toxicity, or withdrawal of study consent.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Main exclusion:",
        "start_page": 160,
        "end_page": 161,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Patients could continue to receive treatment following disease progression as long as the investigator considered them as continuing to inherent clinical benefit in the absence of significant toxicity.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Main exclusion:",
        "start_page": 160,
        "end_page": 161,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Primary, secondary and exploratory endpoints Medicinal product Board Steamfærgevej Amgen Proprietary - For Internal Use Only NCT number: NCT019339 Median duration of follow-up for overall survival: placebo + docetaxel, 12.2 months ( Median duration of follow-up for progression-free survival: placebo + docetaxel, 4.2 months (IQR, 0.03-11.1) Yes Primary Outcome variable: PFS using investigator site assessments according to RECIST 1.1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Health economic model?",
        "start_page": 161,
        "end_page": 161,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "OS ORR using investigator site assessments according to RECIST 1.1 DoR using investigator site assessments according to RECIST 1.1 Time to symptom progression as measured by the Average Symptom Burden Index (ASBI) score of the Lung Cancer Symptom Scale (LCSS) Symptom improvement rate as measured by the ASBI score of the LCSS",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Secondary Outcome Variables:",
        "start_page": 161,
        "end_page": 161,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "• Advise events • Clinical chemistry, hematology, and urinalysis • Vital signs • ECHO/MUGA • Ophthalmological examination",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Safety:",
        "start_page": 161,
        "end_page": 161,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "With regard to the risk/benefit analysis, the Commission considers that the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit analysis of the risk/benefit/benefit analysis of the risk/benefit/benefit analysis. The narrowest treatment difference that would be statistically significant at the final analysis is an OS HR of approximately 0.80 (0.796 if exactly 325 OS events).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Exploratory Outcome Variables:",
        "start_page": 161,
        "end_page": 163,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Female) • Age at randomization (< 65 vs. = 65) • Smoking status (smoker vs. non-smoker) • Status of disease (Locally advanced vs. Metastatic) The purpose of the subgroup analyses is to assess the similarity of treatment effect across expected prognostic factors but from the results observed in Phase II (D1532C00016) it is not expected that these factors will be previous factors for a qualitatively different treatment effect. No adjustment to the signance level for testing will be made since all these analyses will be considered supportive of the primary analysis of PFS. Pages 156/2327-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medicindraet@sevid.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Exploratory Outcome Variables:",
        "start_page": 161,
        "end_page": 163,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The Commission considers that the Commission's decision to initiate the procedure laid down in Article 108 (2) of the Treaty on the Functioning of the European Union to initiate the procedure laid down in Article 108 (3) of the Treaty on the Functioning of the European Union (TFEU) has not been taken into account. M.static disease level at baseline (% IIIB (vs IV) ] % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Other relevant information None",
        "start_page": 163,
        "end_page": 164,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Please consult section 12.1.1 for a comparison of patients across studies.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Comparability of patients across studies",
        "start_page": 164,
        "end_page": 164,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Please consult section 8.2.2.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Comparability of the study populations with Danish patients eligible for treatment",
        "start_page": 164,
        "end_page": 164,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the only way to ensure that the risk is assessed in the light of the above considerations. SELECT-1: AEs were collected from the time of informed consent until 30 days (±7) after the last dose of the last study treatment according to the CTCAE v.4.03 (72). Time to symptom Groenvold, M., Klee, M. progression and C., Sprangers, M., & EORTC QLQ-C30 (73) Aaronson, N. K. (1997) Validation of the EORTC QLQ-C30 quality of life questnaire through combined qualitative and quantitative assessment øgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 menly Clinical relevance g & The minimal clinical difference for OS is a median of 3 months (7). g The minimal clinicly important d difference for treatment due to AEs is 5%.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Definition, validity, and clinical relevance of included outcome measures",
        "start_page": 164,
        "end_page": 166,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Trials of CodeBreak 100 (NCT03600883) (73) Results of CodeBreak 100 (NCT03600883) (73) Estimated Estimated Desc absolute relative of m difference in difference in used effect effect effect estim Outco Study N Result Differe 95% CI P value Differ 95% CI P v v v me arm nce ncnce median Sooras 126 6.8 NA NA NA NA NA PFS ib months (CL95% Median Sooras 126 12.5 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Ib months (CL95% NE) *At the Skoulidi data s et al. cut-off-of- 2021 (7 in 3) March The median PFS is based on the Criteria for Adverse references references methods d for m aile *At the Skoulidi data s et al.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Results per study",
        "start_page": 166,
        "end_page": 167,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "cut-off 2021 (N 7 in 3) Jan-ind 7 in 3) Market Market market market Market i S.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Results per study",
        "start_page": 166,
        "end_page": 167,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Pharmaceutical Council D deBreak 100 oras 126 oras 126 oras 126 oras 126 oras 126 oras 126 Dampfærgevej 0 (NCT03600 j 27-29, 3. th. Amgen Proprieta NA NA NA 6 NA NA NA NA * NA NA NA DK-2100 København ary - For Inte NA NA NA NA NA n Ø +45 70 1 ernal Use Only NA NA NA NA NA NA NA NA NA NA NA NA 10 36 00 medicineraa NA *At the Skoulidi data s et al. cut-off 2021(7 in 3) March NA *At the Skoulidi data s et al. cut-off 2021(7 in 3) March NA *At the data on data file(75) cut-off in March NA *At the Skoulidi data s et al. cut-off 2021(7 in 3)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 167,
        "end_page": 167,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Page 161/237 adet@medicinraadet.dk X X X X X X X X X X X X X X Medicine Council D Steamfae Ærgevej j 27-29, Am , 3. th. DK-21 mgen Propriet 100 Københavtary - For Internal Use Only vn Ø +45 70 10 36 00 medicinera aadet@ X X X X X X X X X X X X @medicinraade et.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 167,
        "end_page": 168,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Medicinsrå atet Dampfae Am ærgevej 27-29, 3.th. DK-21 mgen Proprietary - For Internal Use Only 100 København Ø +45 70 10 36 00 medicins aadet@medici inraade Page 163/237 et.dk Medicationsrå atet Dampfae Am Ærgevej 27-29, 3.th. DK-21 mgen Proprietary - For Internal Use Only 100 København Ø +45 70 10 36 00 medicinsra aadet@@medici inraade",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 169,
        "end_page": 170,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "et.dk Medicinsrå atet Dampfae Am Ærgevej 27-29, 3. th. DK-21 mgen Proprietary - For Internal Use Only 100 København Ø +45 70 10 36 00 mediciera aadet@@medici inraade",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 164/237",
        "start_page": 170,
        "end_page": 171,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "et.dk Am Data cut-off date 01 September 2020 N = number of subjects in the analysis set; n = num Medicinsrådet Dampfærgevej 27-29, 3. th. DK-21 mgen Proprietary - For Internal Use Onlymber of subjects with observed data; SD = stand 100 København Ø +45 70 10 36 00 medicera dard deviation aadet@medici n inraade",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 165/237",
        "start_page": 171,
        "end_page": 172,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "NCT019 Lect-1 (NCT019 Done xel s due to Place s due to Place to Placeb AEs o + NCT019 Lect-1 (NCT01933932) Docet xel AEs o + NCT019 Lect-1 (NCT01933932) Docet xel AEs Selum grade etinib N (NCT019 Lect-1 (NCT01933932) Docet xel AEs Selum grade etinib NCT019 Lect-1 (NCT01933932) Docet xel AEs Selum grade etinib N (NCT019 Lect-1 (NCT019 Lect-1 (NCT01933932) Doct xel AEs Selum grade tinib NC (NCT01933932) Doct xel AEs Selum grade n c 2 3.9 (1.5- 1.1 b 5.9) Mo 4 months Ta b 2 2.8 (1.4 to 6 months m 2 8.7 (CT0.9 0.9 0.9 0.9 b 5) Est d) Est-1 (NCT 1 (NCT0.9 B 5 5 5 5) M 5) M) M M M M 4 months 1 1 b 1 b b b b b 2 7 b B 2 7 7 7 7 7.9 (. (.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 166/237",
        "start_page": 172,
        "end_page": 176,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "8 7 (. 8 9.8 8 9 8 9 8 9 8 8 8 8 8 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8. 8. 8. 8. 8. 8 8 8 8 (. 8 (. 8. 8 8 8 8 8 8 8 8 8 8 8 8 8 8. 8 8 8 8 8 8 8 8 8 8 8 8 8. 8. 8 8. 8. 8. 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8) M 8) M 8) M 8) M 8 8 8 8 8 8 8 8 8 8 8 8 8 8)\n\nNA Seawaywaywayway home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home home\n\n2100 Buy ropriet erven asib (C n de benhav tary - For Internal Untion and co CodeBreak-100)* n=126 Grade 3+ vn Ø +45 70 10 36 0 Use On ompa 00 me nly arator(s) Docetaxel + pl Any Grade NR NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA edicinraadet@medici placebo n=254 inraade o (SELECT-1) Grade 3+ NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA Sid et.dk de 169/237 medicinraadet.dk Amgen Proprietary - For Internal Use Only Neutrophil count decrease 1 (0.8) 1 (0.8) NA Abnormal aminotransferase level 1 (0.8) 1 (0.8) NA * Treatment-related adverse events (TRAEs), Advise events were: use of the Common Tevents version **",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 166/237",
        "start_page": 172,
        "end_page": 176,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Serious adversaries with Ørhing Gatewaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway\n\nHidewaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 46 Serious adverse events",
        "start_page": 176,
        "end_page": 181,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Medicinsrådet Dampfærgevej 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 medicinra aadet@@medici inraade Page 175/237 et.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 52 Treatment related adverse events from SELECT-1",
        "start_page": 181,
        "end_page": 182,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Table 53 Naive comparison of safety data grade 3+ and discontinuation due to AES comparing sotorasib to docetaxel Absolute difference in Relative difference in Method used Result effect effect for used in quantitative the Studies Difference CI P Difference CI P synthesis health included in the value value economic analysis? Grade 3+ CodeBreak 100 16% (61%- NA NA 35.5% NA NA Naïve no adverse events & SELECT-1 45%) comparison CodeBreak 100 -5.8% (8.7%- NA 40% NA Naïve no & SELECT-1 14.5%) comparison Due to AEs ((14.5%-- NA 40% NA Naïve no & SELECT-1 14.5%) comparison due to AEs ((14.5%-",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X",
        "start_page": 182,
        "end_page": 182,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Please consult section 8.3 for information on extrapolations of time-to-event data.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix G - Extrapolation",
        "start_page": 182,
        "end_page": 182,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Page 176/237 Medicinsrådet Dampfærgevej 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 Medicinsraadet@medicinsraadet.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X *generated using muhaz package for ITT population (N =126)",
        "start_page": 182,
        "end_page": 182,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "*genera Appen Not app App App Appen Not app Medicinsrå Amgen Proprietary - For Internal Use Only ated using muhaz package for ITT population (N =123) ndix H - Literature search for HRQoL data plicable, no literature search for HRQoL data has been conducted. ndix I - Mapping of HRQoL data plicable, no mapping of HRQoL data has been conducted.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 183,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Medicinsrådet Dampfærgevej 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 medicinraadet@medici is in Ta ty ana inraadeable 54. All values alysis",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "et.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 178/237",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Medications raw ate D Steamfae Ergevej",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 185,
        "end_page": 185,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "j 27-29, 3. th. Amgen Pr.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 185,
        "end_page": 185,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "DK-2100 Buy roprietary - F",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 185,
        "end_page": 185,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Benhavn Ø + For Internal U",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 185,
        "end_page": 185,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Use On 00 me nly",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 185,
        "end_page": 185,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "edicinraadet@medici inraade et.dk Sid de 179/237 medicraadet.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X",
        "start_page": 185,
        "end_page": 185,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Medications raw ate D Steamfae Ergevej",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 186,
        "end_page": 186,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "j 27-29, 3. th. Amgen Pr.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 186,
        "end_page": 186,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "DK-2100 Buy roprietary - F",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 186,
        "end_page": 186,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Benhavn Ø + For Internal U",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 186,
        "end_page": 186,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Use On 00 me nly",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 186,
        "end_page": 186,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "edicinraadet@medici inraade et.dk Sid de 180/237 medicraadet.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X",
        "start_page": 186,
        "end_page": 186,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Medication raw ate D Steamfa Ergevej Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 187,
        "end_page": 187,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "j 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 medicinadet@medici inraade et.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 187,
        "end_page": 187,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 181/237",
        "start_page": 188,
        "end_page": 188,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The equivalent methods are based on best practices and best practices in the field of health and safety at work.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.1.1.1 Data sources",
        "start_page": 188,
        "end_page": 188,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In this regard, it is considered that the bestappappropriate best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.1.1.2 Compatibility of data sources",
        "start_page": 188,
        "end_page": 189,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key secondary Centrally-qualified PFS; OS",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Endpoint",
        "start_page": 189,
        "end_page": 189,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Investigator-qualified PFS; OS Key: ECOG, Eastern cooperative oncology group; KRAS, MEK, mitogen activated protein kinase; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; VEGFR, vascular endothelial growth factor receptor; WHO, World Health Organization CodeBreak 100 and SELECT-1 were both multicentre studies that recruited patients with confirmed locally advanced or metastatic NSCLC (Stage IIIB",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "endpoints",
        "start_page": 189,
        "end_page": 189,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "SELECT-1, by both inherently central review and by investigator in CodeBreak 100. DK-2100 remains in København Ø +45 70 10 36 00 medicieradet@medicinraadet.dk Amgen Proprietary - For Internal Use Only Gender (% female) 50% 43% Brain metastases (%) 21% NRc Performance status (ECOG or WHO; 70% 59% % PS 1 [vs PS 0]) Race (% white) 82%d 95% % KRAS G12C-mutated 100% 42%b Anti-PD-(L) 1 in prior line(s) 91% 0% Number of prior lines (% with 1/2/3 43%/35%/22% 100%/0% prior lines) Metastatic disease at baseline 96% 96% Histology (% Non-squalmous) 99% 95% Smoking status (% ever smoker) 93%e 92% Other targetable mutations (EGFR, 3% NRf ALK, BRAF, ROS-1) PD-L1 expression at baseline (<5% 48% 58% [vs > baseline) KEYE: ECOG, European Co operative group",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "The two studies reported PFS and OS as primary or secondary endpoints. PFS was assessed by investigators in",
        "start_page": 189,
        "end_page": 190,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The data are considered to reflect PFS and OS findings with soorasib and placebo plus docetaxel following prior therapy in this population of patients. A propensity score weight analysis approach such as as MAIC requires the matching of prognostic patient characteristics to generate robust comparable treatment effect estimates. Due to missing data or other differences between the trials it would not be possible to match across all markets. However, PFS and OS findings are found to exist Perhaps for patients with each successive line of therapy. Given that CodeBreak 100 included 57% of patients with 2 or more prior lines of therapy, a comparison of PFS and OS data from the whole of the CodeBreak 100 NSCLC population against PFS and OS data from patients in SELECT-1, who had received only one prior line of therapy, is useful to be conservative.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.1.1.3 Conclusion on the feasibility of undertaking indirect comparisons",
        "start_page": 190,
        "end_page": 191,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In this regard, the Commission considers that the Commission's assessment of the compatibility of the aid with the internal market does not lead to any distortion of competition within the meaning of Article 107 (3) (c) of the Treaty.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.1.2.1 Estimation of weights",
        "start_page": 191,
        "end_page": 191,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The reduced weights were calculated using the following formula: The robustness of the analyses will be also considered by aiming the effective sample size (ESS). For a weighted estimate, the ESS is the number of independent non-weighted individuals that would be required to give an estimate with the same precision as the weighted sample estimate. A small ESS, relative to the original sample size, is an indication that the weights are highly variable due to a black of population overlap, and that the estimate may be unstable.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.1.2.2 Calculation of rescaled weights",
        "start_page": 191,
        "end_page": 191,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The following formula was used to calculate the ESS:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.1.2.3 Calculation of effective sample size",
        "start_page": 191,
        "end_page": 191,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Even if the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the\n\nIn SELECT-1, howver, aggregate data were presented for the expression groups <5% and ≥5% only; there, it was not possible to perform the matching based on the categories identified as relevant by the physicians.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.1.2.4 Statistical analysis for incorporating weights",
        "start_page": 191,
        "end_page": 192,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Scenarios involving the alternative MAIC approaches are presented in this section. MAIC SET 2 (Section 12.1.3.1) is the scenario where all available covariates were used.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.1.3 Alternative scenarios for use in MAIC",
        "start_page": 192,
        "end_page": 192,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The results for SET 2 are better than Model 1 but these are more uncertain as these are based on narrower ESS. As such, SET 1 was chosen as base case.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.1.3.1 MAIC SET 2 • using all available covariates",
        "start_page": 192,
        "end_page": 192,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Sot, Sotorasib, Doc, Docetaxel, CI, Confidence interval, ESS, Effective sample size, HR, Hazard ratio, PFS, Progression-free survival, OS, Overall survival.. N and ESS are for patients in CodeBreaK 100 arm only. a: Investigator, b: Central Review Page 186/237 Medicine Council Steamfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medicraadet@medicinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X",
        "start_page": 192,
        "end_page": 193,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Table 57 Baseline characteristics for SET 2 can be seen in the table below As reported Pre-matching For docetaxel For sotorasib N = 256 N = 98 Covariates SELECT-1 CodeBreaK 100 ECOG (% PS 1 [vs PS x x Age) x x Metastatic at x x baseline (%) Smoking status (% x x ever smoker) PD-L1 expression x level (<5% vs ≥ 5%) Gender (% female) x Histology (% Non- x x squalous) Medicinal product Council Dampfærgevej 27-29, 3. th. DK-2100 Copenhagen Ø +45 70 10 36 00 medicine aadet@ Post-matching For sotorasib N = 98 CodeBreaK 100 x x x x x x x x x x Page 187/237 @medikraadet.dk Amgen Proprietary - For Internal Use Only Race (% white) 95 95",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 13 Distribution of statistical weights of MAIC for SET 2",
        "start_page": 193,
        "end_page": 194,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "GIC BIC AGIC AG2GIGIG2GIGIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GJIG2GIG2GIG2GIG2GIG2GIG2GIG2GIG2GJIG2GIG2GJIG2GIG2GJIG2GIG2GJIG2GIG2GJIG2GJIG2GJIG2G2G2G2GJIG2GJIG2GJIG2G2GJGJGJGJG2G2G2G2G2G2G2G2G2G2G2G2G2G2G2G2G2G2G2G2G2GJIG2GJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJG2G2G2G2G2G2G2G2G2GJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJJJJJJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGJGGG",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.1.3.1.1 Overall survival",
        "start_page": 194,
        "end_page": 195,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "et.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 189/237",
        "start_page": 195,
        "end_page": 196,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: MAIC, matching-adjusted indirect comparison; OS, overall survival.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 15. Schoenfeld Residuals Plot for OS Using MAIC SET 2",
        "start_page": 196,
        "end_page": 196,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: MAIC, matching-adjusted indirect comparison; OS, overall survival. Medication Council Dampfærgevej 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 medicera aadet@@medici inraade",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 16. QQ Plot for OS for MAIC SET 2",
        "start_page": 196,
        "end_page": 196,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "et.dk Amgen Proprietary - For Internal Use Only A plot of adjuvant OS KM data and the standard six parametric functions jointly tied with restricted model presented in Error! Reference source not found..",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 190/237",
        "start_page": 196,
        "end_page": 197,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: Doc, docetaxel; KM, Kaplan-Meier; MAIC, matching-adjusted indirect comparison; OS, overall survival; Sot, sotorasib.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 197,
        "end_page": 197,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "More [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...] [...]",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "1.1.2.1.2 Progression-free survival",
        "start_page": 197,
        "end_page": 198,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: MAIC, matching-adjusted indirect comparison; PFS, progression-free survival.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 17. Log-Cumulative Hazards Plot for PFS Using MAIC SET 2",
        "start_page": 198,
        "end_page": 198,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: MAIC, matching-adjusted indirect comparison; PFS, progression-free survival. Medicinrådet Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medicinra aadet@@medici inraade",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 18. Schoenfeld Residuals Plot for PFS Using MAIC SET 2",
        "start_page": 198,
        "end_page": 198,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "et.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 192/237",
        "start_page": 198,
        "end_page": 199,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: MAIC, matching-adjusted indirect comparison; PFS, progression-free survival. A plot of adjuvanted PFS KM data and the standard six parametric functions join presented in Error! Reference source not found..",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 19. QQ Plot for PFS for MAIC SET 2",
        "start_page": 199,
        "end_page": 199,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: Doc, docetaxel; KM, Kaplan·Meier; MAIC, matching-adjusted indirect comparison; PFS, progress",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 199,
        "end_page": 199,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "See also Case C-107/10 P Commission v Italy EU:C:2011:71, paragraph 52. • One other restriction is that it was not possible to adjust on all key characteristics due to either a black of overlap (KRAS G12C, anti-PD-1 in prior line, number of prior lines) or black of data (% with controlled brain metastases, presence of other targetable mutations is very raw in KRAS mutated patients. • The proportion of patients with controlled brain metastases (both trials excluded patients with active brain metastases) was not reported in SELECT-1 and was 21% in CodeBreak 100 previous matches.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.1.4 Strengths and weaknesses of the MAIC analysis",
        "start_page": 199,
        "end_page": 201,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "21,97% of the retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail retail",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.2 Flatiron property weighting score analysis",
        "start_page": 201,
        "end_page": 202,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The index dates for subjects in CodeBreak 100 refer to the date at which the first dose of sotorasib was administered. Patients from the Flatiron real-world cohort may have received more than one LOT. Therefore, the index date for these patients refers to the date of the selected LOT. In particular, for the Flatiron coin the index date was selected as follows: • If a patient received ≥ 2 but ≤ 4 lines of the study on/before 31 March 2020, the last LOT that met the inclusion criteria was selected. • If a patient received more than more than four lines on/before 31 March 2020, the 4th line was selected in the 4th line contained (a) a clinical study or tested lines on/before 31 March 2020, the 4th line was selected in the 4th line contained.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.2.1 Index date",
        "start_page": 202,
        "end_page": 202,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "• Levels of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis • Level of analysis . Finally, subjects were removed from the comparator arm if their treatment was not chemotherapy based.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.2.1.2 Analysis sets",
        "start_page": 202,
        "end_page": 203,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In particular, active treatments with anti PD-1 and other non-chemotherapy-based treatments were excluded. Page 196/237 Medicinsrådet Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medicinraadet@medicinraadet.dk Amgen Proprietary - For Internal Use Only The KRAS Mutant Analysis Set was defined with the same criteria as the G12C-only Analysis set but including all patients from the FIH-FMI SGDB identified as having any KRAS mutation from an FMI test any time on/before or up to 21 days after the index date, which did not arise in the CodeBreak.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.2.1.2 Analysis sets",
        "start_page": 202,
        "end_page": 203,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The output of clinical expert evaluation to determine the important prognostic factors for NSCLC are presented (Table 61). Page 197/237 Medicinsrådet Dampfærgevej 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 medicraadet@medicinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.2.2 Propensity score analysis expert elicitation",
        "start_page": 203,
        "end_page": 204,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "More than half of the population is considered to be stable; there was no need to adjust on metastasis at baseline specifically. After adjustment with propensity score weighting, the populations remained balanced PD-L1 protein expression (<1%, 1-49%, >50%) No PD-L1 expression was intended as important for patients anti PD-(L) 1 naïve who are considered to be satisfied with anti PD-L1 protein expression (< 1%, 1-49%, > 50%) No PD-L1 expression was intended as important for patients anti PD-L) 1 naïve who are considered to be satisfied with anti PD-L1 protein expression. In addition to this group, continuing index was also tested in the model Smoking status No % of smokers were very high and balanced before adjustment BMI No Distribution of BMI was very similar across populations Presence of liver metastases (Y; N) No % of patients with liver metastases was overall balanced in the two populations and liver metastasis was a less important factor than metastases Presence of bone metastases (Y; N) No Same considerations as for liver metastases Number of metastatic sites (0.1, 2, 3 or more) No There are potential differences in how the number of metastatic sites in CodeBreak 100 and Flatiron are counted.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Covariate Include (Y/N) Adjustment",
        "start_page": 204,
        "end_page": 204,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Medicinsrådet Dampfærgevej 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 medicraadet@medicinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 198/237",
        "start_page": 204,
        "end_page": 205,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The disposition of patients in the Flatiron KRAS-G12C short, Other KRAS short and the Triple WT short are presented (Error! Reference source not found.).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "- Community action in the field of health and safety at work - proposal for a Council Regulation (EEC) amending Regulation (EEC) No 1408/71 on the application of social security schemes to employed persons, to self-employed persons and to members of their families moving within the Community - proposal for a Council Regulation (EEC) amending Regulation (EEC) No 1408/71 on the application of social security schemes to employed persons, to self-employed persons and to members of their families moving within the Community - proposal for a Council Regulation (EEC) amending Regulation (EEC) No 574/72 on the application of social security schemes to employed persons, to self-employed persons and to members of their families moving within the Community - proposal for a Regulation (EEC) amending Regulation (EEC) No 1408/71 on the application of social security schemes to employed persons, to self-employed persons and to members of their families moving within the Community - proposal for a Regulation (EEC)",
        "start_page": 205,
        "end_page": 205,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This section presents the comparison of baseline characteristics of CodeBreak 100 and Flatiron KRAS mutant (Error! Reference source not found. and Figure 20) and KRAS-G12C (Error! Reference source not found. and Figure 21).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "1.2.4 Propensity score analysis baseline characteristics",
        "start_page": 205,
        "end_page": 205,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Si Medicinrådet Dampfærgevej 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 medicraadet@medicinraadet.dk idea 199/237 et.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X",
        "start_page": 205,
        "end_page": 205,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Pharmaceutical Council Dam mpfærg gevej 27 7-29, 3. t A th. DK-Amgen P-2100 Kø Proprie øbenha etary - F avn Ø + For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 206,
        "end_page": 206,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "+45 70 10 36 00 with y dicinraad",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 206,
        "end_page": 206,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "it@medicra aadet.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 206,
        "end_page": 206,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "k Si cinraade idea 200/237 et.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 206,
        "end_page": 206,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Pharmaceutical Council Dam mpfærg gevej 27 7-29, 3. t A th. DK-Amgen P-2100 Kø Proprie øbenha etary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 207,
        "end_page": 207,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "avn Ø +45 70 10 36 00 with y",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 207,
        "end_page": 207,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "dicinraad",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 207,
        "end_page": 207,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "it@medicra aadet.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 207,
        "end_page": 207,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "k Si cinraade idea 201/237 et.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 207,
        "end_page": 207,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Pharmaceutical Council Dam mpfærg gevej 27 7-29, 3. t A th. DK-Amgen P-2100 Kø Proprie øbenha etary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 208,
        "end_page": 208,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "avn Ø +45 70 10 36 00 with y dicinraad",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 208,
        "end_page": 208,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "it@medicra aadet.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 208,
        "end_page": 208,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "k Si cinraade idea 202/237 et.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 208,
        "end_page": 209,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: BMI, body mass index; DUR, duration; ECOG, European Co-operative Oncology Group; ETHN, metastatic; PREV, previous Note: Balance was assessed by mean differences for binary/categorical outcomes and by standard continuous variables, with a difference of > 10% considered impaired Medicine Council Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medikraad",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 20. Baseline Characteristics for CodeBreak 100 and Flatiron KRAS mutant",
        "start_page": 209,
        "end_page": 209,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": ", ethnicity; GRP, group; MET, dized mean differences for det@medicinraadet.dk Page 203/237 cinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X X",
        "start_page": 209,
        "end_page": 210,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: BMI, body mass index; DUR, duration; ECOG, European Co-operative Oncology Group; ETHN, ethnicity; GRP, group; MET, metastatic; PREV, previous Note: Balance was assessed by mean differences for binary/categorical outcomes and by standardized mean differences for continuous variables, with a difference of > 10% considered impaired",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 21. Baseline Characteristics for CodeBreak 100 and Flatiron KRAS-G12C",
        "start_page": 210,
        "end_page": 210,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "12.2.5.1 Variables Overall survival OS was defined as time from index date to death from any cause. Subjects who did not die were censored on the last date the subject was known to be alive. If the date last knew to be alive is after the data cut-off date, the subject was censored at the cut-off date. For the Flatiron cohort, patients who subsequently became a clinical study drug were censored at the start of the LOT containing the clinical study drug. Month-year granulonity for death date was Imputed using the 15th of the month. Patients with only year-level of liquidity for death date were excluded from the survival analysis.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.2.5 Propensity score analysis methods",
        "start_page": 210,
        "end_page": 210,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This analysis, the investigator-rated disease progression was applied disease progression was applied was applied. It contained risks exceeding risks exceeding risks missing model and the populations of OS and PFS should be based. Si The Council of Medicine Fluffggevej 27-29, 3. th. DK-2100 Copenhagen Ø Ø +45 70 10 mediier i 30 mediier @ medicine @ medicine @ medicine. Si The Council of Medicine Fluffggevej 27-29, 3. th. DK-100.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Progression-free survival in CodeBreak 100",
        "start_page": 210,
        "end_page": 211,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "If there is no evidence of progression, or if there is evidence of progression, or if there is evidence of progression of progression, then there is no evidence that the patient has been identified on the last clinical note date, which refers to the date the patient was last evaluated for rwPFS by their causing physical, if they had no evidence of progression or evidence of progression, or had evidence of progression, of progression, of subsequent LOT but no conclusion.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Progression-free survival in Flatiron",
        "start_page": 211,
        "end_page": 211,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The following criteria shall be used to determine whether there is a risk of serious injury to the health of the patient:\n\nDK-2100 København Ø +45 70 10 36 00 medicraadet@medicinraadet.dk idea 205/237 et.dk Amgen Proprietary - For Internal Use Only • Time from prior line initiation to the index date (<3 months, between 3 and 6 months, more than 6 months) • Albumin at baseline • Liver function (ALT, AST) at baseline • Renal function (eGFR) at baseline Serum lactic acid hydrogenase was also identified as being at last somewhat important for assessing the prognoss of patients with advanced NSCLC; however, there were no subjects with observed values for this covariate in the Phase II portion of CodeBreak 100, the underlying serum lactic acid hydrogenase was extracted from all analyses.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Covariates",
        "start_page": 211,
        "end_page": 212,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "I mean the difference between the means of equity and means of analysis of adult (≥ 18 years), patients with advanced NSCLC from two different studies: a clinical trial of risks arising soorasib and a real-world dataset of patients receiving chemotherapy-based standard of care. The relevance score in this context was the relevance of being treated with soorasib 12.2.5.3.5.3 Populations Index date The index date for subjects in CodeBreak 100 references to the date at which the first dose of soorasib was considered.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.2.5.2 Analysis methods",
        "start_page": 212,
        "end_page": 212,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Two analysis sets are considered: for the main analysis, the KRAS Mutant Analysis Set, which for the FLATIRON piece allowed subjects with any KRAS Mutation, and for example analysis and to check for consistency the G12C-only Analysis Set. Data from the Flatiron piece were filtered to match the key primary inclusion criteria from the CodeBreak 100 Phase II NSCLC portion. The CodeBreak 100 key reliability criteria included in the CodeBreak 100 Phase II trial and who received at least one dose of soolasib were included in the analysis. • The selected LOT does not contain an anti-PD(L)1 drug, unless the subject has already had prior exposure to anti PD-(L)1 drugs in the previous lines • Baseline ECOG ≤ 1.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Analysis set",
        "start_page": 212,
        "end_page": 213,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Finally, subjects were removed from the comparator arm if their treatment was not chemotherapy based. In particular, active treatment with anti PD-1 and other non-chemotherapy-based treatments were excluded. The KRAS Mutant Analysis Set was defined with the same criteria as the G12C-only Analysis set but including all patients from the FIH-FMI SGDB identified as having any KRAS mutation from an FMI test any time on/before or up to 21 days of the index date, which did not comply with the patient's decision.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Analysis set",
        "start_page": 212,
        "end_page": 213,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The steps to carry out the statistical analysis were as follows: 1. Develop the propensity score model by selecting variables considered relevant for discriminating between those who were and were not treated with sotorasib. The final model was used for generating each patient. 2. Evaluate the balance between treatment groups with respect to their propensity score by comparing before and post weighting via box-plots. 3. If a balance is already agreed, conduct the clinical outcome using the resulting weights.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.2.5.4 Statistical methods",
        "start_page": 213,
        "end_page": 213,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Candidate covariates were entered into a logic regression model with sotorasib treatment as the binary response. Covariates identified as being very important were fixed in the property score model, regardless of their statistical signification. The exception to this was PD-L1 protein expression, which had a high proportion of missing data. A stepwise variable selection algorithm was run on the covariates identified as being somewhat important, whereby the AIC (to be limited) was used as the criteria of adding or removing covariates to or from the model. The covariate eGFR was excluded from the model selection due to the high proportion of missing data.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Propensity score model development",
        "start_page": 213,
        "end_page": 213,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "For a continuous variable, the standard differences are calculated according to which the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference between the difference",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Balance diagnostics",
        "start_page": 213,
        "end_page": 214,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The certainty of the result is that the use of PS matching was used for this analysis as the limited sample size of the two studies poses the use of PS matching. The ATT weight, which balances the covariates of the control population to fit the characteristics of the treated population, was applied (136, 137). It works by giving all soorasib treated subjects from the CodeBreak 100 study equal weighting of one and control patients large weight scores: where the subscript i denotes the its subject, Z is approved a value of 1 for treated (sotorasib) subjects and 0 for unlimited subjects, e representatives the property score and want, which is considered a value of 1 for treated (sotorasib) subjects and 0 for unlimited subjects.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Propensity score adjustment method",
        "start_page": 214,
        "end_page": 214,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Though property score weighting methods are useful in reducing the effects of confining, they also lead to a reduction in the effective sample size (ESS). The effective sample size is an estimate of the number of dependent weighted subjects that would be required to maintain the same level of precision as the weighted sample, and can be calculated as follows: ESS = . A small ESS is useful to negatively impact the precision of the estimate. The ESS was calculated for each analysis set for the sotorasib treated and unspecified subjects separately. For the ATT weights, all sotorasib Treated Si Medicinsrat Damfærgevej 27-29, 3. th.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Effective sample size",
        "start_page": 214,
        "end_page": 215,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "DK-2100 København Ø +45 70 36 00 medicins Vervad@edevacik.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Effective sample size",
        "start_page": 214,
        "end_page": 215,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "A propensity score analysis can only be performed when all the variables are observed, including the outcom Covariates PD-L1 protein expression and eGFR were excluded from the property score model developme due to high levels of missing data, particularly within the historical comparator arm. Other covariates, including smoking history, BMI, albumin, ALT and AST, had only a small proportion of missing data (n=7), and so subjec with missing values for these variables were included from the analysis, resulting in a reduction in sotoras short size to 119. A summary of missing data is presented (Table 62).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Missing values",
        "start_page": 215,
        "end_page": 216,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Table 62. (g/m2) (0.8) BMI (kg/m2) n (%) 12 (5.3) n (%) 12 (5.3) 1 (0.8) 1 (0.8) n (%) 12 (5.3) 1 (0.8) Albumin (g/L) n (%) 11 (4.9) n (%) 11 (4.9) 1 (0.8) 1 (0.8) n (%) 11 (4.9) 1 (0.8) N (%) 11 (4.9) 1 (0.8) BMI (kg/m2) n (%) 7 (3.1) 3 (2.4) Smoking history n (%) 0 (0.0) 3 (0.0) 2 (2.0) 3 (2.4) •p.G12C-only) analysis N 92 126 PD-L1 protein expression n (%) 7 (3.1) 3 (2.4) Smoking history n (%) 0 (0.0) 1 (0.0) 3 (0.0) 2 (2.4) •p.) G12C-only lysis N 92 126 PD-L1 protein expression n (%) n (%) 89 (96.7) 2 (96.7) 26 (0.6) 26 PD-L1 protein expression n (%) 89 (= n (%) 89 (.7) 89 (.7) 2 (.7) 26.) 26.) G) G (G) G (G (= n (%) G (= n (%) 89 ($ ($ ($ ($ ($) ($ ($) ($) ($ ($) (right) (right) (right) (i) (right) (i) (right) (g) (g) (SSSSSSSSSSSS) (g) (g) (SSSSSSSSSSSSSS) (S) (S) (g) (g) (g) (g) (g) (S) (G) (S) (G) (G) (G) (GSSSSS) (G) (G)) (G) (G) (S) (G (%)) (S) (G (%), (g) (g) (g) (g) (g) (g) (g) (g) (g) (S) (g) (S) (G) (G) (G) (G) (G)) (G) (SSS) (G) (G) (SS) (SSS",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Missing values",
        "start_page": 215,
        "end_page": 216,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Figure 22 shows the boxplots in the KRAS Mutant Analysis Set before weighting. The distribution between both treatment arms differs substantially. After ATT weighting (Figure 23), the distribution of the propensity scores between both arms is reasonably balanced. Figure 22. Distribution of the Propensity Score in the KRAS mutant Analysis Set Before Weighting",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.2.6 Efficacy results",
        "start_page": 216,
        "end_page": 216,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Figure 23. Distribution of the Propensity Score in the KRAS mutant Analysis Set After ATT Weighting Key: ATT, Average treatment effect of the treated Page 210/237 Medicinsrådet Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 Medicinsraadet@medicinraadet.dk Amgen Proprietary - For Internal Use Only When the Flatiron copyright is restricted to G12C subjects, the balance after propensity score weighting is less good (Figure 24 and Figure 25). After ATT weighting, a noteable difference in the lower quartile was observed. Furthermore, there is a series of subjects classified as •outliers",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Key: None",
        "start_page": 216,
        "end_page": 217,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Figure 25. Distribution of the Propensity Score in the G12C-only Analysis Set After ATT Weighting Key: ATT, Average treatment effect of the treated The ATT weights for the KRAS Mutant Analysis set are shown in Figure 26. The correspondence sensitivity analysis for the G12C only comparator coin in Figure 27. For the KRAS mutant comparator coin, no outliers Page 211/237 Medicinsådet Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00medicinraadet@medicinraadet.dk Amgen Proprietary - For Internal Use Only or subjects with a very high weight are observed. Conversely, for the G12C only, one subject has an ATT weight of 25, where only other reasons 26.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Key: None",
        "start_page": 217,
        "end_page": 218,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: ATT, Average treatment effect of the treated The balance between treatment groups with respect to the baseline covariates after ATT adjustment is compared in Figure 28. After ATT adjustment, 10 of the 19 covariates have absolute standardized differences >0.1; however, only one of these, smoking history, has a p-value < 0.05. Though this result occurs a statistically significant imbalance between the two treatment groups, the difference in the proportion of patients with a Page 212/237 Medicine Council Dampfærgevej 27-29, 3. th. DK-2100 Copenhagen Ø +45 70 10 36 00 medicineraadet@medicindraadet.dk Amgen Proprietary - For Internal Use Only history of smoking is limited (99.5% for in the historical control v.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 27. ATT Weights in the G12C-only Analysis Set",
        "start_page": 218,
        "end_page": 219,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The effective sample size for the Flatiron control with KRAS mutation (any type) reduced from 206 (unadjusted to 104.8 when adjuvanted (Table 63). The effective sample size for the Flatiron control with KRAS G-12C mutatio reduced from 85 (unadjusted) to 17.8 when adjuvanted. Table 63. Effective sample size Control Sotorasib KRAS mutant Unadjusted 206 119 Adjusted (ATT) 104.8 119",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.2.7 Effective sample size",
        "start_page": 219,
        "end_page": 219,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Unadjusted 85 119 Adjusted (ATT) 17.8 119 Key: ATT, Average treatment effect of the treated",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "G12C",
        "start_page": 219,
        "end_page": 219,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This section presents the model outcomes for the balance of all denominations for CodeBreak 100, Flatiron KRA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.2.8 Propensity score analysis results",
        "start_page": 219,
        "end_page": 219,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "(Figure 28 and Figure 29), Model 2 (Figure 30 and Figure 31) and Model 3 (Figure 32 and Figure 33). Medicinsrådet Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00medicinraadet@medicinraadet.dk ely ed) on AS l 1 Si cinraade ide 213/237 et.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "G12C and KRAS mutation. The results for KRAS G12C and KRAS mutantly respectively are presented for Model",
        "start_page": 219,
        "end_page": 220,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: BMI, body mass index; DUR, duration; ECOG, European Co-operative Oncology Group; ETHN, ethnicity; GRP, group; MET, metastatic; PREV, previous Note: Balance was assessed by mean differences for binary/categorical outcomes and by standardized mean differences for continuous variables, with a difference of > 10% considered impaired",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 28. Propensity Score Model 1. Balance of All Covariates. Flatiron KRAS G12C",
        "start_page": 220,
        "end_page": 220,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: BMI, body mass index; DUR, duration; ECOG, European Co-operative Oncology Group; ETHN, ethnicity; GRP, group; MET, metastatic; PREV, previous Note: Balance was assessed by mean differences for binary/categorical outcomes and by standardized mean differences for continuous variables, with a difference of > 10% considered impaired Medicine Council Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medikraadet@medikraadet.dk www w.medic",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 29. Propensity Score Model 1. Balance of All Covariates. Flatiron KRAS Mutant",
        "start_page": 220,
        "end_page": 220,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "cinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 214/237",
        "start_page": 220,
        "end_page": 221,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: BMI, body mass index; DUR, duration; ECOG, European Co-operative Oncology Group; ETHN, ethnicity; GRP, group; MET, metastatic; PREV, previous Note: Balance was assessed by mean differences for binary/categorical outcomes and by standardized mean differences for continuous variables, with a difference of > 10% considered impaired Figure 31. Propensity Score Model 2. Balance of All Covariates. Flatiron KRAS Mutant Key: BMI, body mass index; DUR, measurement; ECOG, European Co-operative Oncology Group; ETHN, ethnicity; GRP, group; MET, metastatic; PREV, previous Note: Balance was assessed by mean differences for Copenhagen, medicine.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 30. Propensity Score Model 2. Balance of All Covariates. Flatiron KRAS G12C",
        "start_page": 221,
        "end_page": 221,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "cinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 215/237",
        "start_page": 221,
        "end_page": 222,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: BMI, body mass index; DUR, duration; ECOG, European Co-operative Oncology Group; ETHN, ethnicity; GRP, group; MET, metastatic; PREV, previous Note: Balance was assessed by mean differences for binary/categorical outcomes and by standardized mean differences for continuous variables, with a difference of > 10% considered impaired Figure 33. Propensity Score Model 3. Balance of All Covariates. Flatiron KRAS Mutant Key: BMI, body mass index; DUR, measurement; ECOG, European Co-operative Oncology Group; ETHN, ethnicity; GRP, group; MET, metastatic; PREV, previous Note: Balance was assessed by mean differences for Copenhagen, medicine.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 32. Propensity Score Model 3. Balance of All Covariates. Flatiron KRAS G12C",
        "start_page": 222,
        "end_page": 222,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "cinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 216/237",
        "start_page": 222,
        "end_page": 223,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The objective of this analysis was to compare OS and PFS in patients with advanced NSCLC with KRAS G12C mutation from the Phase II portion of the CodeBreak 100 study to the Flatiron chemotherapy-treated real-world cohort. The rational of this analysis was to address some of the key limitations of the MAIC analysis: (i) as patients from the SELECT-1 trial were naive to anti PD-(L)1 treatment, which does not represent current clinical and relief landscapes (ii) to address potential biases in the unanchored MAIC adjustment.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.3 Chemotherapy-based standard of care using Flatiron",
        "start_page": 223,
        "end_page": 223,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The FIH-FMI CGDB database and the average cost to be paid is a real-world data base which links the Flatiron Health electronic health record to the comprehensive genetic mapping database from Foundation Medicine and contains over 25,000 cancer patients treated in over 275 community oncology centres in the US from January The ability to weight analysis (PWSA) was determined to qualitatively compare the benefit of soorasib vs. chemotherapy-based standard of care treatment. In the particular case, PD-(L)1 analysis was conducted from the comparator arm, as it is normally used in 1L in current clinical practice (clinical advisory board (11 February 2011) concluded by Amgen (138). For validity assessment, a Cox regression model was also run where the comparator was restricted to KRAS G12C patients only. The intention of this analysis was to demonstrate the consistency of the results with the KRAS-mutant cohort and to demonstrate the implications on stochastic unity. Due to the small Si Medicinsrådet Dampfærgevej 27-29, 3.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.3.1 Flatiron database",
        "start_page": 223,
        "end_page": 224,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "th. DK-2100 København Ø +45 70 10 36 00 medicraadet.dk ide 217/237 et.dk Amgenal Proprietærevej 27-29, 3.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.3.1 Flatiron database",
        "start_page": 223,
        "end_page": 224,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "For the purposes of hedge, it is reasonable that the best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best selling, best best best best best best best best best best best best best selling, best best best best best best best selling, best best best best best best achieve, best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best reasonably, best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.3.2.1 Propensity score weighting analysis results",
        "start_page": 224,
        "end_page": 224,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Levels of risk/benefit/losses: Yes 28.16% 21.0% 20.89% Metastatic: Yes 92.72% 97.48% 97.88% Presence of EGFR/ALK/BRAF/ROS-1 mutation 8.25% 3.36% 3.43% Age (categories) 18 to 64 years 43.20% 52.10% 50.82% 65 to 74 years 33.98% 39.50% 41.02% ≥ 75 years 22.82% 8.40% 8.15% Number of prior lines of therapy Si Medicinsådet Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medicraadet@medicinraadet.dk ide 218/237 et.dk Amgen Proprietary - For Internal Use Only Prior PD-(L) 1 immunotherapy: Yes 73.30% 90.76 Prior platinum-based chemotherapy: Yes 84.47% 89.08 Advocate (g/L) 37. DK-2100 København Ø +45 70 10 36 00 medicraadet@me ogy Gro -ligand ns for ca nt • p.G asib edicinra oup, eGFR, estimated d 1 athegorical variables G12C-only • Analysis After ATT Adjustment Control aadet.dk ds Si cinraade ide 219/237 et.dk Amgen Proprietary - For Internal Use Only Key: AST, aspartate transaminase; Body, body mass index; ECOG, Eastern Cooperative Oncology Group, eGFR, estimated glomerular filtration rate; PD-1, program with cell death protein 1; PD-L1, program with death-ligand 1 Note: Values correspond to sample means for continuous variables (BMI and albumin) and proportions for categorica variables",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "ECOG: 1 74.27% 70.59% 70.46%",
        "start_page": 224,
        "end_page": 226,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The number and proportion of patients in the control cohort receiving each category of chemotherapy-base treatment, before and after ATT-weighting, is shown in Table 66. Overall, ATT-weighting decreased th proportion of patients receiving platinum-based chemotherapy (from 31.07% to 23.04% in the main KRA mutant",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.3.2.1.1 Treatment regimens in the comparator cohort",
        "start_page": 226,
        "end_page": 226,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Platinum-based chemotherapy 64 31.07% 27.78 23.04% Chemotherapy monotherapy (including docetaxel) 61 29.61% 32.48 26.94% Docetaxel plus ramucirumab 45 21.84% 41.24 34.20% Docetaxel monotherapy 21 10.19% 12.16 10.09% Other chemotherapy-based regimens 15 7.28% 6.91 5.73%",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "(N = 206) (N = 120.57)",
        "start_page": 226,
        "end_page": 226,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Platinum-based chemotherapy 25 29.41% 23.83 17.90% Chemotherapy monotherapy (excluding docetaxel) 24 28.24% 30.42 22.85% Docetaxel plus ramucirumab 18 21.18% 64.17 48.21% Docetaxel monotherapy 11 12.94% 8.56 6.43% Other chemotherapy-based regimenns 7 8.24% 6.13 4.61% Medicinsrådet Dampfærgevej 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 medicinraadet@medicinraadet.dk d al ed he AS om xel tly ive Si cinraade ide 220/237 et.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "(N = 85) (N = 133.11)",
        "start_page": 226,
        "end_page": 227,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The effective sample size of the comparator arm was 104.8 for the KRAS mutant short and 17.8 for the p.G12C",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.3.2.2 Results",
        "start_page": 227,
        "end_page": 227,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Cohort.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "HR (95% CI) based on the Cox model was estimated at X for the KRAS mutant short and X for the p.G12C only",
        "start_page": 227,
        "end_page": 227,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In this regard, the Commission considers that the best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best, best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best, best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best, best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best, best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best best\n\nReference of the source-of-fit Statistics for Jointly-Fitted OS Models for KRAS-mutant Patients (ATT Weighting) Model Independent fit • Independent fit - Joint fit Joint fit (restricted) sotorasib chemo (unstricted) AIC BIC AIC BIC AIC BIC AIC BIC Exponential 479.1 481.4 605.1 608.0 1084.2 1091.6 1097.4 Generalized Gamma 472.0 480.1 604.1 614.1 1099.1 1078.8 1098.9 Loglogistic 474.9 484.0 606.6 613.2 1085.0 1100.2 1086.1 1097.4 Generalized Gamma 472.2 480.1 614.1 614.1 1079.8 1098.8 1098.9 1090.9 Loglogistic 474.9 480.5 604.6 611.3 1095.5 1097.9 1095.9 1080.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.3.2.3 Overall survival",
        "start_page": 227,
        "end_page": 228,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Those plots indicated the proportional hazard assumption w not valid. Accelerated failure time for OS was assessed using 3 and the Schoenfeld residuals plot (Figure 35). These plots indicated the proportional hazard assumption w not valid. Accelerated failure time for OS was assessed using using a QQ plot (Figure 35).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 228,
        "end_page": 229,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: OS, overall survival.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 34. OS Log-Cumulative Hazards Plot for Sotorasib and Control",
        "start_page": 229,
        "end_page": 229,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: OS, overall survival. Medication Council Dampfærgevej 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 med y dicinraad det@me edicinra aadet.dk www w.medic",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 35. OS Schoenfeld Residuals Plot for Sotorasib and Control",
        "start_page": 229,
        "end_page": 229,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "cinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 223/237",
        "start_page": 229,
        "end_page": 230,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: OS, overall survival. In summary, and to be related with the approaches taken in the primary analyses, the jointly fitted (restrictive model) extrapolation using the log-normal distribution was used to model OS for the Flatiron dataset.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 36. OS QQ Plot for Sotorasib and Control",
        "start_page": 230,
        "end_page": 230,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The parametric model is offered to the NICE DSU TSD 14 (88) Standard parametric distribution was achieved to the unadjust KM data with independent fitting and joint fitting (unrestricted and restricted model) approach using that statistical software R (ver. 4.0.3) and the smooth-of-fit statistics. The parametric distribution models include exceptional, Weibull, Gompertz, generalized gamma, log-normal and log-log-log-log-log-log-log-log-gistic. All of goodness-of-fit statistics (AIC and BIC for all finished models) were made pointing to the log-normal wealth, log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-log-logistic. for restricted and irregular mode specifically, and indicate a close visual fit of the extrapolation to the KM data.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.3.2.4 Progression-free survival",
        "start_page": 230,
        "end_page": 231,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The proportional hazard assumption was evaluated for PFS using the log cumulative hazard plot (Figure 3 and the Schoenfeld residuals plot (Figure 38). These plots indicated the proportional hazard assumption w not valid. Accelerated time failure for OS was assessed using a QQ plot (Figure 39). The plot indicated as determination either side of the fitted line, but was inclusive as to whether the assumption of accelerated failure time teams. Figure 37. PFS Log-Cumulative Hadards Plot for Sotorasib and Control Key: PFS, progression-free survival. Medicinal products Council Dampfærgevej 27-29, 3.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 231,
        "end_page": 232,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "th. DK-2100 Copenhagen Ø +45 70 10 36 00 medicineraadet@medikraadet.dk",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 231,
        "end_page": 232,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Key: PFS, progression-free survival.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 38. PFS Schoenfeld Residuals Plot for Sotorasib and Control",
        "start_page": 232,
        "end_page": 232,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: PFS, progression-free survival. Medication Council Dampfærgevej 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 med y dicinraad det@me edicinra aadet.dk www w.medic",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Figure 39. PFS QQ Plot for Sotorasib and Control",
        "start_page": 232,
        "end_page": 232,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "cinraadet.dk Amgen Proprietary - For Internal Use Only In summary, the jointly limited restricted extrapolation using the log-normal distribution was selected for PFS in the base case, which was included with the approach used in OS and in the main comparator. 12.3.2.4.1 Results of the Propensity score weighing analysis using CodeBreaK100 and Amgen Flatiron Health real-world evidence This supplementary analysis was taken to explore an alternative data source and method of estimating relative treatment effects for sotorasib vs docetaxel monotherapy (using the basket of standard of care chemotherapy regimenns in the Amgen Flatiron real-world evidence contrary to the theory of theory monotherapy).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Page 226/237",
        "start_page": 232,
        "end_page": 233,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "sotorasib produces a statistically significant reduction in the rate of death versus chemotherapy-based treatment.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "control cohort was estimated at X) prior to adjustment, X after ATT adjustment, indicating that",
        "start_page": 233,
        "end_page": 233,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Si Medicinrådet Dampfærgevej 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 medicraadet@medicinraadet.dk idea 227/237 et.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 233,
        "end_page": 234,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: ATT, Average treatment effect on the treated Note: In the ATT-weighted analysis, the N at risk correspond to the sum of weights in each arm",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 234,
        "end_page": 234,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "PFS outcomes for the KRAS mutant· analysis are shown as Kaplan-Meier curves before an after ATT weighting in Error! Reference source not found. and Error! Reference sourc not found. respectively. In both cases, outcomes show that PFS is higher for the sotorascohort versus the control cohort. The PFS hazard ratio for sotorasib versus the control cohort based on the Cox proportion",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.3.2.5 Progression-free survival",
        "start_page": 234,
        "end_page": 234,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "That sotorasib products an improvement in PFS (allthough this effect is not statistically significant after ATT weighting).The Danish Medicines Council Dampfærgevej 27-29, 3.th. DK-2100 Copenhagen Ø +45 70 10 36 00 medicinraadet@medicinraadet.dk nd ce sib nal ng ly Side 228/237 cinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "hazard model was estimated at X prior to adjustment, and X) after ATT adjustment, indicatin",
        "start_page": 234,
        "end_page": 235,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: ATT, Average treatment effect on the treated Note: In the ATT-weighted analysis, the N at risk correspondents to the sum of weig Medicinrådet Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medicinraad ghts in each arm det@medicinraadet.dk www w.medic Side 229/237 cinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 235,
        "end_page": 236,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "OS outcomes for the experiment •p.G12C-only analysis are shown as Kaplan-Meier curve before and after ATT weighting in Error! Reference source not found. and Error! Referenc source not found., specifically. In both cases, as with the main •KRAS mutant • analysis outcomes show that OS is higher for the sotorasib cohort compared with the control corort. The OS hazard ratio for sotorasib versus chemotherapy based on the Cox proportion",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.3.3.1 Overall survival",
        "start_page": 236,
        "end_page": 236,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "statistically significant reduction in the rate of death versus chemotherapy-based treatment.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "hazard model was estimated at X after ATT adjustment, indicating that sotorasib productions",
        "start_page": 236,
        "end_page": 236,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Medicinrådet Dampfærgevej 27-29, 3.th. DK-2100 København Ø +45 70 10 36 00 medicieraadet@medicinraadet.dk es ce is, nal s a Side 230/237 cinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 236,
        "end_page": 237,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: ATT, Average treatment effect on the treated Note: In the ATT-weighted analysis, the N at risk correspond to the sum of weights in each arm",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 237,
        "end_page": 237,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "PFS outcomes for the .p.G12C-only analysis are shown as Kaplan-Meier curves before an after ATT weighting in Error! Reference source not found. and Error! Reference sourc not found. specifically. In both cases, as with the main •KRAS mutant • analysis, outcome show that PFS is higher for the sotorasib cohort versus the control cohort. The PFS hazard ratio for sotorasib versus chemotherapy based on the Cox proportion",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "12.3.3.2 Progression-free survival",
        "start_page": 237,
        "end_page": 237,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "An improvement in PFS (allthough this effect is not statistically significant). Medication Council Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medicinraadet@medicinraadet.dk nd ce es nal es Page 231/237 cinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "hazard model was estimated at X after ATT adjustment, indicating that sotorasib produce",
        "start_page": 237,
        "end_page": 238,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Key: ATT, Average treatment effect on the treated Note: In the ATT-weighted analysis, the N at risk correspondents to the sum of weig Medicinrådet Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medicinraad ghts in each arm det@medicinraadet.dk www w.medic Side 232/237 cinraadet.dk Amgen Proprietary - For Internal Use Only",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "X",
        "start_page": 238,
        "end_page": 239,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The analyses described in this report are based on the 15th March 2021 data cut. Phase 2 of Study 20170543 was a single-arm clinical trial (with AMG 510 as monotherapy), where quality of life data was collected from subjects using the following patient-reported outcomes (PROMs): EORTC QLQ-",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "This report details the methods and results of analyses to estimate EQ-5D-5L health state utility values using",
        "start_page": 239,
        "end_page": 239,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "for health economic modelling; there, the overall objective of this analysis was to provide such estimates. Additional objectives were to explore utilities over time and within subgroups.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "C30, EORTC QLQ-LC13, NSCLC SAQ, PGIC, PGIS, EQ-5D-5L, and PRO-CTCAE. Utilities for health states are required",
        "start_page": 239,
        "end_page": 239,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Phase 2 of this study was a multicentre, non-randomised, open-label, and aimed to evaluate effectiveness and safety/tolerability of AMG 510 as monotherapy",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Study 20170543 (CodeBreak 100)",
        "start_page": 239,
        "end_page": 239,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "7 PROMs were assessed as part of this study: EORTC QLQ-C30, EORTC QLQ-LC13, NSCLC SAQ, PGIC, PGIS, EQ-",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "PROM assessments",
        "start_page": 239,
        "end_page": 239,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "PROMs were completed on Day 1 pre-dose of every cycle (cycle length: 21 days) until cycle 6, and then on Day 1 of every other cycle from cycle 7 until treatment interruption. Additional PROM completion occurred at the end of treatment visit and at the safety follow-up visit.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "5D-5L, and PRO-CTCAE. The provider of this report will focus on the EQ-5D-5L.",
        "start_page": 239,
        "end_page": 239,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The EQ-5D is a generic instrument for describing and valuing health developed by the EuroQol group. It classes health in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 level of responses: no problems, light problems, moderate problems, severe problems, and extreme problems.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "EQ-5D-5L",
        "start_page": 239,
        "end_page": 239,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Vertical 0 to 100 visual analogue scale, with 0 labeled as \"the worst heat you can imaginable' and 100 labeled as \"the best health you can imaginable.\"The scale is market in invitations of •1 , with values labeled at each Si Medicinrådet Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medicraadet@medikraadet.dk ide 233/237 et.dk Amgen Proprietary - For Internal Use Only decile. A minimal important difference (MID) of 7 points has been proposed for the VAS in cancer patients (139,",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Visual Analog Score (VAS): The last EQ-5D-5L request requests respondents to rate their present health status on a",
        "start_page": 239,
        "end_page": 240,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The EQ-5D-5L health states were converted into a single summary index (referred to as the EQ-5D-5L utility index) by applying a formula that attaches values (also called weights or tariffs) to each of the levels in each dimension",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Detection of utility scores",
        "start_page": 240,
        "end_page": 240,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "For the Denmark Index, utility scores were contained using the Denmark EQ-5D-5L value set(86). When scoring in this manner, utilities range from 1 (full health) to -0.757 (worse than death). To date, no specific MID has been proposed for the Denmark Index; there, the largest country-specific MID (UK Index: 0.08) will be used as a conservative estimate of the Denmark Index MID.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "EQ-5D-5L Denmark Index",
        "start_page": 240,
        "end_page": 240,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Different health states defined in a variety of ways were explosiond. This included by progression status (pre- and",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Health states of interest",
        "start_page": 240,
        "end_page": 240,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "and time to death. Therefore, health states were defined as follows:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "post-progress response), tumour response (time-varying and day 1 cycle 3), ECOG score, treatment status,",
        "start_page": 240,
        "end_page": 240,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The date of progression was derived from progression-free survival data, using the Independent Review Committee definition.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Progression status",
        "start_page": 240,
        "end_page": 240,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "assigned according to to time-varying response status by looking at the 30 days prior to and including the date of EQ-5D-5L assessment. The tumor response assessment made close to the date of EQ-5D-5L assessment within this window will be assigned. If there was no assessment of tumor response in a 30-day window, response status was coded as missing.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Response status as per independent review committee definition was used. EQ-5D-5L ratings were",
        "start_page": 240,
        "end_page": 240,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "EQ-5D-5L ratings were assigned to ECOG categories by looking at the 30 days prior to and including the date of EQ-5D-5L assessment. The ECOG assessment made close to the date of EQ-5D-5L assessment within",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "ECOG score",
        "start_page": 240,
        "end_page": 240,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Missing.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "this window was assigned. If there was no assessment of ECOG in a 30-day window, ECOG score was coded as",
        "start_page": 240,
        "end_page": 240,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The date of AMG510 discontinuation was used. EQ-5D-5L assessments were defined as on- or off-treatment as follows: Si Medicinrådet Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medicinraadet@medicinraadet.dk idea 234/237 et.dk Amgen Proprietary - For Internal Use Only • On o PROM assessment date prior to discontinuation date, OR o Censored discontinuation date • Off o PROM assessment date on or after discontinuation date",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Treatment status",
        "start_page": 240,
        "end_page": 241,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Date of death was derived from overall survival data, in addition to the last known alive date. EQ-5D-5L assessments were defined as follows: • Within 30 days of death o Death date - PRO assessment date ≤30 • 31-90 days until death o 31 ≤ Death date - PRO assessment date ≤90 • 91-183 days until death o 91 ≤ Death date - PRO assessment date ≤183 • ≥184 days until death o Death date - PRO assessment date ≥184, OR o Last known alive date - PRO assessment date ≥184 If death date was missing (i.e. censored) and last known alive date - PRO assessment date ≤184, PRO assessment was excluded from the time to death analysis.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Time to death",
        "start_page": 241,
        "end_page": 241,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "EQ-5D-5L ratings were assigned to adverse event categories by looking at the 21 days prior to and including the date of EQ-5D-5L assessment. EQ-5D-5L ratings were assigned to Severe, mild/moderate or absent as follows: • Severe: A grade 3 or 4 adverse event (emergent or about) within the 21 days prior to an EQ-5D-5L assessment • Mild/moderate: A grade 1-2 adverse event (emergent or about) within the 21 days prior to an EQ-5D-5L assessment • Absent: No adverse event (emergent or about) within the 21 days prior to an EQ-5D-5L assessment",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Advertise events - Anemia",
        "start_page": 241,
        "end_page": 241,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This analysis primarily used the EQ-5D-5L analysis set, consisting of all subjects in the Phase 2 NSCLC cohort Full Analysis Set with a non-missing utility index (i.e. all five dimensions complete) for at least one timepoint across the whole study period. An alternative analysis set was used for change from baseline mixed models for revised measures (MMRMs): the subset of the phase 2 NSCLC cohort Safety Set who had both a baseline and at least one subsequent EQ-5D assessment. Analysis was performed using SAS version 9.4, with additional expertise plots of missing data being produced R version 3.6.0.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Statistical methodology",
        "start_page": 241,
        "end_page": 242,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Si Medicine Council Damfergevej 27-29, 3. th. DK-2100 København Ø 45 10/237 For medicine @adra",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Statistical methodology",
        "start_page": 241,
        "end_page": 242,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Completion rates for EQ-5D-5L scores for each utility index were assessed across timepoints at Baseline, Cycles 1-25, End of Treatment Phase, and Safety Follow-Up (total number of subjects completing assessments, percent of Full Analysis Set, and number and total number and partial of expected subjects to complete assessment). Additionally, parallel boxplots(141) were produced exploring the association between scores at a visit and missing EQ-5D-5L score in the subsequent visit. These were designed to assess the intellectualhood of data being missing at random, a key assessment for the MMRM analyses.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Completion rates and descriptive statistics",
        "start_page": 242,
        "end_page": 242,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "MMRMs were fit that included change from baseline scores as the dependent variable, study visit (categorical) and baseline score as fixed effects, and study visit as a repeated effect (repeated by subject). Models were fit using a heterogeneous compound crime structure. The number of subjects, least squares (LS) means, standard error and 95% confidence intervals (CIs) for the value of utility scores was presented.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Change from baseline MMRM",
        "start_page": 242,
        "end_page": 242,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "To the estimate he achieved value as with each health state, a mixed model approach was used to account for proven PROM assessments per subject within a health state using separate MMRMs under the assumption of missing at random.(143, 144) Models were fit with health utility index scores measured at any visit (baseline, cycles, and follow-up) as the dependent variable, with health state as a categorical fixed effect and a random interaction for each subject. Models were run using an unstructured covariance matrix.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Health state utility values MMRM",
        "start_page": 242,
        "end_page": 242,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Overall, 124 subjects were presented in the Phase 2 NSCLC Cohort Full Analysis Set. Of these, 124 had at least one EQ-5D assessment at any time point and thus compromised the EQ-5D-5L Full Analysis Set for analysis of completion rates, descriptive statistics, and health utility values (see main body). An alternative substance submitted in the Safety Si Medicinrådet Dampfærgevej 27-29, 3. th. DK-2100 København Ø +45 70 10 36 00 medicraadet@medicinraadet.dk ide 236/237 et.dk Amgen Proprietary - For Internal Use Only Set who had both a baseline utility and one subsequent EQ-5D assessment yielded 86 subjects for analysis Change from Baseline MMRMs.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Subject population",
        "start_page": 242,
        "end_page": 243,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Table 69 shows that completion of the EQ-5D-5L at Baseline compromised 70.97% of the Full Analysis S Completed, with number of participants dropping below 50% of the Full Analysis Set at Cycle 7. The proportion of completed assessments out of those expected to complete remained at least 70% until Cycle 23, at which point 10 assessments were available for analysis. As such, subsequent analyses exploring EQ-5D-5L scores over time focus on visits up to and including Cycle 23.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Completion rates",
        "start_page": 243,
        "end_page": 243,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 69. EQ-5D-5L Collection rates by assessment time points",
        "start_page": 243,
        "end_page": 243,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Date for treatment in •28.09.2022; Row 2: •Medical Council • Row 3: Provider •Amgen • Row 4: • Medical remedy • Lumykras (sotorasib) Row 5: Requested indication • Second-line treatment of incurable non-small cell lung cancer with KRAS G12C mutation •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI>",
        "start_page": 5,
        "end_page": 5,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: False • Stronger • AIP • Current SAIP • Negotiated • Discount rate Row 3: • SAIP • Lift. AIP Row 4: • Row 5: • Lumykras •120 mg/stk•240 pieces • 57.464,13 • 57.464,13 •XXXXXXXXX •XXXXXX • Row 6: • • Sotorasib)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI>",
        "start_page": 5,
        "end_page": 5,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: XXXXXXX",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI>",
        "start_page": 5,
        "end_page": 5,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI>",
        "start_page": 5,
        "end_page": 5,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Number of Row 2: packs/year",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Lumykras Row 2: (sotorasib)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: xxXXXXXXXXXXXXXXXXXXXXXX Row 2:  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page, column 1)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page, column 1)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XXXXXXXXXXXXXX Row 2: XXXXXXXXXXXXXX Row 3: XXXXXXXXXXXXXXXX Row 4: XXXXXXXXXXXXXXX",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page, column 2)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: • Packing price Row 3: • SAIP Row 4: • Row 5: • XXXXXXXXX",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page, column 2)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:  XXXXXXXX Row 2: XXXXXXXX Row 3: XXXXXXXX Row 4: XXX",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page, column 3)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: • An paknin • An Row 3: • Paknin Row 4: • Row 5: • Row 6: X • 12, •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page, column 3)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XXXXX Row 2: XXXXX Row 3: XXXXX",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page, column 4)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Ntal Row 3: reg/y Row 4: Row 5: Row 6: Row 7: ,18 Row 8:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page, column 4)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:  XXXXXXXXXXXX Row 2: XXXXXXXXXXXX Row 3: XXXXXXXXXXXX",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page, column 5)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: • Annual Doctor Row 3: year • Row 4: • SAIP per Row 5: • Row 6: •XXXX •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page, column 5)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: meanp Row 3: r. year Row 4: Row 5: Row 6: Row 7: XXXXXX Row 8: Row 9:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page, column 6)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Price Row 3: Row 4: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <DBS, SNI> (from previous page, column 7)",
        "start_page": 6,
        "end_page": 6,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Contact information • Row 2: Name • Nicholas Sroczynski",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <lder in Amgen Denmark>",
        "start_page": 12,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Jannick Burmester",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <lder in Amgen Denmark>",
        "start_page": 12,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Contact Information Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <lder in Amgen Denmark> (column 1)",
        "start_page": 12,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1, Row 2: Nicholas Sroczynski",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <lder in Amgen Denmark> (column 2)",
        "start_page": 12,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Jannick Burmester",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <lder in Amgen Denmark> (column 2)",
        "start_page": 12,
        "end_page": 12,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Abbreviation term·Definition",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < units, and concentrations> (from previous page)",
        "start_page": 14,
        "end_page": 14,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Define",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < units, and concentrations> (from previous page, column 8)",
        "start_page": 14,
        "end_page": 14,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Baseline characteristics:Danish Row 2: • KRAS G12C Row 3: • Patients",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <5.1.5 Epidemiology>",
        "start_page": 29,
        "end_page": 29,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Analysis Set...N. with event...Median OS, Months...6-month OS,...12-month OS, Row 2:...(95% CI) •% (95% CI) •% (95% CI) Row 3: •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <5.1.5 Epidemiology>",
        "start_page": 29,
        "end_page": 29,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Analysis Set...N. with event...Median OS, Months...6-month OS,...12-month OS, Row 2:...(95% CI) •% (95% CI) •% (95% CI) Row 3: •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <5.1.5 Epidemiology>",
        "start_page": 29,
        "end_page": 29,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row one, Row two, Row two, Row one, Row two, Row one, Row two, Row two, Row two, Row two, Row two, Row two, Row two, Row two, Row two, Row two, Row number two, Row number two, Row two, Row number two, Row two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two,",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <5.1.5 Epidemiology>",
        "start_page": 29,
        "end_page": 29,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Year • 2022 • 2023 • 2024 • 2025 • 2026",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <5.2.1 Current treatment options>",
        "start_page": 30,
        "end_page": 30,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Subject·Description",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table during heading <treatment:>",
        "start_page": 32,
        "end_page": 32,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Subject·Description",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <ministered with other medications>",
        "start_page": 33,
        "end_page": 33,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Reference: Trial name--NCT number--Dates of study Row 2: (title, author, journal, year)---(start and Row 3:--- Row 4:--expected Row 5:--- Row 6:--completion Row 7:--date)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7. Efficacy and safety>",
        "start_page": 35,
        "end_page": 35,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • N • mOS Row 2: Patient subgroups • Row 3: • • OS) • months (95% CI) Row 4: •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 9. CodeBreak 100 results",
        "start_page": 36,
        "end_page": 36,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Outcome-Study arm...N..Result...Reference...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 9. CodeBreak 100 results",
        "start_page": 36,
        "end_page": 36,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •Outcome •Student arm •N •Result (IQR) •References •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 10. SELECT-1 results",
        "start_page": 39,
        "end_page": 39,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Element·Sotorasib (CodeBreak 100) •Docetaxel (SELECT-1) Row 2: Blinding •Open label •Double-blinded Row 3: Inclusion criteria •Male or female patients (> 18 years) Histologically confirmed locally advanced or metastatic NSCLC •Male or female patients (> 18 years) Histologically confirmed locally advanced or metastatic NSCLC WHO Performance Status 0 • 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.1.1 MAIC overview>",
        "start_page": 42,
        "end_page": 42,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "With respect to the substance, it is recommended that the substance should not be used as a medicinal product for human and veterinary use, but should not be used as a medicinal product for use as a medicinal product for human and veterinary use.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.2.1.2 Population characteristics>",
        "start_page": 43,
        "end_page": 43,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rowwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.2.1.3 MAIC approach>",
        "start_page": 44,
        "end_page": 44,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rowwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Category Covariate>",
        "start_page": 45,
        "end_page": 45,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Category Row 2: Very important Row 3: Somechat important Row 4: Additional covariates reported in other MAIC",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Category Covariate> (column 1)",
        "start_page": 45,
        "end_page": 45,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Covariates...All variables pre-specified as important (Set1) •All available variables (Set2) Row 2: ECOG (% PS 1 [vs PS 0]) •X •X Row 3: Age (mean) •X Row 4: Metastatic disease stage at baseline (% IIIB [vs IV]) •X •X Row 5: Smoking status (% ever smoker) •X •X Row 6: PD-L1 expression level •X Row 7: Gender (% female) •X Row 8: Histology (% Non-squamous) •X Row 9: Race (% white) •X Row 10: Key: ECOG, Eastern Co-operative Oncology Group; PS, performance status.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.2.1.4 MAIC Results>",
        "start_page": 46,
        "end_page": 46,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X°X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.2.1.4 MAIC Results>",
        "start_page": 46,
        "end_page": 46,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: For sotorasib Row 2: CovariatesSELECT-1 •CodeBreak 100 •CodeBreak 100 Row 3: Age (mean) 60.9 •62.9 •65.9 Row 4: ECOG (% PS 1 [vs PS 0]) •59% •70% •59% Row 5: Metastatic disease stage at baseline (% IIIB [vs IV]) •96% •96% Row 6: Smoking status (% ever smoker) •92% b•92% Row 7: Key: ECOG, European Co-operative Oncology Group; PD-(L1), program with death-ligand 1; PS, performance status. Note: a, when adjusting for four covariates b, 2 percent points of the resulting 7%.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.2.1.4 MAIC Results>",
        "start_page": 46,
        "end_page": 46,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX Row 2: X A B",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 48,
        "end_page": 48,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX Row 2: A B",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 48,
        "end_page": 48,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X°",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 48,
        "end_page": 48,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X· X* X* X* Row 2: X* X* X* X* Row 3: X* X* X* X* X* Row 4: • X* Row 5: • X*",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.2.2.1 Discontinuations due to adverse events>",
        "start_page": 49,
        "end_page": 49,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Treatment n (%) • Median duration of treatment •References",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.2.2.1 Continuations due to adverse events> (from previous page)",
        "start_page": 50,
        "end_page": 50,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Advertise events... Sotorasib (CodeBreak-100)*...Docetaxel + placebo (SELECT-1)**... Row 2:... n=126... n=254 Row 3:...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.2.2.1 Continuations due to adverse events> (from previous page)",
        "start_page": 50,
        "end_page": 50,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Treatment N",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.2.2.1 Discontinuations due to adverse events> (from previous page, column 1)",
        "start_page": 50,
        "end_page": 50,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Advertise events Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.2.2.1 Discontinuations due to adverse events> (from previous page, column 1)",
        "start_page": 50,
        "end_page": 50,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •n (%) •Median duration of treatment •References",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.2.2.1 Discontinuations due to adverse events> (from previous page, column 2)",
        "start_page": 50,
        "end_page": 50,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Sotorasib (CodeBreak-100)*·Docetaxel + placebo (SELECT-1)** Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <7.2.2.1 Discontinuations due to adverse events> (from previous page, column 2)",
        "start_page": 50,
        "end_page": 50,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Patient population...Clinical documentation /..Used in the model...Danish clinical practice Row 2: ...indirect comparison etc...(including source) Row 3: Important baseline... Row 4: characteristics...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 19.",
        "start_page": 54,
        "end_page": 54,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Intervention·Clinical documentation·Used in the model·Expected Danish clinical Row 2: •(including source) •(number/value including•practice (including source Row 3: • Row 4: •source) •if known) Row 5: •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 21. Comparator",
        "start_page": 55,
        "end_page": 55,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Customizable documentationUsed in the model",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 21. Comparator",
        "start_page": 55,
        "end_page": 55,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Advertise reaction outcome Sotorasiba·Docetaxelb",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 22.",
        "start_page": 56,
        "end_page": 56,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X • Row 2: X • X • X • Row 3: X • X • X • X • X • Row 4: X • X • X • X • Row 5: • X • X • X • X • Row 6: Key: CI, confidence interval; ESS, effective sample size; HR, hazard ratio; MAIC, matching-adjusted indirect comparison; mth, months; OS, overall survival; PFS, progression-free survival. • Row 1: X • Row 2: X • X • X • X • X • Row 3: X • X • X • X • Row 4: X • X • X • • Row 5: • X • X • X • X • X • X • X • X • Row 5 • X • X • X • X • X • • • Row 5 • Row 5: • X • X • X • X • X • X • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <A B>",
        "start_page": 57,
        "end_page": 57,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX Row 2: A B",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <A B>",
        "start_page": 57,
        "end_page": 57,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "21,1 6,16,16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 17, 17, 17, 16, 17, 17, 17, 16, 19, 21, 8, 8, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 16, 16,7, 7, 7, 16, 7, 16, 7, 7, 16, 7, 16, 7, 16, 7, 16, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 16, 16, 16, 16, 16, 6, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 16, 8, 8, 8, 8, 8, 8, 8, 8, 16, 8, 8, 8, 16, 16, 16, 8, 8, 16, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Statistical goodness-of-fit>",
        "start_page": 58,
        "end_page": 58,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX • Row 2: • Exp • Gompertz • Weibull • GG • Log-logistic • Log-normal Row 3: Sotorasib • Row 4: 2 months • 91.3% • 91.0% • 92.9% • 95.8% • 94.7% • 95.5% Row 5: 6 months • 76.0% • 75.6% • 77.7% • 76.9% • 78.0% • 77.4% Row 6: 12 months • 57.8% • 57.7% • 57.9% • 55.7% • 56.0% • 56.1%",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XX>",
        "start_page": 61,
        "end_page": 61,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Doceteknavel • Row 2: 2 months •85.8% •85.5% •88.3% •89.1% •89.2% •89.3% Row 3: 6 months •63.3% •62.7% •65.5% •60.7% •62.0% •61.6% Row 4: 12 months •40.0% •39.9% •39.9% •38.2% •37.0% •38.1% Row 5: Key: Exp, exponential; GG, Generalized gamma; OS, overall survival.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <sotorasib at 5-years (X and 10-years (X were considered reasonable given the observed response rate, duration>",
        "start_page": 62,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX°-Row 2: X°-X°-X°-X°-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <sotorasib at 5-years (X and 10-years (X were considered reasonable given the observed response rate, duration>",
        "start_page": 62,
        "end_page": 62,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX Row 2: A B",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Statistical goodness-of-fit>",
        "start_page": 63,
        "end_page": 63,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The Court of First Instance 1 1 16, 16, 16, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 7, 8, 8, 7, 8, 8, 8, 8, 8, 8, 8, 8, 7, 7, 9, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 6, 6, 7, 7, 7, 7, 7, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7 Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Statistical goodness-of-fit> (from previous page)",
        "start_page": 64,
        "end_page": 64,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •X •X •X •X •X X • Row 2: X • Row 3: X •X • X • • • X • • Row 4: X • X • X • X • • Row 5: X • X • X • X • X • X • • Row 6: X • Row 7: X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • • • X • X • • • • X • X • X • X • X • X • X • • • • X • X • • • X • • X • X • X • • • • • • • X • • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • • X • • • X • • • • • • • • X • X • X • X • • • • • • • • • • • • •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Base-case parametric survival curve selection>",
        "start_page": 67,
        "end_page": 67,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX • Row 2: • X • Row 3: • X • X • Row 4: X • X • Row 5: X • X • Row 6: X • X • Row 7: X • X • Row 8: X • X • Row 9: X • X • X • Row 10: X • X • X • Row 11: X • X • X • Row 12: X • X • X • Row 13: X • X • X • Row 14: • X • X • X • Row 15: X • X • X • Row 16: X • X • Row 17: • X • X • X • Row 17: • X • X •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "stable across timepoints, decreasing X. This did not change meaningfully and remained within the Denmark",
        "start_page": 72,
        "end_page": 72,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1, XX... Row 2: X... X... X.. X... X... X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "stable across timepoints, decreasing X. This did not change meaningfully and remained within the Denmark",
        "start_page": 72,
        "end_page": 72,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1, XX... Row 2: X... X... X.. X... X... X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.4.3 Reverse reactions and treatment mode discipline>",
        "start_page": 73,
        "end_page": 73,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X· X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.4.3 Reverse reactions and treatment mode discipline>",
        "start_page": 73,
        "end_page": 73,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X· X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* Row 2: X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X*",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.4.3 Reverse reactions and treatment mode discipline>",
        "start_page": 73,
        "end_page": 73,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Advertise event...Mean (95% CI)*...Source Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.5.1 Intervention and comparator costs and resource use>",
        "start_page": 74,
        "end_page": 74,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Drug•Unit·Unit *Reference *Dosing *Reliative *Cost per Row 2: *[DKK) *dose *Month Row 3: * Row 4: *Intensity *[DKK)d Row 5: *",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.5.2.2 Monitoring and disease management costs>",
        "start_page": 75,
        "end_page": 75,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Drug•Cost (DKK)•Source",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.5.2.2 Monitoring and disease management costs>",
        "start_page": 75,
        "end_page": 75,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: • Unit cost • Row 3: Blood sample • Source Row 4: • R.K.K.K.) • Row 5: • Row 6: • Row 6: • Row 1: • Row 2: • Row 2: • Unit cost • Row 3: Blood sample • Source Row 4: • Row 5: • Row 5: • Row 5: • Row 5: • Row 5: • Row 5: • Row 5: • Row 5: • Row 5: • Row 5: • Row 5: • Row 5: • Row 5:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.5.2.2 Monitoring and disease management costs>",
        "start_page": 75,
        "end_page": 75,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: Units • Cost per unit (DKK) • Source Row 3: •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 29.",
        "start_page": 76,
        "end_page": 76,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: • Health states • Row 3: • Row 4: • First cycle • Progression-free • Row 5: Units • Accountance-free • Subsequential cycle • Post-progress Row 6: • Frequency per cycle) •(frequency per cycle) •(frequency per cycle) • Frequency per cycle)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 29.",
        "start_page": 76,
        "end_page": 76,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: Advertise event • Cost (DKK) • Source a",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.5.2.6 Patient and transport cost>",
        "start_page": 77,
        "end_page": 77,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •Unit cost • Row 2: Resource •Source Row 3: • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.5.2.6 Patient and transport cost>",
        "start_page": 77,
        "end_page": 77,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: \"Time usage\" Row 2: \"Resource\"\"Source Row 3: \"(mins.) \"",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <importance· (SET 1) samples size.>",
        "start_page": 78,
        "end_page": 78,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Category...Base-case analysis...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <importance· (SET 1) samples size.>",
        "start_page": 78,
        "end_page": 78,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX-- Row 2:-- Row 3:--X--X--X--X--X--- Row 4:--",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.7.1 Deterministic sensitivity analyses>",
        "start_page": 80,
        "end_page": 80,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: No...Scenario...Base-case Assumption...Rationale",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.7.2 Scenario analysis>",
        "start_page": 81,
        "end_page": 81,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: No...Scenario...Base-case Assumption...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.7.2 Scenario analysis> (column 1)",
        "start_page": 81,
        "end_page": 81,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.7.2 Scenario analysis> (column 2)",
        "start_page": 81,
        "end_page": 81,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Rationale",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <8.7.2 Scenario analysis> (column 3)",
        "start_page": 81,
        "end_page": 81,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X· X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXX>",
        "start_page": 82,
        "end_page": 82,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX... Row 2: X...X...X...X...X...X...Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <source not found.), sotorasib has a X% probability of being cost-effective versus docetaxel considering the DKK>",
        "start_page": 83,
        "end_page": 83,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Year 1 • Year 2 • Year 3 • Year 4 • Year 5 Row 2: • Year 2 • Year 3 • Year 4 • Year 5 Row 2: • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <9.3 Scenario analysis>",
        "start_page": 86,
        "end_page": 86,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Year 1 • Year 2 • Year 3 • Year 4 • Year 5 Row 2: • Year 2 • Year 3 • Year 4 • Year 5 Row 2: • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2 • Year 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <9.3 Scenario analysis>",
        "start_page": 86,
        "end_page": 86,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X° Row 2: X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X°",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <9.3 Scenario analysis>",
        "start_page": 86,
        "end_page": 86,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <with docetaxel monotherapy (X]), exceeding the minimal clinically important difference of 3 months in median>",
        "start_page": 87,
        "end_page": 87,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <with docetaxel monotherapy (X]), exceeding the minimal clinically important difference of 3 months in median>",
        "start_page": 87,
        "end_page": 87,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Xxxxxxxxxxxxxrow 2: • xxxxxxxxxxxxxxxxx",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion> (from previous page)",
        "start_page": 90,
        "end_page": 90,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Xxxxx Row 2: • xxxxx",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Conclusion> (from previous page, column 1)",
        "start_page": 90,
        "end_page": 90,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: xxxxxxxx Row 2: xxxxxxxx",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Conclusion> (from previous page, column 2)",
        "start_page": 90,
        "end_page": 90,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: xxx Row 2: xxxxx",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion> (from previous page, column 3)",
        "start_page": 90,
        "end_page": 90,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: xx Row 2: xx",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Conclusion> (from previous page, column 4)",
        "start_page": 90,
        "end_page": 90,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In this case, the Commission shall also:: \"Searches', \"Results Row 2: 1 •exp non smal cell lung cancer/.own8821 Row 3: 2 lairlung cancer/ and non small cell.ti,ab: 1pexp non small cell.ti,a 4: 3 ossclccccc.ti,ab: 8181646 Row 5: 4  wellnon small cell.ti,ab: 102425 Row 6: 5 osccinom$ or cancer$ or cancer$ or cancer$ or cancer$ or neoplas$).ti,ab.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase • original search>",
        "start_page": 99,
        "end_page": 99,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: 1 Row 3: 2 Row 4: 3 Row 5: 4 Row 6: 5 Row 7: 6 Row 8: 7 Row 9: 8 Row 10: 9 Row 11: 10 Row 12: 11 Row 13: 12 Row 14: 13 Row 15: 14 Row 16: 15 Row 17: 16 Row 18: 17 Row 19: 18",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase • original search> (column 1)",
        "start_page": 99,
        "end_page": 99,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Results Row 2: 98821 Row 3: 14730 Row 4: 81646 Row 5: 102425 Row 6: 3177270 Row 7: 933416 Row 8: 156582 Row 9: 690342 Row 10: 2272961 Row 11: 2372831 Row 12: 4395903 Row 13: 2158432 Row 14: 16155 Row 15: 6524 Row 16: 9631 Row 17: 2485 Row 18: 3950 Row 19: 6435",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase • original search> (column 9)",
        "start_page": 99,
        "end_page": 99,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row1 to RowRow1 to Row1 to Row1 to Row1 to Row1 to Row1 to Row1 to Row1 to Row2 to Row2 to Row 2: 1 to exp non small cell lung cancer/",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase original search> (from previous page)",
        "start_page": 100,
        "end_page": 100,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: # Row 2: 1 Row 3: 2 Row 4: 3 Row 5: 4 Row 6: 5 Row 7: 6 Row 8: 7 Row 9: 8 Row 10: 9 Row 11: 10 Row 12: 11 Row 13: 12 Row 14: 13 Row 15: 14",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase original search> (from previous page, column 1)",
        "start_page": 100,
        "end_page": 100,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row=========================================================================================================================;====================================================================================================================================================================================================================================================================================================================###############################################################################",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase original search> (from previous page)",
        "start_page": 101,
        "end_page": 101,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: # Row 2: 1 Row 3: 2 Row 4: 3 Row 5: 4 Row 6: 5 Row 7: 6 Row 8: 7 Row 9: 8 Row 10: 9 Row 11: 10 Row 12: 11 Row 13: 12 Row 14: 13 Row 15: 14 Row 16: 15 Row 17: 16 Row 18: 17 Row 19: 18",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase original search> (from previous page, column 1)",
        "start_page": 101,
        "end_page": 101,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Results Row 2: 4213 Row 3: 3559 Row 4: 9389 Row 5: 11599 Row 6: 169791 Row 7: 51312 Row 8: 13703 Row 9: 137 Row 10: 1118684 Row 11: 1118699 Row 12: 2072 Row 13: 1117419 Row 14: 9466 Row 15: 4281 Row 16: 4213 Row 17: 3559 Row 18: 9389 Row 19: 11599",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase original search> (from previous page, column 6)",
        "start_page": 101,
        "end_page": 101,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 19·8312 Row 3: 21·15 or 16 or 17 or (18 and 19 and 20) 13703 Row 4: 22·crossover procedure/ or double-blind procedure/ or randomized controlled trial/ or single-blind procedure/·137 Row 5: 23·(random$ or factoral$ or crossover$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (single$ adj blind$) or assign$ or allocat$ or volunteer$).ti,ab.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase - 2021 update>",
        "start_page": 102,
        "end_page": 102,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •Searches •Results Row 2: 1 •exp non small cell lung cancer/ •105188 Row 3: 2 •lung cancer/ and non small cell.ti,ab. •14842 Row 4: 3 •nsclc.ti,ab. •85349 Row 5: 4 •non small cell.ti,ab. •106532 Row 6: 5 •(carcinom$ or cancer$ or neoplas$).ti,ab. •3202195 Row 7: 6 •lung$.ti,ab. •930054 Row 8: 7 •1 or 2 or 3 or (4 and 5 and 6) •16314 Row 9: 8 •crossover procedure/ or double-blind procedure/ or randomized controlled trial/ or single-blind procedure/ •708522",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase - 2021 update>",
        "start_page": 102,
        "end_page": 102,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 19 Row 2: 20 Row 3: 21 Row 4: 22 Row 5: 23 Row 6: 24 Row 7: 25 Row 8: 26 Row 9: 27 Row 10: 28",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Embase - 2021 update> (column 1)",
        "start_page": 102,
        "end_page": 102,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: 1 Row 3: 2 Row 4: 3 Row 5: 4 Row 6: 5 Row 7: 6 Row 8: 7 Row 9: 8",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Embase - 2021 update> (column 1)",
        "start_page": 102,
        "end_page": 102,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 169791 Row 2: 51312 Row 3: 13703 Row 4: 137 Row 5: 1118684 Row 6: 1118699 Row 7: 2072 Row 8: 1117419 Row 9: 9466 Row 10: 4281",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Embase - 2021 update> (column 6)",
        "start_page": 102,
        "end_page": 102,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Results Row 2: 105188 Row 3: 14842 Row 4: 85349 Row 5: 106532 Row 6: 3202195 Row 7: 930054 Row 8: 163414 Row 9: 708522",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Embase - 2021 update> (column 6)",
        "start_page": 102,
        "end_page": 102,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "orrandom$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (single$ adj blind$) or assign$ or allocat$ or volunteer$).ti,ab.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase - 2021 update> (from previous page)",
        "start_page": 103,
        "end_page": 103,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 9 Row 2: 10 Row 3: 11 Row 4: 12 Row 5: 13 Row 6: 14 Row 7: 15 Row 8: 16 Row 9: 17 Row 10: 18 Row 11: 19 Row 12: 20 Row 13: 21 Row 14: 22",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Embase - 2021 update> (from previous page, column 1)",
        "start_page": 103,
        "end_page": 103,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 2312465 Row 2: 2412281 Row 3: 4232620 Row 4: 2193742 Row 5: 16797 Row 6: 6842 Row 7: 9955 Row 8: 2796 Row 9: 4278 Row 10: 7074 Row 11: 230158 Row 12: 383 Row 13: 265 Row 14: 505",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Embase - 2021 update> (from previous page, column 8)",
        "start_page": 103,
        "end_page": 103,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "RowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRow 2: 1=exp non small cell lung cancer/=55ow28 Row 3: 2=lung cancer/ and non small cell.ti,ab: ^45910 Row 4: 3=nsclcccccccc.ti,ab.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase - 2021 update> (from previous page)",
        "start_page": 104,
        "end_page": 104,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: # Row 2: 1 Row 3: 2 Row 4: 3 Row 5: 4 Row 6: 5 Row 7: 6 Row 8: 7 Row 9: 8 Row 10: 9 Row 11: 10 Row 12: 11 Row 13: 12 Row 14: 13 Row 15: 14 Row 16: 15 Row 17: 16 Row 18: 17",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Embase - 2021 update> (from previous page, column 1)",
        "start_page": 104,
        "end_page": 104,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2*Row2Row2*Row2*Row2*Row2Row2*Row2*Row2*Row2*Row2*Row2Row2*Row2Row2*Row2Row2Row2Row2*5Sow3Row2*3Row3Row3Row3Row3Row3Row3Row3Row3Row3Row3Row3Row3Row3Row3Row3Row3Row3Row3Row3Row3Row3::::3Sear4LJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJ",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Embase - 2021 update> (from previous page)",
        "start_page": 105,
        "end_page": 105,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: # Row 2: 1 Row 3: 2 Row 4: 3 Row 5: 4 Row 6: 5 Row 7: 6 Row 8: 7 Row 9: 8 Row 10: 9 Row 11: 10 Row 12: 11 Row 13: 12 Row 14: 13 Row 15: 14",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Embase - 2021 update> (from previous page, column 1)",
        "start_page": 105,
        "end_page": 105,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Results Row 2: 4365 Row 3: 3663 Row 4: 9820 Row 5: 12057 Row 6: 178044 Row 7: 54134 Row 8: 14278 Row 9: 137 Row 10: 1178914 Row 11: 1178929 Row 12: 2106 Row 13: 1177616 Row 14: 9948 Row 15: 517",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Embase - 2021 update> (from previous page, column 2)",
        "start_page": 105,
        "end_page": 105,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row$8ârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârârâ ... ... ... ... ...'rârârârârârârârârârârârâ ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 9909>",
        "start_page": 107,
        "end_page": 107,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 9909>",
        "start_page": 107,
        "end_page": 107,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "7: 12.11.10 or 11.30 (6) 660 Row 8: 13.01 epi epi epi epi epi epidemiology/or epi Ras or RASK2 or RASK2 or RASK2 or RASK2 or RASK2 or RASK$ or RASK$ or RASK$ or RASK2 or RASK or RASK2 or RASK or RASK or RASK2 or RASK or RAS) adj5Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 9909> (from previous page)",
        "start_page": 108,
        "end_page": 108,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "RowRowRowRow right). (RowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRow 3: •Row 4: •mutation$ or mutant$ or mutant$ or mutated Row 5:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 9909> (from previous page, column 1)",
        "start_page": 108,
        "end_page": 108,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: -K-ras or V-Ki-ras or v ki ras or c-ki-ras or c Row 2: S1P or RASK or RASK1 or RASK2 or Kirste Row 3: or status or exon or gene$ or translo Row 4: fusion$ or expression$ or over?expr Row 5: n$)).ti,ab. Row 6: Row 7: w. Row 8: Row 9: Row 10: urvival* or long term survival* or overall Row 11: ab,kw. Row 12: on free survival or progression-free survival Row 13: Row 14: nse or TTR).mp. Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 9909> (from previous page, column 2)",
        "start_page": 108,
        "end_page": 108,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: c-k-ras Row 2: en RAS Row 3: oratio Row 4: ressio Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: surviv Row 11: Row 12: al).ti,a Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 9909> (from previous page, column 3)",
        "start_page": 108,
        "end_page": 108,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: s or ki-•26 944 Row 2: S) adj5 • Row 3: • Row 4: on$ or • Row 5: on$ or • Row 6: • Row 7: • • 30 660 Row 8: • 418 811 Row 9: • 1 108 289 Row 10: • 974 387 Row 11: val* or • 434 023 Row 12: • Row 13: • Row 14: ab,kw. • 106 597 Row 15: • 33 752 Row 16: • 22 485 Row 17: • 1 200 009 Row 18: • 3 683 830 Row 19: • 62 816 Row 20: •388 029 Row 21: • 1 024 171 Row 22: • 1 465 246 Row 23: • 3 497 123 Row 24: • 4845 Row 25: • 4 222 885 Row 26: • 4770 Row 27: • 4680",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 9909> (from previous page, column 4)",
        "start_page": 108,
        "end_page": 108,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 31°limit 30 to (editorial or erratum or letter or note or patent or reports or \"review\" or short·569 Row 2: •survey or tombstone) • Row 3: • Row 4: 32°systematic review/ or \"systematic review (topic) \"/ or systematic review.mp. or meta-•406 496 Row 5: •analysis/ or \"meta analysis (topic) \".mp. or meta-analysis.mp. • Row 6: • Row 7: 33°31 not 32°491 Row 8: 34°30 not 33°4189 Row 9: 35°remove duplicates from 34°4064",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293>",
        "start_page": 109,
        "end_page": 109,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square stone square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US US USS",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293>",
        "start_page": 109,
        "end_page": 109,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right left left right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right left right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page)",
        "start_page": 110,
        "end_page": 110,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 12°10 or 11 Row 2: 13°epedipeology/or epidemiology.ti, Row 3: 14°incident/or incidence.ti,ab,kw. Row 4: 15°prevalence/or survival.ti,ab,kw Row 5: 16°Survival Analysis/or (disease spec Row 6:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 1)",
        "start_page": 110,
        "end_page": 110,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: ,ab,kw Row 3: Row 4: w. Row 5: Pacific su Row 6: l$).ti,a Row 7: Gressio Row 8: p. Row 9:espon Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: tic re Row 23: \".mp.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 2)",
        "start_page": 110,
        "end_page": 110,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: w. Row 3: Row 4: Row 5: Urvival* or long term Row 6: ab,kw. Row 7: on free survival or pro Row 8: Row 9: nse or TTR).mp. Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: view (topic)\"/ or sy Row 23: or meta-analysis.mp",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 3)",
        "start_page": 110,
        "end_page": 110,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: m surv Row 6: Row 7: Ores Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Ystem Row 23: p.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 4)",
        "start_page": 110,
        "end_page": 110,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: vival* Row 6: Row 7: ssion-f Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: matic Row 23:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 5)",
        "start_page": 110,
        "end_page": 110,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: or ov Row 6: Row 7: free s Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Revie Row 23:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 6)",
        "start_page": 110,
        "end_page": 110,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Verall Row 6: Row 7: Surviva Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: ew.mp Row 23:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 7)",
        "start_page": 110,
        "end_page": 110,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Surviv Row 6: Row 7: al).ti,a Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: p. or Row 23:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 8)",
        "start_page": 110,
        "end_page": 110,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: ..22 786 Row 2: ..172 050 Row 3:..805 391 Row 4:...660 077 Row 5: val* or...313 126 Row 6:... Row 7:... Row 8: ab,kw...39 360 Row 9:..18 412 Row 10:..13 580 Row 11:...1 660 331 Row 12:..3 220 374 Row 13:...2 033 482 Row 14:...291 514 Row 15:...1 035 818 Row 16:....2 916 737 Row 17:....2 783 864 Row 18:....1613 Row 19:.....4 559 823 Row 20:.....1610 Row 21:....1561 Row 22:.........",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 9)",
        "start_page": 110,
        "end_page": 110,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 33·31 not 32·131 Row 2: 34·30 not 33·1430 Row 3: 35·remove duplicates from 34·1427",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page)",
        "start_page": 111,
        "end_page": 111,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay. Row2 Row square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square or square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square or or or or or or or or or or or or or or square square square square square square square square square square square square square square square square square square square square square square square square square square square or or or or or or or or or or or or or or or or or or or or or or or square square square square square square square square square square square square square square square square or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or not not not or not not not not not: not: not not not not not: not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not not-s or not-s or not-s or not not not not not or not-s or not-s or not-small-s or not-s or not-s or not-s or not-s or not-s or not-small or not-",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page)",
        "start_page": 111,
        "end_page": 111,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 33 • 31 not 32 Row 2: 34 • 30 not 33 Row 3: 35 • remove duplicates from 34",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 1)",
        "start_page": 111,
        "end_page": 111,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square stone square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or orororororororororororororororor or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 1)",
        "start_page": 111,
        "end_page": 111,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •131 Row 2: • 1430 Row 3: • 1427",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 2)",
        "start_page": 111,
        "end_page": 111,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12 293> (from previous page, column 2)",
        "start_page": 111,
        "end_page": 111,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 24. • Letter/ • 0 Row 2: 25. •or/22-24. •2133 Row 3: 26. •21 not 25. •238 919 Row 4: 27. •9 and 12 and 26. •651 Row 5: 28. •(animal$ not human$).sh,hw. •2033 Row 6: 29. •27 not 28. •651 Row 7: 30. •limit 29 to English language [Limit not valid in ACP Journal Club,CDSR,DARE,CLCMR; records •521 Row 8: •were retarded] • Row 9: 31. •limit 30 to (editorial or review) [Limit not valid in ACP Journal •9 Row 10: •Club,CDSR,DARE,CLEED,CLHTA,CLCMR; records were established • Row 11: 32. systematic review/ or \"systematic review (top) • 34. • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021>",
        "start_page": 112,
        "end_page": 112,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row*106879 Row 3: 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021>",
        "start_page": 112,
        "end_page": 112,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 24° Letter/ Row 2: 25°or/22-24 Row 3: 26°21 not 25 Row 4: 27°9 and 12 and 26 Row 5: 28°(animal$ not human$).sh,hw. Row 6: 29°27 not 28 Row 7: 30°limit 29 to English language [Limit not valid in ACP Journal Club Row 8:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021> (column 1)",
        "start_page": 112,
        "end_page": 112,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: # •Searches Row 2: 1 •exp lung non small cell cancer/ • Row 3: 2 •(nsclc or non-small cell lung cancer). • Row 4: 3 • 1 or 2 • Row 5: 4 •limit 3 to yr=\"2019 -Current\" • Row 6: 5 •exp colon cancer/ or exp rectum cancer/ or colorectal tumor/ • Row 7: 6 •(colorect$ or rect$ or rectum$ or colon$ or sigma$ or sigmo$ • Row 8: •anal or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan • Row 9: • Row 10: •or adenocarcinoma$ or meta-sta$ or sarcoma$ or a • Row 11: • 5 or 6 • Row 12: 8 •limit 7 to rayr= • • 10\" • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021> (column 1)",
        "start_page": 112,
        "end_page": 112,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: b,CDSR,DAR Row 8: Row 9: valid in Row 10: Row 11: Ematic Revi Row 12: Row 13: Row 14: Row 15:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021> (column 2)",
        "start_page": 112,
        "end_page": 112,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: $ or rectos Row 8: n$ or tumo Row 9: adenom$o Row 10: Row 11: Row 12: Row 13:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021> (column 2)",
        "start_page": 112,
        "end_page": 112,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: RE,CLCMR; reco Row 8: Row 9: n ACP Jour Row 10: Row 11: jew.mp. or me Row 12: Row 13: Row 14: Row 15:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021> (column 3)",
        "start_page": 112,
        "end_page": 112,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: sigm$ or bowl$ Row 8: o?r$ or carcinoma Row 9: or lesion$)).ti,ab Row 10: Row 11: Row 12: Row 13:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021> (column 3)",
        "start_page": 112,
        "end_page": 112,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021> (column 4)",
        "start_page": 112,
        "end_page": 112,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: \"Results Row 2: \"106879 Row 3: \"116340 Row 4: \"160606 Row 5: \"34076 Row 6: \"339744 Row 7: $ or \"367191 Row 8: \" Row 9: \" Row 10: \" Row 11: \" 442830 Row 12: \"62540 Row 13: \"94311 Row 14: \"11065",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021> (column 4)",
        "start_page": 112,
        "end_page": 112,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "7: 12.11.10 or 11 .35639 Row 8: 13 • epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epi epit epit epit epit epit epit epit epit epit epit epit epie epidemicology/ or or epi epi epi epi epie epie epi epie epie epi epi epi epi epi epie epie epidemicology/or epidemic or epidemic etc Row Row Row 6: igment$ or mutant$ or mutant$ or mutant$ or mutated or mutated or muted or reputation$ or RRASOK or RASK or RASK or RASK or RASK or RASK or RASK or RASK or RASK or RAS or RASK or RAS or RAS or RAS) or RAS or RAS) or RS or RS2 or RAS2 or RAS or RAS) or RS) or or or Rash or Rash or Rash or Rash or Rash or RAS or Rash or R RAS) or Rash or RS or Ras or RS, or RAS, respectively, or RAS, respectively, respectively, or RAs or RAs or RAs or RAs or RAS, or RAS, or Rj5, or Rj5, or Rj5, or Raj, or RAs, or Rj5, or Rj5, or Rj5, or RAs, or Rj5, or Rj5, respectively, or Rj5, or Rjon Rj5, or Rj5, or Rj5, respectively, or Rj5, or Rj5, or Rj5, or Rj5, or Rj5, or Rj 5, or Rj 5, or Rj5, respectively, or Rj5, or Rjright, or Rj 5, or Rjright, or Rj, or Rj, or Rj, or Rjon RA, or Rj",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021> (from previous page)",
        "start_page": 113,
        "end_page": 113,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: or or or or or or or or or or or or or or or or or or or or or or or or or or or or or row: or row: or row: or row: or row: or or row: or or or or or row: or row: or or row: or row: or or or or or row: or row: or row: or or or or row: or row: or row: or row: or r right; row: or Row: Row: Row: Row: Row: or Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021> (from previous page, column 1)",
        "start_page": 113,
        "end_page": 113,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: c-k-ra Row 2: en RA Row 3: oratio Row 4: ressio Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: survi Row 11: Row 12: val).ti, Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021> (from previous page, column 2)",
        "start_page": 113,
        "end_page": 113,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: as or ki-...31465 Row 2: AS) adj5• Row 3: • Row 4: on$ or • Row 5: on$ or • Row 6: • Row 7: • 35639 Row 8: • 463878 Row 9: • 1249736 Row 10: • 1124407 Row 11: ival* or • 523163 Row 12: • Row 13: • Row 14: ,ab,kw • 132750 Row 15: • 42707 Row 16: • 26376 Row 17: • 1261807 Row 18: • 4119933 Row 19: • 76518 Row 20: • 442402 Row 21: • 1118459 Row 22: • 162549 Row 23: • 3912144 Row 24: • 1245 Row 25: • 4444 Row 26: • 1204 Row 27: • 1191",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < • Embase • updated search: 10 March 2021> (from previous page, column 3)",
        "start_page": 113,
        "end_page": 113,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 31°limit 30 to (editorial or erratum or letter or note or patent or reports or \"review\" or short",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <10 k ras oncogene/ 12466>",
        "start_page": 114,
        "end_page": 114,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Raw square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square or square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or other 3: 3: 2: 2: 2: 2: 2 two-sinninninninninninninninninnnnnnnnnnnnnnnnnnnnnnnnnnnnnninninninninnnnnninninninninninninninninninninninninninninnin-sin-sin-sin-sinn-sinn-sin-sin-sinn-sinn-sinn-sinnnnnnnnnnnn",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <10 k ras oncogene/ 12466>",
        "start_page": 114,
        "end_page": 114,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rowwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayswaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway:::::::::::::S:::::::::::::::::::::S::::::::::::::::::::::S::S::::::::::::::::::::::::::::::::::::S222222222222222",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <10 k ras oncogene/ 12466> (from previous page)",
        "start_page": 115,
        "end_page": 115,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 22: 22: 22: 20: 20;adverse effects.fs. Row 12: 20: 20: 20: 20;adverse effects.fs. Row 12: 21: 21: 21: 21: 21: 21: 13: 13: 20: 21: 13: 20: 20: 20: 20: 20: 20: 20: 20: 20: 20: 20: 20: 20: 20: 20: 20: 21: 21: 21: 21: 21: 13: 20: Row 12: 22: 20: 20: 20: Row 12: 22: 21: 20: 22: 22: 20: Row 10: 22: 26: 22: 26: 25: 25: 25: 22: 21: 13: 20: Row 12: 22: 20: 22: 22: 22: 21: 20: 22: 21: 20: 22: 22: 22: 22: 21: 20: 22: 21: 20: 22: 22: 22: 21: 22: 22: 21: 22: 21: 22: 22: 21: 21: 22: 21: 22: 22: 22: 22: 21: 22: 21: 22: 20: 22: 22: 22: 22: 22: 22: 22: 22: 22: 22: 22: 22 to organisation organisation of organisation of organisation of to organisation of response of response of response of response of response of response of response of response of response or response or response or response response or 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <10 k ras oncogene/ 12466> (from previous page, column 1)",
        "start_page": 115,
        "end_page": 115,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: and term s Row 6: Row 7: Ival or prog Row 8: Row 9: mp. Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: )\"/ or sys Row 23: alysis.mp.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <10 k ras oncogene/ 12466> (from previous page, column 2)",
        "start_page": 115,
        "end_page": 115,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Surviv Row 6: Row 7: Gress Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Stama Row 23:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <10 k ras oncogene/ 12466> (from previous page, column 3)",
        "start_page": 115,
        "end_page": 115,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: val* o Row 6: Row 7:sion-f Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: atic Row 23:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <10 k ras oncogene/ 12466> (from previous page, column 4)",
        "start_page": 115,
        "end_page": 115,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: or ov Row 6: Row 7: free s Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: review Row 23:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <10 k ras oncogene/ 12466> (from previous page, column 5)",
        "start_page": 115,
        "end_page": 115,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Verall Row 6: Row 7: Surviv Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: w.mp Row 23:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12466> (from previous page, column 6)",
        "start_page": 115,
        "end_page": 115,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: survi Row 6: Row 7: val).ti, Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: p. or Row 23:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12466> (from previous page, column 7)",
        "start_page": 115,
        "end_page": 115,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •24918 Row 2: •198048 Row 3: •888464 Row 4: •745199 Row 5: Ival* or •361241 Row 6: • Row 7: • Row 8: ,ab,kw. •50329 Row 9: •21857 Row 10: •15139 Row 11: •1778356 Row 12: •3535848 Row 13: •2158984 Row 14: •328403 Row 15: •1123553 Row 16: •3123899 Row 17: •3073118 Row 18: •430 Row 19: •4750851 Row 20: •429 Row 21: •426 Row 22: •23 Row 23: meta-",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < 10 k ras oncogene/ 12466> (from previous page, column 8)",
        "start_page": 115,
        "end_page": 115,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 33...31 not 32...19 Row 2: 34...30 not 33...407 Row 3: 35... remove duplicates from 34...407",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <• Cochrane • updated search: 10 March 2021>",
        "start_page": 116,
        "end_page": 116,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Rright: Row: Row: Rright: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: R-exp CarcinomaomaRow: 1-exp Carcinomaomaoma, Non-small cell lung cancer).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <• Cochrane • updated search: 10 March 2021>",
        "start_page": 116,
        "end_page": 116,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 33 • 31 not 32 Row 2: 34 • 30 not 33 Row 3: 35 • remove duplicates from 34",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <• Cochrane updated search: 10 March 2021> (column 1)",
        "start_page": 116,
        "end_page": 116,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square stone square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square square or or or or or or or or or orororororororororororororororororor not valid in DARE or record or record in DARE or record or records were established]] 0 DARE or records were established] 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0: 5: 5: 5: 5: 5: 5: 5 0 0 0: 5: 5: 5 Expexexexexexexexex exported to 0: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5: 5",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <• Cochrane updated search: 10 March 2021> (column 1)",
        "start_page": 116,
        "end_page": 116,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: \"19 Row 2: \" 407 Row 3: \" 407",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <• Cochrane updated search: 10 March 2021> (column 2)",
        "start_page": 116,
        "end_page": 116,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •Rests Row 2: •4656 Row 3: •14347 Row 4: •14819 Row 5: •2010 Row 6: •8922 Row 7: wel$ or •25271 Row 8: inoma$ •Row 9: • Row 10: ti,ab. • Row 11: •26344 Row 12: •3676 Row 13: •5654 Row 14: •66 Row 15: as or ki-•1344 Row 16: AS) adj5 • Row 17: • Row 18: on$ or",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <• Cochrane updated search: 10 March 2021> (column 2)",
        "start_page": 116,
        "end_page": 116,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rowwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <• Cochrane updated search: 10 March 2021> (from previous page)",
        "start_page": 117,
        "end_page": 117,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right left left left left left left left left right left left left left left left left left right left left left left left left left left left left left left left right right right right left left left left left left left right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right Ruright right right right right right right Ruright Ruright Ruright Ruright Ru right Ru right Ruright Ruright Ru right Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ru Ru Ru Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ruright Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru Ru",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <• Cochrane updated search: 10 March 2021> (from previous page, column 1)",
        "start_page": 117,
        "end_page": 117,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: val* or overall Row 4: Row 5:sion-free surviv Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: DSR,DARE,CLCM Row 19: Row 20: aid in AC Row 21: Row 22: atic review.mp Row 23: Row 24:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <• Cochrane updated search: 10 March 2021> (from previous page, column 2)",
        "start_page": 117,
        "end_page": 117,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • 123869 Row 2: • 41883 Row 3: survival* or • 105477 Row 4: • Row 5: • Row 6: val).ti,ab,kw. • 25533 Row 7: • 29151 Row 8: • 5931 Row 9: • 2083 Row 10: • 272783 Row 11: • 0 Row 12: • 2708 Row 13: • 0 Row 14: • 2708 Row 15: • 272193 Row 16: • 76 Row 17: • 2133 Row 18: • 76 Row 19: MR; records • 66 Row 20: • Row 21: • Row 22: Journal • 1 Row 23: • Row 24: • Row 25: p. or meta-",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <• Cochrane updated search: 10 March 2021> (from previous page, column 3)",
        "start_page": 117,
        "end_page": 117,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 34°30 not 33°65 Row 2: 35°remove duplicates from 34°65",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <35 remove duplicates from 34 65>",
        "start_page": 118,
        "end_page": 118,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row: Row: Row: Rive: Criteria-Include: •Ex-safe •Row 2: Population •Adults (18 years) of KRAS mutated locally acquired and expected participants if information specific to adults was reported separately '. Subgroups of particular interest including but not limited to: • PD-L1 expression • Patients with cancers other than NSCLC • Early-stage NSCLC patients (Stage< IIIB-B) • Paediatric and adolescent (<18 years) patients • Patients with cancers other than NSCLC • Early-stage NSCLC patients (Stage< IIIB) • Paediatric and adolescent (<18 years) patients • Patients with cancers other than NSCLC • Early-stage NSCLC clients • Early vs late vs la late clients • Paed and adolescent (< (< (< 18 years) patients • Patients with patients with cancers other than NS C C C C C C C C C through through through through through means means • Ear market market third patients (St third (St C'",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <35 remove duplicates from 34 65>",
        "start_page": 118,
        "end_page": 118,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "• Level-level • Level-level • Level-level • Level-level • Level-level • Level-level • Detailed response (PR) • Complete response (CR) • Odds ratio for response rates • Duration of response • Disease control rate or clinical benefit rate • Treatment duration and dose (median duration, mean duration, mean number of doses, cumulative doses, etc.) Safety and tolerability: • All-grade treatment-earning AEs • Treatment related grade 3 or 4 AEs • Treatment related grade 3 or 4 AEs • Study design/secting • Long-term management and interruptions, discontinuation (any reason), discontinuation (due to AEs)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Safety and tolerability:>",
        "start_page": 119,
        "end_page": 119,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table under heading < Safety and tolerability:> (column 1)",
        "start_page": 119,
        "end_page": 119,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "• Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life • Non-life insurance • Non-life • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance life insurance • Non-life insurance • Non-life insurance life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance life insurance • Non-life insurance life insurance • Non-life insurance life insurance • Non-life insurance • Non-life insurance life insurance life insurance • Non-life insurance life insurance • Insurance • Non-life insurance • Non-life insurance life insurance life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance • Non-life insurance life insurance • Non-life insurance • Insurance • Insurance life insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance • Insurance •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table under heading < Safety and tolerability:> (column 2)",
        "start_page": 119,
        "end_page": 119,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rowwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <2) SLR Screen:>",
        "start_page": 120,
        "end_page": 120,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Date Row 2: restrictions",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <2) SLR Screen:>",
        "start_page": 120,
        "end_page": 120,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •Eligibili Row 2: •criteria Row 3: Popula •Popula Row 4: •Interve Row 5: •Compa Row 6: Outcom •Outcom Row 7: Study d •Study d Row 8: Date restrictively •Date Row 9: •Restrict Row 10: •Langua Row 11: •Restrict",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <2) SLR Screen:> (column 1)",
        "start_page": 120,
        "end_page": 120,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: ity Row 2: a Row 3:ation Row 4: Row 5: entry Row 6: Row 7: arator Row 8: mes Row 9: Row 10: design Row 11: Row 12: Row 13:tions Row 14: Row 15: age Row 16: tions",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <2) SLR Screen:> (column 2)",
        "start_page": 120,
        "end_page": 120,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "RowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRow RowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowRowR right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <2) SLR Screen:> (column 3)",
        "start_page": 120,
        "end_page": 120,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <2) SLR Screen:> (column 3)",
        "start_page": 120,
        "end_page": 120,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: usion Criteria Row 2: Row 3: or types other than NS Row 4: Row 5: otherapy or surger Row 6: accustomed comparator arm) Row 7: Row 8: Row 9: Row 10: out animal/in vitro Row 11: ies and case reports Row 12: Row 13: Row 14: Row 15: Row 16:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <2) SLR Screen:> (column 4)",
        "start_page": 120,
        "end_page": 120,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: SCLC Row 4: Row 5: reputation (u Row 6: Row 7: Row 8: Row 9: Row 10: studio Row 11: Row 12: Row 13: Row 14: Row 15: Row 16:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <2) SLR Screen:> (column 5)",
        "start_page": 120,
        "end_page": 120,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Unless Row 6: Row 7: Row 8: Row 9: Row 10: ies, c Row 11: Row 12: Row 13: Row 14: Row 15: Row 16:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <2) SLR Screen:> (column 6)",
        "start_page": 120,
        "end_page": 120,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: s a Row 6: Row 7: Row 8: Row 9: Row 10: case Row 11: Row 12: Row 13: Row 14: Row 15: Row 16:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <2) SLR Screen:> (column 7)",
        "start_page": 120,
        "end_page": 120,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Publication type...All publication types, except editorials and... Row 2: reviews, but including systematic reviews...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Figure 1. Study flow of included and excluded RCTs>",
        "start_page": 121,
        "end_page": 121,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Level of ownership: Level of ownership, NCT ID, Study design, Study names, Phase of study.Dates of study, Study location or region\n\nPatients who received >2 prior systemic therapys were expected to receive 1) Histologically proven NSCLC, were greater than 18 years of age, had an ECOG performance status of 0 , adequate organ function 2) Treated brain metastases were allowed if not required steroid or antiepileptic medications...1) Uncontrolled disease related to the primary malignancy and a history of prior EGFR TKI (erlotinib) or an MEK inhibitor...1°: ORR",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria",
        "start_page": 123,
        "end_page": 123,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish Row 2: submission and Row 3: reason",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria",
        "start_page": 123,
        "end_page": 123,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Blumenschein et al Row 2: 2015(101) Row 3: NCT01362296 Row 4: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria",
        "start_page": 123,
        "end_page": 123,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01229150; CTEP: 8444 Row 2: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria",
        "start_page": 123,
        "end_page": 123,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trial name, NCT ID, Study design, Study names, Phase of study, Students of study location or region",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria",
        "start_page": 123,
        "end_page": 123,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In this case, according to the above above above, according to the above above above, according to the above above above, according to the above above above, according to the above above above, to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right to the right, right, right to the right, right to the right, right, right to the right, right to the right to the right to the right right right right right right right, right, right, right to the right, right right right right right, right, right right, right, right to the right, right right right right right right right right right right right right right right right right right right right right right right right, right, right, right, right, right, right, right, right, right, right, right to to right to the right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right to the right, right, right, right, right, right, right, right, right, right, right, right, right, right, right, right right right, right, right, right, right, right, right, right, right, right, right, right, right, right right right, right, right, right, right, right right, right, right, right, right, right, right, right, right, right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria",
        "start_page": 123,
        "end_page": 123,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish submission and reason Row 2: Row 3: Included Docetaxel arm too small and does not hold sufficient data on the baseline characteristics of affected patients to allow its consideration as data source in indirect comparative analyses with sotorasib. Row 4: Included No relevant intervention Row 5: Included No relevant intervention",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Appendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria",
        "start_page": 123,
        "end_page": 123,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the same as across across across across, NCT ID, Study design, Study names, Phase of study.Dates of study, Study location or region.Interventions details, Number of patients.Prior study names, Phase of study, Study location, Study location or region.Interventions details, Number of patients.Primary and secondary endpoint.Included in Danish submission and warrant Row 2: •2011 and June 2013 vigivantinib, 360 mg orally twice daily (n=51) Investigator's choice 500 mg/m2 day 1 every 21 days) (n=45)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 124,
        "end_page": 124,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish Row 2: submission and Row 3: reason",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 124,
        "end_page": 124,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02152631 Row 2: Phase 3",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 124,
        "end_page": 124,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "(n=45) •a documented 1 mg/m2 days 1 and 8 every 21 days 1 and 8 every 21 days, sleeps 75 mg/m2 day 1 every 21 days, or pemetrexed 500 mg/m2 day 1 every 21 days, and 1 and 8 every 21 days, sleepables 75 mg/m2 day 1 every 21 days, or pemetrexed 500 mg/m2 day 1 every 21 days) (n=45)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 1)",
        "start_page": 124,
        "end_page": 124,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish submission and reason Row 2: Row 3: Included No relevant intervention",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 3)",
        "start_page": 124,
        "end_page": 124,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the right value, NCT ID, Study design, Study names, Phase of study.Dates of study, Study location or region.Interventions details, Number of patients.Prior study names, Phase of study, Study location, Study location or region.Interventions details, Number of patients.Privacy and secondary endpoint.Included in Danish submission and reason Row 2:\n\n2nd place of businessR a right stock of 1 own business line of business for equityd disease, a centrally confirmed KRAS-mutant tumor) With WHO performance status of 0 or 1 January1) Mixed small cell and non steroids and anti-convulsants for ≥ 4 weeks prior to screening)....1°: PFS 2°: OS, ORR, DOR, TTP, safety and tolerability, --- Included in application Row 4: Papadimitmitrakopoulos et al 2016 (106) BATTLE-2 store 2 Phase 2us study Arm 1, erlotinib 150 mg once daily (n=22) Arm 2, erlotinib 150 mg daily (n=22) Arm 2, erlotinib 150 mg once daily and to the day cannot be applied.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 125,
        "end_page": 125,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish Row 2: submission and Row 3: reason",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 125,
        "end_page": 125,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01933932 Row 2: SELECT-1 Row 3: Phase 3",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 125,
        "end_page": 125,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 2016 (106) Row 2: BATTLE-2 Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 125,
        "end_page": 125,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: Janne et al 2017 NCT01933932 SELECT-1 Phase 3 • Janne et al 2017 Row 3: • NCT01933932 Row 4: • SELECT-1 Row 5: • phase 3 Row 6: Papadimitrakop 2016 (106) BATTLE-2 Phase 2 • Papadimitrakop Row 7: • 2016 (106) Row 8: • BATTLE-2 Row 9: • phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 1)",
        "start_page": 125,
        "end_page": 125,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the right right stock stock, Study location or region.Interventions details, Number of patients.Prior above the rightInclusion to receive study.Inclusion criteria Row 2:\n\nRow 4: erlotinib 150mg once per day and the ACT inhibitorMK-2206 135mg once weekly (n=42) Arm 3, MEK inhibitor AZD6244",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 2)",
        "start_page": 125,
        "end_page": 125,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 2)",
        "start_page": 125,
        "end_page": 125,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish submission and reason Row 2: Row 3: Included in application Row 4: Included No relevant intervention",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 3)",
        "start_page": 125,
        "end_page": 125,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Level 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year year 1 year year year 1 year 1 year year 1 year 1 year 1 year 1 year 1 year 1 year year year 1 year 1 year 1 year 1 year 1 year year 1 year 1 year 1 year 1 year year year 1 year year year year 1 year 1 year 1 year 1 year year year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year year year year year year year year year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year year 1 year year year year year year 1 year 1 year year year year 1 year year year year year year year year year year year 1 year 1 year 1 year year year 1 year 1 year 1 year 1 year year year year year year year 1 year 1 year 1 year 1 year 1 year 1 year 1 year year year year year year year year year year year year 1 year 1 year year year year 1 year 1 year year year year 1 year year year year year year year year 1 year 1 year 1 year 1 year 1 year 1 year 1 year year year year 1 year 1 year 1 year year year year year year year 1 year 1 year year year year",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 126,
        "end_page": 126,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish Row 2: submission and Row 3: reason",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 126,
        "end_page": 126,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT00637910 Row 2: TAILOR Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 126,
        "end_page": 126,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "2206 100 mg once weekly (n=75) Arm 4, sorafenib 400 mg orally twice daily daily (n=75) Patients with unstable/untreated brain metases Row 3: Rulli et al 2015 (102) NCT0063 NCT0063 NCT006379110 TAIL OR",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 1)",
        "start_page": 126,
        "end_page": 126,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •Borghaei et al 2015 (107) •International study (United States, Argentina, •Nivolumab 3 mg/kg every 2 weeks •1) Patients who had received one prior •1) Patients aged ≥ 18 years with stage IIIB or IV or currently non •1) Patients with autoimmune disease, symptomatic interstitial Row 2: •NCT01673867 •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 1)",
        "start_page": 126,
        "end_page": 126,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish submission and reason Row 2: Row 3: Included No relevant intervention Row 4: Row 5: Excluded",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 2)",
        "start_page": 126,
        "end_page": 126,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the same as across across across across across across across across across across across across across across across markets of study, Study location or location or region.Interventions details, Number of patients.Prior tomorrow, Study, India, Austria, Brazil, Canada, Chile, Czechia, France, Germany, Hong Kong, Hungary, Italy, Mexico, Norway, Peru, Poland, Romania, Russian Federation, Singapore, Spain, Switzerland) concluded b Between November 2012 and December 2013.....[n=292) Docetaxel 75 mg/m2 or every 3 weeks (n=290) (n=290) dress, Singapore, Spain, Switzerland, Switzerland, Switzerland) concluded b  between November 2012 and November 2012 and December 2013...... (n=292) Doceumerum-base in dispute, Singapore, Spain, Switzerland, Switzerland) prepared b Between November, Brazil, Canada, Canada, Canada, Canada, Canada, Canada, Canada, Canada, Canada, Canada, Canada, Canada, Canada, Canada, Germany, Hong Kong, Hungary, Canada, Canada, Mexico, Canada, Mexico, Norway, Norway, Norway, Norway, Norway, Norway, Norway, Norway, Mexico, Norway, Norway, Norway, Norway, Norway, Norway, Canada, Canada, Norway, Canada, Norway, Canada, Canada, Norway, Norway, Norway, Norway, Norway, Canada, Canada, Canada, Canada, Norway, Canada, Norway, Norway, Norway, Norway, Norway, Canada, Norway, Norway, Norway, Canada, Norway, Canada, Canada, Canada, Canada, Canada, Norway, Norway, Norway, Norway, Canada, Norway, Norway, Norway, Norway, Norway, Norway, Norway, Norway, Norway, Norway, Canada, Norway, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Canada, Canada, Canada, Norway, Norway, Singapore................................................, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia, Russia\n\n3) Prior adjuvant chemotherapy was permissible providing patients had completed at least 1 year prior to relapse/recurrence of...1) Patients aged ≥ 18 years with clinically and/or radiologically documented diagnosis of NSCLC and ECOG PS 0...1) Concurrent treatment with other investigational drugs or anti-cancer therapy 2) Patients with unreated brain metastases, unreated spinal cord compression or meningeal metastases...1°: PFS 2°: OS, ORR, experimental translational analyses...Excluded Population with no relevant mutation",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 127,
        "end_page": 127,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish Row 2: submission and Row 3: reason",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 127,
        "end_page": 127,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Phase 3 Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 127,
        "end_page": 127,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01708993 Row 2: CCTG IND211 Row 3: Phase 2 Row 4:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 127,
        "end_page": 127,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the same as across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across between Austria, Brazil, Canada, Chile, Czechia, France, Germany, Hong Kong, Hungary, Italy, Mexico, Norway, Peru, Poland, Romania, Russia, Russia, Russian Federation, Singapore, Spain, Switzerland, Switzerland) concluded b between November 2012 and December 2013 (n=292) Docetaxel 75 mg/m2 every 3 weeks (n=290)  much-based double-based double-based or otherwise organisational regime. Patients who achieved last last lasted priority with immune-s-storey anti-series anti- tumble across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market;;;;;;; market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market market\n\n3) Prior adjuvant chemotherapy was permissible providing patients had completed at least 1 year prior to relapse/recurrence of...1) Patients aged ≥ 18 years with clinically and/or radiologically documented diagnosis of NSCLC and ECOG PS 0...1 (1) Concurrent treatment with other investigational drugs or anti-cancer therapy 2) Patients with unreated brain metastases, untreated spinal cord compression or meningeal metastases",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 1)",
        "start_page": 127,
        "end_page": 127,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish submission and reason Row 2: Population with no relevant mutation Row 3: Included Population with no relevant mutation",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 2)",
        "start_page": 127,
        "end_page": 127,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the same as across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across across through through through through through through through through through through through through through through through through through through through through through through through through through through through through through through through through through through through through TCID50 IV over 60 min on days 1 January 3, every 21 days (n=39) Arm D, sleep 75 75 mg/m2, IV over 60 min on day, every 21 days, every 21 days D, sleep 75 mg/m2, IV on day, IV on day, IV on day on day on day on day, IV, IV on day on day one, IVone, IV one one, IVone, IV on day, IVone, every TID' on every TID 50 TID 50 IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV IV",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 128,
        "end_page": 128,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish Row 2: submission and Row 3: reason",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 128,
        "end_page": 128,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT00556322 Row 2: TITAN Row 3: Phase 3",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 128,
        "end_page": 128,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the same as in 2012, according to the same design, Study names, Phase of study.Dates of study, Study location or location or region.Interventions details, Number of patients.Prior tomorrow names, Study names, Phase of study, Study places of study, Study location or region.Interventions details, Number of patients.Prior every 21 days and plareorep 4.5×1010 TCID50 IV more than 60 min on days 1 , 3 , every 21 days, every 21 days, every 21 days and plareorep 4.5×1010 TCID50 IV more than 60 min on days 1 , every 21 days (n=33), every 21 days (n=38) ordise and the patient should be taken 75 mg/m2, IV more than 60 min on day one, every 21 days and every 21 days andpelareorep 4.5 4.5 4.5× 4.5× 4.5× 101010 TCID50 IV more than 60 min on days 1 , every 21 days, every 21 days (n=38) etcy 21 days (n=38) (n=38) ordisease and the patient D D D D, if and the patient had established oneved oneved oneved one year one year, every one year year, every one year year year year year year year year year, first year year year 21 1 21 first one to year) than 21 1 21 1 21 1 year) year year year year year year year year) than One to year) than 1 21 1 21 1 21 1 21 year) than One to last year) than than than One to last year) N to year. to year.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 1)",
        "start_page": 128,
        "end_page": 128,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "to year. to last year) than than than 1 year.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 1)",
        "start_page": 128,
        "end_page": 128,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Row 1: Included in Danish submission and reason Row 2: Row 3: Included Population with no relevant mutation",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 3)",
        "start_page": 128,
        "end_page": 128,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay, okay. Level 1 villa holder, NCT ID, Study design, Study names, Phase of study.Dates of study, Study location or region.Interventions details, Number of patients.Prior tomorrow names, Phase of study, Study location criteriaExclusion criteriaPrimary and secondary end points.Included in Danish submission and warrant Row 2: Pillai et al 2020 (110) NCT01798485 GALAXY-2 Phase 3 International study conducted b  between April 2013 and December 2015",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 129,
        "end_page": 129,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish Row 2: submission and Row 3: reason",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 129,
        "end_page": 129,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01798485 Row 2: GALAXY-2 Row 3: Phase 3",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 129,
        "end_page": 129,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: (111) Row 2: GALAXY-1 Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 129,
        "end_page": 129,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02008227 Row 2: OAK Row 3: Phase 3",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 129,
        "end_page": 129,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "If the answer to the first question is yes, the answer to the first question must be yes or no, the answer to the first question must be yes or no. 2) Patients with stable and still still still still still still still remains actually actually remains ¡S1°: TTP 2°, OS, ORR, safety, safety •Ex considered No relevant intervention Row 5: Scagliotti et al 2015 (114) NCT01244191 MARQUEE Phase 3 International study (Europe and Russia, the United States, Latin America, Canada, and Australia) concluded between January 2011 and July 2012 (cut-off December 15, 2012) •Erlotinib 150 mg once daily orally + Tivvantinib 360 mg twice daily orally (n=526) Placebo + erlotinib 150 mg once daily 2011 and July 2012 (cut-off December 15, 2012) •Erlotinib 150 mg once daily daily daily + Tivantinib 360 mg twice daily daily orally (n=522) • Placebo + erlotinib 150 mg once daily orally (n=522) •1) Patients who who had received 1 January 2 or previous previous 2 or previous system anticancer trends, including patient-based based based chemical, including chemical, within across creates, within across across across across across across across across across across would would would would would would would would would would would would lead lead lead lead lead to market market market market market would would would would would would would would would would would would would would would would be market market market market, without across across across across across across across across across across across market market market market market market, without market, without market market market market, without market market market market market market, without market market market market market market, without across across across across across across across across market market market market market market market market market market, without market, without market market market market, without market market market market, without market market market market market, without market market market market, without market market market market market market, without market market market market market, without market market market market market, without market market market market market, without market market market market market market market, without market, without market market market, without market, without market, without market, without market, without market market market market market market, without market, without market, without market, without market, without market, without market market market market market, without market, without market market market market market market market market market market market, without market market market market market market market market market market market market, without market market market market market market",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 130,
        "end_page": 130,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish Row 2: submission and Row 3: reason",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 130,
        "end_page": 130,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Karampeazis et al 2013 Row 2: (113) Row 3: NCT00440414 Row 4: HORG Row 5: Phase 3",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 130,
        "end_page": 130,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01244191 Row 2: MARQUEE Row 3: Phase 3 Row 4:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 130,
        "end_page": 130,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: OAM4971g (METLung) Row 2: NCT01456325",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 130,
        "end_page": 130,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trial name, NCT ID, Study design, Study names, Phase of study, Study location or region...Inclusion criteria criteria Row 2: further targeting the PD-L1 and PD-1 pathway were expected prior TKI therapy",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 1)",
        "start_page": 130,
        "end_page": 130,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the same as in the first year 2013 (113) NCT00440414 Honorg phase 3  home study concluded b between January 2006 and April 2010;Pemetrexed 500 mg/m2 over 1-hour as IV infusion on day 1, every 3 weeks (n=178) Erlotinib 150 mg/day orally (n=179) •1) Patients who had received taxane or platinum based regime Patients who had received prior prior pemetrexed and TKI were examined) Patients who had received previous previous prior pemetrexed and TKI were treated1) Patients with squaus killed < 65 years with stage IIIB or IV NNCC or IV NNCC who had experienced disease progression after 1 or 2 lines of chemotherapy and ECOG PS 0\n\nRow 3: Spiel et al 2017 (115) OAM4971g (METLung) NCT01456325 • International study conducted between January 2012 and August 2013 (cut-off •Onarzumab 15 mg/kg IV on day 1 of each 21-day cycle + •1) Patients who had received platinum-based chemotherapy •1) Patients with stage IIIB to IV locally advanced or metastatic NSCLC determined to be •1) Patients with unexpected/unstable brain metastases",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 1)",
        "start_page": 130,
        "end_page": 130,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish submission and reason Row 2: Row 3: Row 4: Included No relevant intervention Row 5: Included No relevant intervention Row 6: Included No relevant intervention",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 2)",
        "start_page": 130,
        "end_page": 130,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the right right stock holder, NCT ID, Study design, Study names, Phase of study.Dates of study, Study location or region.Interventions details, Number of patients.Prior tomorrow names, Phase of study, Study location, Study location or region.Interventions details, Number of patients.Primary and secondary end-point.Included in Danish submission and warrant Row 2: Phase 3.October 26, 2013).. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 131,
        "end_page": 131,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Danish Row 2: submission and Row 3: reason",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 131,
        "end_page": 131,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Ciuleanu et al 2017 (116) Row 2: NCT01186861 Row 3: Phase 2 Row 4:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 131,
        "end_page": 131,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trial name, NCT ID, Study design, Study names, Phase of study, Study location or region",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 1)",
        "start_page": 131,
        "end_page": 131,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Patients with diabetes mellitus require insulinotropic or insulin therapy, a fasting glucose ≤ 150 mg/dL and adequate haematopoietic, hepatic and renal function:1) Patients with diabetes mellitus require insulinotropic or insulin therapy, a fasting glucose ≤ 150 mg/dL and adequate haematopoietic, hepatic and renal function:1) Patients with diabetes mellitus require insulinotropic or insulin therapy disease, a defect of poorly control with effect with al 2017 (116) NCT01186861 Phase 2• International study conducted in July 2013 (data cut-off). • Linsitinib 150 mg orally + erlotinib 150 mg daily + erlotinib 150 mg daily for 21 days (n=103) • Patients who had received prior IGF-1R therapy or contemporary maintenance bevacizumab were excluded • 1) Patients with advanced NSCLC stage IIIB or IV following completion of first-line platinum-based chemotherapy, ECOG PS 0 • 1, a fasting glucose ≤150 mg/dL and adequate haematopoietic, hepaticetic and renal function",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 1)",
        "start_page": 131,
        "end_page": 131,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in Row 2: submission Row 3: reason",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 3)",
        "start_page": 131,
        "end_page": 131,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Danish Row 2: and Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 4)",
        "start_page": 131,
        "end_page": 131,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "(n=86) N-Current: 13 (15)Current: 13 (15) Current: 67 (78) 0 (0) 0 0 (n) N-c) Current: 67 (78) 0 (0) 0 (0) 0 0 0 (n) Clinical stalking , n (%))Mutation status, n (%) ]Included in DMC application, warrant for exclusion Row 2: •lle c sa um o mo n a qic u r r a Sco  ] ua om mo anic qr sa n o N-c lle c.PD-L1 expression, n (%) KRASjCurrent: 13 (15) Former: 67 (78) ] ] 0 (0) 0 (0)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 132,
        "end_page": 132,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in DMC Row 2: application, reason for Row 3: exclusion",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 132,
        "end_page": 132,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Blumenschein et Row 2: al 2015 (101) Row 3: NCT01362296 Row 4: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 132,
        "end_page": 132,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: (103) Row 2: NCT01229150; Row 3: CTEP: 8444 Row 4: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 132,
        "end_page": 132,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: (104) Row 2: NCT01395758 Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 132,
        "end_page": 132,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Seawaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway N N N N N N N N N N N N N N N NN N N N N N NN NN N N NN NN NN NN NCTwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway N N N N N N N N N N N N N N N N N N N N N N N N N N NN N N N N N N N N N N N N N N N N N N N N N N N N NN NN NN NN NN NTwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 133,
        "end_page": 133,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in DMC Row 2: application, reason for Row 3: exclusion",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 133,
        "end_page": 133,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: (72) Row 2: NCT01933932 Row 3: SELECT-1 Row 4: Phase 3",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 133,
        "end_page": 133,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: (102) Row 2: NCT00637910 Row 3: TAILOR Row 4:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 133,
        "end_page": 133,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trial name, NCT ID, Study names •Thandling arm (n) •Age, median, years (range) [ 95% CI] •Male, n (%) •Smoking status, n (%) •Histology, n (%) •Clinical stalking , n (%) •Mutation status, n (%) •Included in DMC application, reason for exclusion Row 2: •lle c sa um o mo n a qic u r a Sc •s ua om mo an uic qr sa n o N-clle c•PD-L1 expression, n (%) •KRAS • Row 3: •consideration as data source in indirect comparative analyses with sotorasib.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 134,
        "end_page": 134,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in DMC Row 2: application, reason for Row 3: exclusion",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page)",
        "start_page": 134,
        "end_page": 134,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Age, median, years (range) [ 95% CI] Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 4)",
        "start_page": 134,
        "end_page": 134,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Histology, n (%) • Clinical stagnating , n (%) Row 2: lle c sa um o mo n a qic u r a Scas ua om mo an uic qr sa n o N-c lle c",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 6)",
        "start_page": 134,
        "end_page": 134,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Included in DMC application, reason for exclusion Row 2: consideration as data source in indirect comparative analyses with sotorasib.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Apendix Table 3. Overview of 17 RCTs meeting the broad reliability criteria> (from previous page, column 9)",
        "start_page": 134,
        "end_page": 134,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "In this case, the Court of 2Bright R right right to Right right to rent, KRASG12C mutation; an ECOG PS of 0; 2 (in respect of anti-PD[L]LitRightwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway,,,waywaywaywaywaywaywayway,K,K,K,K,K,K,K,K,K,K,K,K,K,K,K,K,K,",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Sotorasib Row 2: 14",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: > 2 (including anti-Row 2: PD-[L]1 therapies)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Histologically Row 2: confirmed, locally Row 3: advanced or Row 4: metastatic cancer with Row 5: the KRASG12C mutation; Row 6: an ECOG PS of 0 - 2; Row 7: measurable disease Row 8: per RECIST v1.1; for Row 9: patients with NSCLC, Row 10: previous platinum- Row 11: based combination Row 12: therapy, targeted Row 13: therapies, or both",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Active (untreated) Row 2: brain metastases; Row 3: systemic antitumour Row 4: therapy within 28 Row 5: days before initiation Row 6: of sotorasib therapy; Row 7: and radiation Row 8: therapy within Row 9: 2 weeks before Row 10: initiation of sotorasib Row 11: therapy, myocardial Row 12: induction within 6 Row 13: months",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Sotorasib Row 2: 13",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Sotorasib Row 2: 40",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: ≥ 2: 31 (77.5) Row 2: ≥ 3: 19 (47.5)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Hong, 2020 Row 2: International",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Sotorasib Row 2: 59",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Li, 2020 Row 2: International",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Sotorasib Row 2: 126",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Anti-PD-(L)1: 91.3% Row 2: Platinum-based CHT",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 136,
        "end_page": 136,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rivewaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway rightwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT03600883 Row 2: CodeBreak 100 Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Sotorasib Row 2: 126",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Riely, 2021 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT03785249 Row 2: CRYSTAL-1 Row 3: Phase 1/2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Adagasib Row 2: 79",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: CHT and an anti-PD-Row 2: (L)1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: EudraCT: 2005-Row 2: 005393-73 Row 3: Row 4: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Erlotinib Row 2: 34",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: No prior systemic Row 2: treatment for Row 3: advanced NSCLC",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: At least one Row 2: measurable target Row 3: lesion; ECOG PS 0 - 2; Row 4: no prior systemic Row 5: treatment for Row 6: advanced NSCLC",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rowwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 1)",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Exclusive Row 2: riteria Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: n Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: \"Key Primary and Secondary Endpoints/Objects\" Row 2: \"Row 3: \"Row 4: \"NR\" Row 5: \"Row 6: \"PET with both FDG and FLT for accuracy of early prediction of non progression following erlotinib therapy\"PET with both FDG and \"Row 7\": \"FLT for accuracy of early",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 137,
        "end_page": 137,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rive right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02774278 Row 2: International",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02774278 Row 2: Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Jul 2005 Row 2: to Jun Row 3: 2009",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Unstable systemic Row 2: disease; other Row 3: malignancies in the Row 4: last 5 years; brain Row 5: metastases; prior Row 6: treatment with anti-Row 7: EGFR therapy",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: number of Row 2: differentially expressed Row 3: genes associated with Row 4: clinical benefit (including Row 5: KRASm) Row 6: Secondary: ORR, CBR",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Tarhini, 2017 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NR Row 2: Row 3: Phase 1/2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Rilotumumab Row 2: and erlotinib Row 3: 45",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Prior erlotinib, other Row 2: EGFR TKIs, or Row 3: antibiotics targeting Row 4: EGFR",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: safety, RP2D, Row 2: effectiveness (target DCR of Row 3: 70%) Row 4: Secondary: OS, PFS",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Zhao, 2015 Row 2: China",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT00816868 Row 2: C-TONG0807 Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Enrollme Row 2: nt: Feb Row 3: 2009 to Row 4: Sept Row 5: 2009",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Erlotinib and Row 2: capcitabine Row 3: 58",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: None, all naïve to Row 2: lung cancer Row 3: treatment",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: 12-week Row 2: nonprogressive rate Row 3: Secondary: ORR, toxicity, Row 4: PFS, and OS.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Country...Author Row 2: • Country Row 3: NCT0277427 International • NCT0277427 Row 4: • International Row 5: Tarhini, 201 USA • Tarhini, 201 Row 6: • USA Row 7: Zhao, 201 China • Zhao, 201 Row 8: • China",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 1)",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right left right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right: right right right right right right right right right right right right right right right right right right right right right right: right: right: right: right: right: right: right right right right right right: right: right: right: right: right: right right right right: right: right: right: right right right right: right: right: right: right: right: right: right: right: right: right: right: right: right: right right right right right right right right right right right: right right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 78 Row 2: l",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 17 Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 15 Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 138,
        "end_page": 138,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rowwaywaywaywayway right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right left right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Leighl, 2017 Row 2: Canada",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: IND.196 Row 2: Phase 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Jan 2010 Row 2: to Jan Row 3: 2013",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: RP2D Row 2: Secondary: descriptive Row 3: statistics of safety, DLT, Row 4: response, DoR, PK and PD",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Gerber, 2015 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01302808 Row 2: Row 3: Phase 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 2009 to Row 2: 2014a",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Romidepsin and Row 2: erlotinib Row 3: 17",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: safety, Row 2: tolerability, MTD Row 3: Secondary: effectiveness and Row 4: PK",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Ho, 2019 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Antroquinoneol Row 2: 30",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Cytologically or Row 2: histologically Row 3: confirmed non-",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 139,
        "end_page": 139,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right right: right right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02047344 Row 2: International",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02047344 Row 2: Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Oct 2013 Row 2: to 7 Dec Row 3: 2018",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: squamous NSCLC Row 2: (stage IV); disease Row 3: progression after 2 Row 4: Prior LoTs (at least 1 Row 5: platinum-based) or Row 6: patients who refused Row 7: treatment with Row 8: applied treatment; Row 9: at least 1 measurable Row 10: target Lesion per Row 11: RECIST v1.1; fresh or Row 12: archival biopsy tissue Row 13: available; ECOG PS 0 - 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Paik, 2020 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02417701 Row 2: Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 6 Oct Row 2: 2016 to Row 3: 28 Dec Row 4: 2020a",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: TAK228 Row 2: 21",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: ORR Secondary: Row 2: PFS",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Gerber, 2020 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NR Row 2: Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Enrollme Row 2: nt: Sept Row 3: 2013 to Row 4: Jun 2016",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Defactinib Row 2: 55",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Leptomeningeal Row 2: metastasis",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: 12-week PFS Row 2: rate Row 3: Secondary: PFS, OS, ORR, Row 4: and safety",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Country...Author Row 2: • Country Row 3: NCT0204734 Internationa...NCT0204734 Row 4: • Internationa Row 5: Paik, 202 USA...Paik, 202 Row 6: • USA Row 7: Gerber, 202 USA...Gerber, 202 Row 8: U.S.A.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 1)",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the same as 1 last year 1 last year 1 last year 1 last year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 0 year 1 year to year to year to year to 4, year to 4, year to 4, year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year year 1 year 1 year year 1 year 1 year 1 year year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year i last last last last last last last last last last last last last last last last last last last 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 to last last last last last last last last last last last last last last year 1 year 1 year 1 year 1 year 1 year 1 to last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last year 1 N I 1 year 1 year 1 year 1 N I 1 N I 1 N I 1 N I I I I 1 N I 1 N I 1 N I 1 N I 1 N I 1 N I 1 N I 1 N I I I I I 1 N I 1 N I I I I I I I I I I I I I 1 N I I I N I N I I I I I I I I I I I I I I",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 44 Row 2: al",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 20 Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 140,
        "end_page": 140,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right:Key Inclusion Criteria;Key Exclusive Criteria.Key Primary Criteria;Key Primary and Secondary Endpoints Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Nokihara, Row 2: 2019 Row 3: Japan",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT0153656 Row 2: Row 3: Phase 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Enrollme Row 2: nt: 28 Row 3: March Row 4: 2011 to 9 Row 5: Jun 2014",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Cabozantinib Row 2: 20",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: ≥ 3: 20 (100) Row 2: CHT: 20 (100) Row 3: BEV: 10 (50) Row 4: Nivolumab: 1 (5) Row 5: TKI: 19 (95) Row 6: Crizotinib: 1 (5) Row 7: Erlotinib: 10 (50) Row 8: Gefitinib: 13 (65) Row 9: Water anib: 1 (20)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: MTD and/or Row 2: RP2D of capsule and Row 3: tablet formulas Row 4: Safety and effectiveness Row 5: analyses were conducted Row 6: in all patients who Row 7: received ≥ 1 dose of Row 8: cabozantinib.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: Nokihara, 2019 \" Japan\" Nokihara, Row 5: \"2019 Row 6: \"Japan\"",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 1)",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, St Name, Pha Study-NCT ID, St Row 2: • Name, Pha Row 3: • Study Row 4: • Row 5: • NCT015365 Phase 1• NCT015365 Row 6: • Row 7: • Phase 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: tudy Row 2: ase of Row 3:y",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: \"Dates\" Int. Row 2: \"Number o Row 3: \"Patients wi Row 4: \"NSCLC in To Row 5: \"Row 6: 56\" \"Enrollme nt: 28 March 2011 to 9 Jun 2014\" \"Cabozantinib 20\" \"Cabozantinib Row 7: \"20 Row 8: \"",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right left right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 4)",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Ex Row 2: Crit Row 3: Row 4: Row 5: R Row 6:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 5)",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: xclusion Row 2: teria Row 3: Row 4: Row 5: Row 6:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 6)",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •Key Primary and Secondary Endpoints/Objects Row 2: • Row 3: • Primary: MTD and/or RP2D of capsule and tablet forms Safety and effectiveness analyses were conducted in all patients who received ≥ 1 dose of cabozantinib.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 7)",
        "start_page": 141,
        "end_page": 141,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "5 (68.4) KRASm Non-G12C 1: 10 (28.6) 2: 25 (71.4) KOC) + KCT02642042 Phase 1 (31.6) 2: 13 (68.4) KRASm Non-G12C 1:10 (28.6) 2: 25 (71.4) KOceumber and n (%) Row 5: NCT02642042 Phase 2ub.4) 2: 13 (68.4) KRASm Non-G12C 1:10 (28.6) 2: 25 (71.4) KOcetumer and trametinib and 1:16 (29.6) 2: 38 (70.4) KRASG12C 1: 6 (31.6) 2: 13 (68.4) KRASm Non-G12C 1:10 (28.6) 2: 25 (71.4) KM.4) KOcetumerumber and 1:16 (29.6) 2: 38 (70.4): 16 (29.6): 16 (29.6) KN (29.6) KRASGWCRS 1: 12)RARAR Sea SeaR SeaR SeaR SeaR SeaR SeaR1 1 1 1 1 1 1 1 1: R SeaR SeaR SeaR SeaR SeaR SeaR SeaR SeaR SeaR SeaR SeaR SeaR SeaR Sea: R SeaR SeaRSSSSSSSSSSSSSSSSSSSSSSSSSSS right right right right right right: Sea:::: R SeaR right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02642042 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02642042 Row 2: Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 18 Jul Row 2: 2016 to Row 3: 15 May Row 4: 2019",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: ORR in all KRASm Row 2: Secondary: ORR, OS, and Row 3: PFS in KRASG12C and Row 4: KRASm Non-G12C; grade Row 5: 3 - 5 AE",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Gandara, 2017 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01192165 Row 2: Row 3: Phase 1b",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 14 Sept Row 2: 2010 to 7 Row 3: Oct Row 4: 2013a",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trametinib and Row 2: docetaxel plus Row 3: growth factor Row 4: (granulate Row 5: colony- Row 6: stimulating Row 7: factor [G-CSF]) Row 8: or trametinib Row 9: and pemetrexed Row 10:95",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary (Part 1): RP2D Row 2: Primary (expansion Row 3: short): ORR",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Country...Author Row 2: ..Country Row 3: NCT0264204 USA.. ..NCT0264204 Row 4: ..USA Row 5: Gandara, 201 USA... ..Gandara, 201 Row 6: U.S.A.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 1)",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "5 (68.4) KRASm Non-G12C 1:10 (28.6) 2: 25 (71.4):16 (29.6):09.) KRASG12C 1: 6 (31.6) 2: 13 (68.4) KRASm Non-G12C 1:10 (28.6) 2: 25 (71.4):16 (29.6) 2: 38 (29.6) KRASG12C 1: 6 (70.4) 2: 13 (68.4) KRASm Non-G12C 1:10 (28.6) 2: 25 (71.4):16 (29.6) 2: 38 (70.4) KRASG12C 1: 6 (70.4) KRASm Non-G12C 1:10 (28.6) 2: 25 (71.4):16 (29.6):16 (29.6) 2: 38 (70.4) KRASG12C 1: 6 (70.4) KRASG12C 1: 6 (31.6) 2: 13 (31.6) 2: 13 (68.4) KRASm Non-G12C 1: 10 (28): 10 (28 C (28)): 1 3 (29.)): 1 (29): (29.): (29.) N (29.) N (29.) N N N N N N N N N (N N N N N N N N N: N: N: N: N (NRRRRRRRRR): NRRRRRRRRRRRRRRRRRRRRRRRR):RRRRRW):RRRRRRRRRRRW):RRRRRRRRRRRRRRRRRRRRRRRRRRRRRW)), 1:RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR right), 1 1 1 1 1; 1, Right, Right, Right, Right, Right, Right, Right,RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:42 Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 17 Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 142,
        "end_page": 142,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right left right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Barbie, 2018 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02258607 Row 2: NR Row 3: Phase 1b",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Conduct Row 2: ed: Row 3: March Row 4: 2015 to Row 5: March Row 6: 2017",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Momelotinib Row 2: and trametinib Row 3: 21",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: incidence of Row 2: DLTs during first 28-day Row 3: cycle Row 4: Secondary: DCR at week Row 5: 8; ORR; PFS, OS",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Huijberts, Row 2: 2020 Row 3: Netherlands",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02230553 Row 2: Row 3: Phase 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Oct 2014 Row 2: to Dec Row 3: 2019a",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Lapatinib and Row 2: trametinib Row 3: 15",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: RP2R Row 2: Secondary: safety and Row 3: tolerability, preliminary Row 4: anti-tumour activity, PD, Row 5: and PK",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: Barbie, 201 USA \"Barbie, 201 Row 5: \"USA Row 6: Huijberts, 2020 Netherlands \"Huijberts, Row 7: \"2020 Row 8: \"Netherlands",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 1)",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • NCT ID, St Name, Pha Study • NCT ID, St Row 2: • Name, Pha Row 3: • Study Row 4: • Row 5: 18 • NCT0225860 NR Phase 1b • NCT0225860 Row 6: • NR Row 7: • phase 1b Row 8: • NCT0223055 Phase 1• NCT0223055 Row 9: • Row 10: • phase 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: tudy Row 2: ase of Row 3:y",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: \"Dates\" Dates Row 2: \"Row 3: \"07\" Conduct ed: March 2015 t March 2017 \"Conduct Row 4: \"Added: Row 5: \"March Row 6: \"2015 t Row 7: \"March Row 8: \"2017 Row 9: \"Oct 201 to De 2019\" Oct 201 Row 10: \"To De Row 11: \"2019a",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 53 Row 2: Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rowway 1 R right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right left right left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left left: right right right right right right right left left left left left left left left left left left left left left left left left left left left left left left right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 4)",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 14 Row 2: ec Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 4)",
        "start_page": 143,
        "end_page": 143,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Hops Hops Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Bedard, 2015 Row 2: 5 countries: Row 3: USA, Canada, Row 4: and Europe.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01155453 Row 2: Row 3: Phase 1b",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Enrollme Row 2: nt: May Row 3: 2010 to Row 4: Jan 2013",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: All Cancers Row 2: Buparlisib and Row 3: trametinib 17",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: All Cancer Row 2: 3 (1 - 14)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: incidence rate of Row 2: DLT in cycle 1 Row 3: Secondary: safety, PK; Row 4: effectiveness, and Row 5: predictive/PD biomarkers",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: \"Bedard, 201 5 countrie USA, Canad and Europe.'\"Bedard, 201 Row 5: \"5 countrie Row 6: \"USA, Canad Row 7: \"and Europe.\"",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 1)",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "HopsRowwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayswaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 144,
        "end_page": 144,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right, right right right right right right right right right, right right right right right right, right, right, right, right, right, right, right, right right right, right right right right right right right right right right right right right right right right right, right right right right right right right right right right right right right right right right right right right right, right right right right right right, right, right right right right right right right right right right right right right right right right right right, right right right right, right, right right right right right right, right right right right, right right, right, right, right, right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Bardia, 2020 Row 2: International",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01363232 Row 2: Row 3: Phase 1b",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 15 Aug Row 2: 2011 to Row 3: 24 March Row 4: 2014 Row 5: (data Row 6: cutoff)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Advanced solid Row 2: tumors; disease Row 3: progression after Row 4: standard therapy Row 5: and/or no effective Row 6: standard therapy Row 7: available; evaluable Row 8: disease per RECIST Row 9: v1.1; ECOG PS 0 to 2.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: safety and MTD Row 2: Secondary: effectiveness, PK, Row 3: PD",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Froesch, 2020 Row 2: Switzerland",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02964689 Row 2: Row 3: Phase 1b",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Enrollme Row 2: nt: May Row 3: 2017 to Row 4: Dec 2019",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Binimetinib, Row 2: pemetrexed and Row 3: cisplatin Row 4: 18",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Desai, 2020 Row 2: Australia & Row 3: New Zealand",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NR Row 2: Row 3: Phase 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Conduct Row 2: ed: 20 Row 3: Nov 2013 Row 4: to 19 Oct Row 5: 2017",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Lifirafenib Row 2: 19 (9 dose Row 3: escalation + 10 Row 4: dose expansion)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: All cancers: ≥ 3 (inc. Row 2: B-RAF inhibitor Row 3: treatment) 50% Row 4: prior surgery ≥ 75%",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary during dose Row 2: escalation: safety and Row 3: tolerability, including DLT Row 4: and TEAEs. Row 5: Secondary: PK, ORRS, PFS, Row 6: DoR, duration of SD",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 145,
        "end_page": 145,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rightway right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: van Geel, 2020 Row 2: Netherlands",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02039336 Row 2: Row 3: Phase 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Enrollme Row 2: nt: Apr Row 3: 2014 to Row 4: Apr 2018",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Damomitinib/PD-Row 2: 0325901 Row 3: 11",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: At least 2: Row 2: antineoplastic Row 3: therapy for advanced Row 4: disease",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: RP2D and Row 2: schedule Row 3: Secondary: safety and Row 4: tolerability, antitumour Row 5: activity, PK",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Nogova, 2020 Row 2: Germany",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NR Row 2: Row 3: Phase 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Enrollme Row 2: nt: Oct Row 3: 2009 to Row 4: Dec 2013",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Everolimus and Row 2: sorafenib Row 3: 16",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: dose finding Row 2: Secondary: safety, PK, PD Row 3: using FDG-PET, objective Row 4: response",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT00098254, Row 2: 2021 Row 3: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT00098254 Row 2: Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Dec 2004 Row 2: to Jan Row 3: 2011",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: BAY 43-9006 Row 2: (Sorafenib) Row 3: 37",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: van Geel, 202 Netherlands...\"van Geel, 202 Row 5: \"Netherlands Row 6: Nogova, 202 Germany...\" \"Nogova, 202 Row 7: \"Germany Row 8: NCT0009825 2021.\" \"NCT0009825 Row 9: \"2021 Row 10: \"USA\"",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 1)",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: \"NCT ID, St Name, Pha Study-NCT ID, St Row 2: \"Name, Pha Row 3: \"Study Row 4: \" Row 5: \" 20 \" NCT020393 Phase 1 \" NCT020393 Row 6: \" Row 7: \" phase 1 Row 8: \" NR Phase 1 \" NR Row 9: \" Row 10 \": \" phase 1 Row 11 \": \" NCT000982 Phase 2 \" NCT000982 Row 12: \" Row 13: \" phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 20 Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 54, Row 2: Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: tudy Row 2: ase of Row 3:y",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right left right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 54 Row 2: Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 146,
        "end_page": 146,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rowwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Tolcher, 2015 Row 2: NR",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01021748 Row 2: NR Row 3: Phase 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: MK-2206 and Row 2: selumetinib Row 3: 19",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Lopez-Chavez, Row 2: 2015 Row 3: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01306045 Row 2: CUSTOM Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Selumetinib Row 2: monotherapy Row 3: for KRAS, HRAS, Row 4: NRAS, or BRAF Row 5: mutationb Row 6:481",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Histologically Row 2: confirmed recurent or Row 3: advanced NSCLC, SCLC Row 4: (including lung Row 5: neuroendocrine Row 6: tumors), or thymic Row 7: malignancies",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Huijberts, Row 2: 2020 Row 3: Netherlands",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT2450656 Row 2: Row 3: Phase 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: RP2R Row 2: Secondary: anti-tumor Row 3: activity PK and PD",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: Tolcher, 201 NR \"Tolcher, 201 Row 5: \"NR Row 6: Lopez-Chave 2015 \" USA \" Lopez-Chave Row 7: \" 2015 Row 8: \"USA Row 9: \"Huijberts, 2020\" Netherlands \"Huijberts, Row 10: \"2020 Row 11: \"Netherlands",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 1)",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: ez, Row 2: Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: xclusion Row 2: teria Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: \"Key Primary and Secondary Endpoints/Objectives\" Row 2: \"correction of response\" Row 3: \"with KRASm· Row 4: \"Dose finding: MTD in· Row 5: \"patients with locally· Row 6: \"advanced or metastatic\" Row 7: \"solid tumor\" Row 8: \"MTD expansion: confirmation\" Row 9: \"the MTD in a select\" Row 10: \"cohort of patients with \"Row 11: \"KRASm NSCLC· Row 12: \"Primary: ORR 40% Second: OS, PFS·Primary: ORR 40%\" Row 13: \"Second: ORR,\" PFS\"",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 4)",
        "start_page": 147,
        "end_page": 147,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right: right right right right right right right right right right right: right right right right right right right right right right right right right right right: right right right right right: right right right right right: right right right right right: right right right right right right right right: right right right right right right right right right right: right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right: right right right right right right right right right: right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: ClinicalTr Row 2: ils.gov",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Zimmer, 2014 Row 2: 12 European Row 3: sites",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NR Row 2: Row 3: Phase 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 1: 2 (8) Row 2: 2: 12 (50) Row 3: ≥ 3: 10 (42)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Histological or Row 2: cytological evidence of Row 3: NSCLC with KRASm; Row 4: ECOG PS ≤ 1; life Row 5: Expectancy ≥ 12 Row 6: weeks; measurable Row 7: disease per RECIST Row 8: v1.1; ≤ 3 Prior LOTs for Row 9: NSCLC",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: History of retinal vein Row 2: occlusion, glaucoma, Row 3: central serous Row 4: retinopathy, corneal Row 5: erosion, or risk Row 6: factors for these Row 7: ocular disorders",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NR, phase 1 expansion Row 2: study assessed safety, PD, Row 3: and antitumour activity",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02031458 Row 2: BIRCH Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Atezolizumab Row 2: 667",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Cohort 1: none Row 2: Cohort 2: 1 Row 3: Cohort 3: ≥ 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Histologically or Row 2: cytologically confirmed Row 3: IIIB or IV or currently Row 4: NSCLC; Tumour PD-L1 Row 5: expression; ECOG PS 0 Row 6: or 1; Measurable",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: CNS metastases, Row 2: history of Row 3: pneumonitis, Row 4: autoimmune Row 5: diseases, or chronic Row 6: viral diseases; Prior Row 7: treatment with",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 148,
        "end_page": 148,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The Commission shall also see R right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right: right right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: disease per RECIST Row 2: v1.1.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: CD137 agonists or Row 2: ICIs",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Atezolizumab Row 2: 204",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 27 Dec Row 2: 2013 to 9 Row 3: May Row 4: 2016",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Atezolizumab Row 2: and cobimetinib Row 3: 28",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: ECOG PS 0 or 1; Row 2: Measurable Disease Row 3: per RECIST v1.1.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: safety and Row 2: tolerability Row 3: Secondary: best overall Row 4: response; DoR, PFS, OS",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Pujol, 2020 Row 2: Unclear",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT02779751 Row 2: Row 3: Phase 1b",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Abemaclib and Row 2: pembrolizumab Row 3: 50",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Cohort A: CHT-naïve Row 2: Cohort B: 68% 1 prior Row 3: line of CHT",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Cohort A CHT-naïve Row 2: with ≥ 1% TC PD-L1 Row 3: sustaining, KRASm non-Row 4: squamous NSCLC Row 5: Cohort B squamous Row 6: subtype; ≤ 1 prior Row 7: platinum-containing Row 8: CHT regimenn",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: number of Row 2: participants with SAEs Row 3: and non-SAEs Row 4: Secondary: ORR, DCR, Row 5: DoR, PFS, OS, PK",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: \"Eberhardt, Row 5: \"2017 Row 6: \"Unclear Row 7: \"Hellmann, 2019 \" International \"Hellmann, Row 8: \" 2019 Row 9: \" International Row 10: Pujol, 202 Unclear \"Pujol, 202 Row 11: \"Unclear",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 1)",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The right holder is right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 20 Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 149,
        "end_page": 149,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right left right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right: right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Gulley, 2017 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01772004 Row 2: JAVELIN Row 3: Phase 1b",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Enrollme Row 2: nt and Row 3: treatmen Row 4: t Row 5: initiation Row 6: : 10 Sept Row 7: 2013 to Row 8: 24 Jun Row 9: 2014",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary:occurrence of Row 2: DLT during the first Row 3: 3 weeks of treatment Row 4: Secondary: BOR, DoR, Row 5: PFS, OS, safety and Row 6: activity according to PD-Row 7: L1 expression on TC and Row 8: IC",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Rizvi, 2014 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Nivolumab Row 2: 129",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: ≥ 3 prior therapies: Row 2: 54%",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Reuss, 2020 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Enrollme Row 2: nt: Jul Row 3: 2017 to Row 4: March Row 5: 2018",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Nivolumab and Row 2: ipilimumab Row 3: 9",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Rectable stage Row 2: IB - IIIA treatment- Row 3: naïve, histologically Row 4: confirmed NSCLC; Row 5: ECOG PS 0 • 1ALK",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: safety and Row 2: feasibility with a planned Row 3: enrollment of 15 patients Row 4: Pathologic response was Row 5: a key secondary endpoint",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: Gulley, 201 USA...\"Gulley, 201 Row 4: \"USA Row 5: Rizvi, 201 USA...\"Rizvi, 201 Row 6: \"USA Row 7: Reuss, 202 USA...\" \"Reuss, 202 Row 8: \"USA.\"",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 1)",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, St Name, Pha Study-NCT ID, St Row 2: •Name, Pha Row 3: •Student Row 4: NCT0177200 JAVELIN Phase 1b •NCT0177200 Row 5: •JAVELIN Row 6: •Phase 1b Row 7: •NR Row 8: •NR Row 9: •Phase NR Row 10: NCT0225962 Phase 1b / •NCT0225962 Row 11: • Row 12: •Phase 1b/2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 17 Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 14 Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 20 Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: tudy Row 2: ase of Row 3:y",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rowwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:04 Row 2: Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 3)",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •Key Primary and Secondary Endpoints/Objects Row 2: •Primary:occurrence of DLT during the first 3 weeks of treatment Secondary: BOR, DoR, PFS, OS, safety and activity according to PD-L1 expression on TC and IC Row 3: •NR Row 4: un",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 4)",
        "start_page": 150,
        "end_page": 150,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "RightRightRightRightRight rightRight right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right:: right: right: right right right:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 151,
        "end_page": 151,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 151,
        "end_page": 151,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 151,
        "end_page": 151,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 151,
        "end_page": 151,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 151,
        "end_page": 151,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Crombet, 2020 Row 2: Unclear",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 151,
        "end_page": 151,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01124864 Row 2: NR Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 151,
        "end_page": 151,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Conduct Row 2: ed: Oct Row 3: 2010 to Row 4: Nov 2014",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 151,
        "end_page": 151,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: AUY922 Row 2: 153",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 151,
        "end_page": 151,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Histologically or Row 2: cytologically Row 3: confirmed, advanced Row 4: NSCLC; ≥ 2 Lots, Row 5: except for less Row 6: preceded EGFR Row 7: cohort (EGFR < 2).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 151,
        "end_page": 151,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "1 (2.9) : •KRASwt 1 (2.9) : RowkAwwwwwwwwwwwwwwwwwwwwwt 1 (2.9) : Row 11 (2.9) : Row 11: •KRASm 6 (2.4) •KRASm 6 (2.4) •KRASm 6 (2.4) •KRASm 6 (2.4) •KRASm 6 (2.21.) •Row 8: •All 64 (41.8) •Row 9: •!Other: •Row 10: •KRASwt 1 (2.) •KRASwt 1 (2.9) •KRASm 11: •KRASm 6 (2.4) •KRASm 6 (21.4) •) •Row 8: •All 64 (41.8)) •Row 5:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Study Row 2: Name, Phase of Row 3: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Exclusive Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary and Row 2: Secondary Row 3: Endpoints/Objects",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Drilon, 2019 Row 2: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT 01833143 Row 2: Row 3: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 11 Apr to Row 2: 28 Aug Row 3: 2019a",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Bortezomib Row 2: 16",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Uncontrolled Row 2: metastatic disease Row 3: involved the CNS; at Row 4: least grade 2 Row 5: peripheral Row 6: neuropathy; Row 7: hypersensitivity to Row 8: boron or mannitol",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: response rate Row 2: Secondary: PFS, OS, and Row 3: toxicity",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Malhotra, Row 2: 2018 Row 3: USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT01649947, Row 2: NCT00728845 Row 3: Row 4: Phase 1b",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation>",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Country...Author Row 2: \"Country Row 3: \" Row 4: \"Drilon, 201 USA \"Drilon, 201 Row 5: \"USA Row 6: Malhotra, 2018 USA \"Malhotra, Row 7: \"2018 Row 8: \"USA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 1)",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "RowRowRow Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho NCT ID, Show Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho Ho",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation> (from previous page, column 2)",
        "start_page": 152,
        "end_page": 152,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "RowRowwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation:>",
        "start_page": 153,
        "end_page": 153,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Outcome reported by KRASm mutation status Row 2: Clinical evidence Row 3: • Overall survival Row 4: • Progression-free survival Row 5: • Advertise events Row 6: HRQoL evidence Row 7: Note, search strings were limited by outcomes Row 8: and do not include HRQoL terms.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Local adaptation:>",
        "start_page": 153,
        "end_page": 153,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Publication type--All publication types, except editorials and/or Row 2: reviews, but including systematic reviews*... Row 3: ... Row 4:... Country...Not restricted... Row 5: Other criteria...Other criteria...Sucient patient population (size) and... Row 6: reporting (baseline characteristics) to allow for Row 7: ...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Right of rightRight right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right, right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right:::::::::::::::: right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Author Row 2: Country",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT ID, Row 2: Study Row 3: Name, Row 4: Phase of Row 5: Study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Date Row 2: s",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Prior Row 2: Therapy Row 3: Row 4: LOT Median Row 5: (Range), Row 6: Number or n Row 7: (%)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Inclusion Row 2: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Row 2: Exclusion Row 3: Criteria",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Key Primary Row 2: and Secondary Row 3: Endpoints/Obj Row 4: ectives",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Skoulidis Row 2: ,2021",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT03600 Row 2: 883 Row 3: CodeBrea Row 4: k 100 Row 5: Phase 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Data- Row 2: cutof Row 3: f date Row 4: 15, Row 5: Marc Row 6: h Row 7: 2021.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Anti-PD-Row 2: (L)1: 91.3% Row 3: Platinum-Row 4: based CHT Row 5: and anti-PD-Row 6: (L)1: 81.0%",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Primary: Row 2: safety, Row 3: including the Row 4: incidence of a Row 5: DLT Row 6: secondary: PK, Row 7: ORR, DoR, DCR, Row 8: PFS, duration Row 9: of SD",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation>",
        "start_page": 154,
        "end_page": 154,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •\n\n\"Row right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Platinum-Row 2: based Row 3: combination Row 4: therapy, Row 5: targeted Row 6: therapies, or Row 7: both",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Janne, Row 2: 2017",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT019339 Row 2: 32, Row 3: SELECT-1, Row 4: Internatio Row 5: nal study",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: cond Row 2:ucted Row 3: betw Row 4: one Row 5: Octo Row 6: ber Row 7: 2013 Row 8: and Row 9: Janua Row 10: ry Row 11: 2016",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 75 mg of Row 2: selumetin Row 3: ib Row 4: (hydroge Row 5: n Row 6: sulphate) Row 7: twice Row 8: daily + 75 Row 9: mg/m2 of Row 10: docetaxel Row 11: intraveno Row 12: usly on Row 13: day 1 of Row 14: every 21- Row 15: day cycle Row 16: (n=254) Row 17: Row 18: Matched Row 19: placebo Row 20: plus Row 21: docetaxel Row 22: (same Row 23: schedule) Row 24: (n=256)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 1) Patients 18 Row 2: years or Row 3: older, with Row 4: histologically Row 5: or Row 6: cytologically Row 7: confirmed Row 8: locally Row 9: advanced or Row 10: metastatic Row 11: NSCLC (stage Row 12: IIIB•IV). Row 13: 2) Patients Row 14: had failure of Row 15: 1 previous Row 16: line of Row 17: therapy for Row 18: advanced Row 19: disease, a Row 20: centrally Row 21: confirmed Row 22: KRAS-mutant Row 23: tumor Row 24: 3) With WHO Row 25: performance Row 26: status of 0 or Row 27: 1",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 1°: PFS Row 2: 2°: OS, ORR, Row 3: DOR, TTP, Row 4: safety and Row 5: tolerability,",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1, Row 2: Yes 2· Yes Row 3: • 2",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page, column 1)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Anne, Row 3: 2017 Row 4:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page, column 2)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: • NCT01 32, SELEC Intern nal stu • NCT01 Row 3: • 32, Row 4: • SELEC Row 5: • Intern Row 6: •nal stu",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page, column 3)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: \" Row 2: 19339 \"con uct bet one Oct ber 201 and Jan ry 201 \"con Row 3: \"uct Row 4: CT-1, \"bet Row 5: \"een Row 6: udy\" Oct Row 7: \"ber Row 8: \"201 \" Row 9: \"and Row 10: \"Jan Row 11: \"ry Row 12: \"201\"",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page, column 4)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •\n\nRow right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page, column 5)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: FS Row 3: OS, ORR, Row 4: , TTP, Row 5: Ty and Row 6: Rability,",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading < Conclusion of the global SLRs and the local adaptation> (from previous page, column 6)",
        "start_page": 155,
        "end_page": 155,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trial name: CodeBreak 100°NCT number: NCT03600883",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Unpublished data> (from previous page)",
        "start_page": 157,
        "end_page": 157,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:00°NCT number: NCT0360088",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Unpublished data> (from previous page, column 3)",
        "start_page": 157,
        "end_page": 157,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trial name: CodeBreak 100°NCT number: NCT03600883",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Unpublished data> (from previous page)",
        "start_page": 158,
        "end_page": 158,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:00°NCT number: NCT03600883",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Unpublished data> (from previous page, column 4)",
        "start_page": 158,
        "end_page": 158,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trial name: CodeBreak 100°NCT number: NCT03600883",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 40: SELECT-1 • Study Characteristics",
        "start_page": 159,
        "end_page": 159,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trial name: SELECT-1°NCT number: NCT01933932",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 40: SELECT-1 • Study Characteristics",
        "start_page": 159,
        "end_page": 159,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trial name: SELECT-1°NCT number: NCT01933932",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Main exclusion:>",
        "start_page": 160,
        "end_page": 160,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT number: NCT01933932",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Main exclusion:> (column 5)",
        "start_page": 160,
        "end_page": 160,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trial name: SELECT-1°NCT number: NCT01933932",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Exploratory Outcome variables:>",
        "start_page": 161,
        "end_page": 161,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT number: NCT019339",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Exploratory Outcome variables:> (column 2)",
        "start_page": 161,
        "end_page": 161,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trial name: SELECT-1°NCT number: NCT01933932",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Exploratory Outcome Variables:> (from previous page)",
        "start_page": 162,
        "end_page": 162,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: NCT number: NCT01933932",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Exploratory Outcome variables:> (from previous page, column 6)",
        "start_page": 162,
        "end_page": 162,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Trial name: SELECT-1°NCT number: NCT01933932",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Other relevant information None>",
        "start_page": 163,
        "end_page": 163,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Inclusion Criteria: Sotorasib • Docetaxel Row 2: • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Other relevant information None>",
        "start_page": 163,
        "end_page": 163,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rowwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Definition, validity, and clinical relevance of included outcome measures>",
        "start_page": 164,
        "end_page": 164,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:Outcome measure...Definition...Validity...Clinical relevance.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Definition, validity, and clinical relevance of included outcome measures>",
        "start_page": 164,
        "end_page": 164,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Baseline characteristics (CodeBreak 100) N = 126 Row 2: Age (mean) 62.9 Row 3: Gender (% female) •50% Row 4: Brain metastases (%) •21% Row 5: ECOG (% PS 1 [vs PS 0]) •70% Row 6: Race (% white) •82%c Row 7: % KRAS-G12C•100% Row 8: Anti-PD-(L) 1 in prior line(s) •91% Row 9: Number of prior lines (% with 1/2/3 prior lines) •43%/35%/22% Row 10: Metastatic disease stage at baseline (% IIIB [vs IV]) •97% Row 11: Histology (% Non-squamous) •99% Row 12: Smoking status (% ever smoker) •93%e Row 13: Otte Row 13: Other targetable mutation (vs IV]) •97% Row 11: Histology (% Non-squamous) •99% Row 12: Smoking status (% ever Smoking status (% ever Smoking) •93% Row 13: ORRow 13: ORRow 13: Other Targetable ROW====RowROW===R=R======R=============G%%%%%%%%%%%%%%%%%%%%%%%%%%%%%",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Definition, validity, and clinical relevance of included outcome measures> (column 1)",
        "start_page": 164,
        "end_page": 164,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Outcome meansDefinition:Validity:Clinical relevan",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Definition, validity, and clinical relevance of included outcome measures> (column 1)",
        "start_page": 164,
        "end_page": 164,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:Outcome measure...Definition...Validity...Clinical relevance.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Definition, validity, and clinical relevance of included outcome measures> (from previous page)",
        "start_page": 165,
        "end_page": 165,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Defining Validity",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Definition, validity, and clinical relevance of included outcome measures> (from previous page, column 4)",
        "start_page": 165,
        "end_page": 165,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Clinical survival",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Definition, validity, and clinical relevance of included outcome measures> (from previous page, column 5)",
        "start_page": 165,
        "end_page": 165,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:Outcome measure...Definition...Validity...Clinical relevance.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Results per study>",
        "start_page": 166,
        "end_page": 166,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Outcome meansDefinition:Validity:Clinical relevan",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Results per study> (column 1)",
        "start_page": 166,
        "end_page": 166,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX... Row 2:... X Row 3:... Row 4:... X... Row 5:.. X... Row 6:.. X... X... Row 7:.. X.. X Row 8:.. X.. X Row 9:.. X.. X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X>",
        "start_page": 167,
        "end_page": 167,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX-- Row 2:-- Row 3:-- Row 4:--X Row 5:--X Row 6:--X Row 7:--X Row 8:--X Row 9:--X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X> (column 1)",
        "start_page": 167,
        "end_page": 167,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X> (column 2)",
        "start_page": 167,
        "end_page": 167,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: • Row 3: • Row 4: • Row 5: • Row 6: • Row 7: • Row 7: • Row 5: • Row 5: • Row 6: • Row 7: • Row 7: • Row 7: • Row 5: • Row 5: • Row 5: • Row 5: • Row 2: • Row 2: • Row 3: • Row 3: • Row 4: • Row 5: • Row 5: • Row 6: • Row 7: • Row 7: • Row 7: • Row 2: • Row 2: • Row 3: • Row 4: • Row 4: • Row 5: • Row 5: • Row 5: • Row 6: • Row 7: • Row 7: • Row 2: • Row 3: • Row 3: • Row 3: • Row 3: • Row 4: • Row 4:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X> (column 6)",
        "start_page": 167,
        "end_page": 167,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X Row 2: Row 3: X Row 4: X Row 5: X Row 6: X Row 7: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X> (column 7)",
        "start_page": 167,
        "end_page": 167,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • X Row 2: X • X Row 3: X • X Row 4: X • X Row 5: X • X Row 6: • Row 7: X • X Row 8: X • Row 9: X • X Row 10: X • X Row 11: X • X Row 12: X • X Row 13: X • X Row 14: X • X Row 15: X • X Row 16: X • X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X> (from previous page)",
        "start_page": 168,
        "end_page": 168,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: X Row 3: X Row 4: X Row 5: X Row 6: Row 7: X Row 8: X Row 9: X Row 10: X Row 11: X Row 12: X Row 13: X Row 14: X Row 15: X Row 16: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X> (from previous page, column 1)",
        "start_page": 168,
        "end_page": 168,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X> (from previous page, column 2)",
        "start_page": 168,
        "end_page": 168,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • Row 2: • Row 3: • Row 4: • Row 5: • Row 6: • Row 7: • Row 8: • Row 9: • Row 10: • Row 11: • Row 12: • Row 13: • Row 14: • Row 15: •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X> (from previous page, column 7)",
        "start_page": 168,
        "end_page": 168,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X Row 2: X Row 3: X Row 4: X Row 5: X Row 6: Row 7: X Row 8: X Row 9: X Row 10: X Row 11: X Row 12: X Row 13: X Row 14: X Row 15: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X> (from previous page, column 9)",
        "start_page": 168,
        "end_page": 168,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Treatment related adverse events... Sotorasib (CodeBreak-100)*...Docetaxel + placebo (SELECT-1)**...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 166/237> (from previous page)",
        "start_page": 175,
        "end_page": 175,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Treatment related adverse eve Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 166/237> (from previous page, column 1)",
        "start_page": 175,
        "end_page": 175,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: enter Sotora Row 2: • Row 3: •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 166/237> (from previous page, column 2)",
        "start_page": 175,
        "end_page": 175,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: asib (C Row 2: n",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 166/237> (from previous page, column 3)",
        "start_page": 175,
        "end_page": 175,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: CodeBreak-100)* Row 2: n=126",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 166/237> (from previous page, column 4)",
        "start_page": 175,
        "end_page": 175,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row one, Row two, Row two, Row one, Row two, Row one, Row two, Row two, Row two, Row two, Row two, Row two, Row two, Row two, Row two, Row two, Row number two, Row number two, Row two, Row number two, Row two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two, Row number two,",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 166/237> (from previous page, column 5)",
        "start_page": 175,
        "end_page": 175,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Docetaxel + pl Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 166/237> (from previous page, column 6)",
        "start_page": 175,
        "end_page": 175,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: placebo Row 2: n=254",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 166/237> (from previous page, column 7)",
        "start_page": 175,
        "end_page": 175,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: o (SELECT-1) Row 2: 4",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 166/237> (from previous page, column 8)",
        "start_page": 175,
        "end_page": 175,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: )** Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 166/237> (from previous page, column 9)",
        "start_page": 175,
        "end_page": 175,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Serious adverse event...Sotorasib (CodeBreak-100)*...Docetaxel + placebo (SELECT-1)**... Row 2: ...n=126 (%)...n=254 (%)... Row 3:...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 46 Serious adverse events",
        "start_page": 176,
        "end_page": 176,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Seriously adverse event...Sotorasib (CodeBreak-100)*...Docetax Row 2: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 46 Serious adverse events",
        "start_page": 176,
        "end_page": 176,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 46 Serious adverse events",
        "start_page": 176,
        "end_page": 176,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Row 1: xel + placebo (SELECT-1)** Row 2: n=254 (%)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 46 Serious adverse events",
        "start_page": 176,
        "end_page": 176,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rowwayway 1, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 7, 5, 6, 6, 6, 6, 6, 8, 8, 7, 6, 6, 8, 8, 7, 6, 6, 6, 8, 6, 8, 8, 8, 8, 7, 6, 8, 8, 7, 6, 8, 8, 7, 6, 8, 6, 6, 8, 6, 6, 8, 8, 7, 6, 6, 6, 8, 8, 8, 8, 6, 6, 6, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 6, 6, 6, 6, 6, 6, 6, 6, 32 (25, (25, (25, 25, 25, 25, (31, 7, 7, 7, 8, 8, 6, 8, 6, 8, 6, 6, 8, 1, 1, 1, 8, 8, 7, (, 1, 1, 1, 1, 1, 1, 1, 1, (, 7, 7, 17, 7, 7, 7, 7, (, 17, 17, (, 7, 7, 7, 17, 7, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (, 7), (,2), (,2), (,2), (,2), (,2), (, 7), (,2), (,2), (,2), (,2), (,2), (,2), (,2), (,2), (,2), (,2), (,2), (,2), (,2), (,2), (,2), (,2), (,2)), (,2)), (,2), (,2), (,2)), (,2)), (,2),",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page)",
        "start_page": 177,
        "end_page": 177,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Treatment related a Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 1)",
        "start_page": 177,
        "end_page": 177,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Advert Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 2)",
        "start_page": 177,
        "end_page": 177,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: see Eve Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 3)",
        "start_page": 177,
        "end_page": 177,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Ents Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 4)",
        "start_page": 177,
        "end_page": 177,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Sotorasib (C Row 2: n=",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 5)",
        "start_page": 177,
        "end_page": 177,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: CodeBreak-100)* Row 2: =126 (%)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 6)",
        "start_page": 177,
        "end_page": 177,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 7)",
        "start_page": 177,
        "end_page": 177,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Docetaxel + p Row 2: n=",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 8)",
        "start_page": 177,
        "end_page": 177,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: placebo Row 2:=254 (%",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 9)",
        "start_page": 177,
        "end_page": 177,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: o (SELECT-1) Row 2: %)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 10)",
        "start_page": 177,
        "end_page": 177,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: )** Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 11)",
        "start_page": 177,
        "end_page": 177,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Rash •8 (6.3) •0 (0) •28 (11.0) •1 (0.4) Row 2: Headache •11 (8.7) •0 (0) •26 (10.2) •NA Row 3: Myalga •8 (6.3) •0 (0) •37 (14.6) •NA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page)",
        "start_page": 178,
        "end_page": 178,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Rash...8 (6.3)...0 (0) Row 2: Headache...11 (8.7)...0 (0) Row 3: Myalgager...8 (6.3)...0 (0)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 1)",
        "start_page": 178,
        "end_page": 178,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 1 (0.4) Row 2: NA Row 3: NA",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Table 46 Serious adverse events> (from previous page, column 2)",
        "start_page": 178,
        "end_page": 178,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX° Row 2: X° X° X° X° X° Row 3: X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X *generated using muhaz package for ITT population (N =126)>",
        "start_page": 182,
        "end_page": 182,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1, NA-NA-Naïve no adverse events & SELECT-1 45%) Comparison ((61%- 45%)) /45%) Row 12: Discontinuation CodeBreak 100 -5.8% (8.7%-NA 40% NA-NA-NA-Naïve noadverse events & SELECT-1 45%)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X *generated using muhaz package for ITT population (N =126)>",
        "start_page": 182,
        "end_page": 182,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "X-X-S-X-S-X-S-X-S-X-S-X-S-X-S-X-X-S-X-S-X-S-X-S-X-S-X-S-X-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 178/237>",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 178/237>",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 178/237>",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 178/237>",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 178/237>",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 178/237>",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X· X* X* X* X* Row 2: · X* X*",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 178/237> (column 1)",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X· X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 178/237> (column 1)",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X... X... X.. X.. X.. X... X... X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X.. X. X.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 178/237> (column 1)",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • X • X • X • X • X • X Row 2: X • X • X X • X • Row 3: X • X • X • X • X • Row 4: X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 178/237> (column 1)",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X· X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X* X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 178/237> (column 1)",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Page 178/237> (column 2)",
        "start_page": 184,
        "end_page": 184,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court CourtXXXXXXXXXX Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court CourtX Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court CourtX Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XX>",
        "start_page": 185,
        "end_page": 185,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XX> (column 1)",
        "start_page": 185,
        "end_page": 185,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XX> (column 5)",
        "start_page": 185,
        "end_page": 185,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X°X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XX> (column 10)",
        "start_page": 185,
        "end_page": 185,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court CourtX Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court CourtXXXXXX Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court CourtX Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court CourtX Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court Court",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XX>",
        "start_page": 186,
        "end_page": 186,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XX> (column 1)",
        "start_page": 186,
        "end_page": 186,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XX> (column 5)",
        "start_page": 186,
        "end_page": 186,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X°X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XX> (column 10)",
        "start_page": 186,
        "end_page": 186,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X~X·X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~X ~",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Side 181/237>",
        "start_page": 187,
        "end_page": 187,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X • X • X • X Row 2: X • X • X Row 3: X • X • X Row 4: X • X • X • X Row 5: X • X X • X Row 6: X • X • X • X Row 7: X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Side 181/237> (column 5)",
        "start_page": 187,
        "end_page": 187,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Study characteristics·Sotorasib (CodeBreak 100) (87)·Placebo plus docetaxel (SELECT-1) (72) Row 2: Blinding·Open label·Double-blinded Row 3: Inclusion criteria·Male or female patients (> 18 years) Histologically confirmed locally advanced or metastatic NSCLC KRAS p.G12C mutation identified through molecular testing ECOG Performance Status 0",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <12.1.1.2 Compatibility of data sources>",
        "start_page": 188,
        "end_page": 188,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the first time that the disease has been diagnosed in the last 12 months, and the first time that the disease has been diagnosed in the last 12 months, the first time that the disease has been diagnosed in the last 12 months, the first time that the disease has been diagnosed in the last 12 months, the first time that the disease has been diagnosed in the last 12 months, the first time that the disease has been diagnosed in the last 12 months, the first time that the disease has been diagnosed in the last 12 months, the second time that the disease has been diagnosed in the last 12 months, the second time that the disease has been diagnosed in the last 12 months, the second time that the disease has been diagnosed in the last 12 months, the second time that the disease has been diagnosed in the last 12 months, the second time that the disease has been diagnosed in the last 12 months, the second time that the disease has been diagnosed in the last 12 months, the second time that the disease has been diagnosed in the last 12 months; the second time that the disease has been diagnosed in the last 12 months; the first time that the disease has been diagnosed in the last year; the first time that the first time that the first time that the first time that it has been diagnosed in the first time that the disease has been diagnosed in the first time that the disease has been diagnosed in the disease has been diagnosed in the disease has been diagnosed in the disease has been treated in the disease has been treated in the disease has been treated in the first time that it has been treated in the disease has been treated in the last two months; the last three months; the first time; the first time that the first time that the first time that the last three months; the first time that it has been assessed in the last three months; the first time that it has been assessed in the last three months; the last year; the last year; the first time that the last year; the last year; the last year; the first time that the last year; the last year; the last year; the first time that the first time that the first time; the last year; the last year; the last year; the previous year; the last year; the first time that the disease has been assessed the period has been tested has been assessed has been assessed has been assessed has been assessed has been assessed has been assessed has been assessed has been assessed has been assessed has been assessed has been assessed has been assessed has",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <The two studies reported PFS and OS as primary or secondary endpoints. PFS was assessed by investigators in>",
        "start_page": 189,
        "end_page": 189,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Baseline characteristics a· Sotorasib (CodeBreak 100) n=126(87) ·Placebo plus docetaxel (SELECT-1) (n=256) (130) Row 2: Age·62.9 (mean) ^69.9 (mean)",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <The two studies reported PFS and OS as primary or secondary endpoints. PFS was assessed by investigators in>",
        "start_page": 189,
        "end_page": 189,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "This is the case in the case of non-squamous fish, which can be found in Table 1 of the Annex to Implementing Regulation (EU) No 540/2011.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <12.1.1.3 Conclusion on the feasibility of undertaking indirect comparisons>",
        "start_page": 190,
        "end_page": 190,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X • Row 2: X • X • X • X • X • Row 3: X • X • X • X • X • Row 4: X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXXXXXX>",
        "start_page": 192,
        "end_page": 192,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: • As reported For docetaxel N = 256 • Pre-matching For sotorasib N = 98 • Post-matching For sotorasib N = 98 Row 2: Covariates • SELECT-1 • CodeBreaK 100 • CodeBreaK 100 Row 3: ECOG (% PS 1 [vs PS 0]) • x • Row 4: Age (mean) • x • x • Row 5: Metastatic at baseline (%) • x • x • x • Row 6: Smoking status (% ever smoker) • x • x • Row 7: PD-L1 expression level (<5% vs. ≥ 5%) • x • x • x Row 8: Gender (% female) • x • x •x Row 9: History (% Non-squamous) •x ~x ~x",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Figure 13 Distribution of statistical weights of MAIC for SET 2>",
        "start_page": 193,
        "end_page": 193,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: As reported For docetaxel N = 256 Row 2: CovariatesSELECT-1 Row 3: ECOG (% PS 1 [vs PS 0]) •x Row 4: Age (mean) •x Row 5: Metastatic at baseline (%) •x Row 6: Smoking status (% ever smoker) •x Row 7: PD-L1 expression level (<5% vs ≥5%) •x Row 8: Gender (% female) •x Row 9: Histology (% Non-squamous) •x",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Figure 13 Distribution of statistical weights of MAIC for SET 2> (column 1)",
        "start_page": 193,
        "end_page": 193,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Race (% white) ...95...81...95...",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <12.1.3.1.1 Overall survival>",
        "start_page": 194,
        "end_page": 194,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row1.14.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <12.1.3.1.1 Overall survival>",
        "start_page": 194,
        "end_page": 194,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row14.247.61.61.61.61.61.61.61.51.61.61.51.51.61.51.51.61.51.61.51.51.61.51.61.51.61.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.61.51.51.61.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.61.51.51.51.51.51.61.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51.51..BIC.BIC..IIC.I.I.BIC.BIC.BIC.BIC.BIC.BIC.BIC.I.BIC.BIC.IIC.IIC.BIC.IIC.BIC.BIC.BIC.BIC.BIC.BIC.BIC.BIC.BIC.BIC.BIC.BIC.BIC.BIC.BIC.BIC.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <12.1.3.1.2 Progression-free survival>",
        "start_page": 197,
        "end_page": 197,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "21,2 7,2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2Rwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <12.2 Flatiron property weighting score analysis>",
        "start_page": 201,
        "end_page": 201,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Covenier than 75 75 (Y/N))Justification Row 2: Baseline ECOG (0 or 1) Yes ECOG was considered as the most important baseline characteristics for the forecast of NSCLC patients; Row 3: Presence of brain metastas (Y; N) Yes Brain metastas was considered the second most important economic factor Metastatic at baseline (Y; N) No In both populations, the proportion of patients not metastatic at baseline were low; there was no need to adjust on metasis at baseline (Y; N) No In both populations, the proportion of patients not metastatic at baseline were low; there was no need to adjust on metasis at baseline (Y; N) There was no need to adjust on metasis at baseline (Y; N) No In both populations, the proportion of patients not metastatic at baseline was not measured balanced balanced PD-L1 protein expression at low; there was no need to adjust on metastas at baseline. In addition to the above, the Commission considers that the Commission's assessment of the impact of the aid on competition and trade between Member States is not sufficient to assess whether the aid is compatible with the internal market.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 61. Output of Clinical Expert Award for Covariates Related to Forecasts",
        "start_page": 204,
        "end_page": 204,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX° ° Row 2: ° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° Row 11: X° X° X° X° X° X° Row 12: X° X° X° X° X° Row 13: X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° Row 12: X° X° X° X° X° X° X° X° X° X° X° X° X° X° Row 12: X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X°",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXX>",
        "start_page": 205,
        "end_page": 205,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX • Row 2: X • X Row 3: • X • Row 4: • X • X • Row 5: X • X • X • Row 6: X • X • X • Row 7: X • X • X • Row 8: X • Row 9: X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X • X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XXXX>",
        "start_page": 205,
        "end_page": 205,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "X-X-X-S-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X>",
        "start_page": 206,
        "end_page": 206,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X° Row 2: X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X°",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X>",
        "start_page": 207,
        "end_page": 207,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: XX°-Row 2: X°-X-X-Row 3: X°-X-°-X-Row 4: X°-X-°-X-°-Row 5: X°-X-°-X-°-Row 6: X°-X-°-X-°-X-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°-°",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X>",
        "start_page": 207,
        "end_page": 207,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X>",
        "start_page": 208,
        "end_page": 208,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X° X° X° X° Row 2: X° Row 3: X° X° X° X° X° Row 4: X° X° X° X° X° Row 5: X° X° X° X° Row 6: X° X° X° X° X° Row 7: X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X° X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XX>",
        "start_page": 209,
        "end_page": 209,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X°X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XX> (column 1)",
        "start_page": 209,
        "end_page": 209,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X-X-Row 2: X-X-Row 3: X-X-Row 4: X-X-X-Row 2: X-X-Row 3: X-X-Row 4: X-X-Row 2: X-X-Row 2: X-X-Row 3: X-X-Row 4: X-X-Row 2: X-X-Row 3: X-X-Row 4: X-X-Row: X-X-Row 2: X-X-Row 2: X-X-Row 3: X-X-Row 3: X-X-Row 4: X-X-Row 4: X-X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <XX> (column 1)",
        "start_page": 209,
        "end_page": 209,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row2 right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right, right right right right right right right right right right right right right right right right right right right right, right right right right right right right right right right right right right right right right right right right right right right, right right right right right right right right right right right right right right right right, right right right right right right right right right right right right, right right right right right right right right right right right, right right right right, right right right, right right right, right right, right right right right, right, right, right right right right, right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right rightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightrightright",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Missing values>",
        "start_page": 215,
        "end_page": 215,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: d Row 19: e Row 20: Row 21:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <Missing values> (column 2)",
        "start_page": 215,
        "end_page": 215,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •Control • Sotorasib Row 2: KRAS mutant • Row 3: Unadjusted • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <G12C and KRAS mutation. The results for KRAS G12C and KRAS mutantly respectively are presented for Model>",
        "start_page": 219,
        "end_page": 219,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <G12C and KRAS mutation. The results for KRAS G12C and KRAS mutantly respectively are presented for Model> (column 2)",
        "start_page": 219,
        "end_page": 219,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Baseline characteristics:Before Adjustment:After ATT Adjustment Row 2:",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <ECOG: 1 74.27% 70.59% 70.46%>",
        "start_page": 224,
        "end_page": 224,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 23.30%•23.53%•22.28%\" Row 3: Prior PD-(L)1 immunotherapy: Yes·73.30%•90.76%•90.64%\" Row 4: Prior platinum-based chemotherapy: Yes·84.47%•89.39%\" Row 5: Albumin (g/L)37.26.00•38.00\" Row 6: Key: AST, aspartate transaminase; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group, eGFR, estimated lomerular filtration rate; PD-1, program with cell death protein 1; PD-L1, program with death-ligand 1 Note: Valuescorrespond to sample meaning for continuous variables (albumin) and proportions for categorical",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <ECOG: 1 74.27% 70.59% 70.46%> (from previous page)",
        "start_page": 225,
        "end_page": 225,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "22.6% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% Rows1 and 22.0% ***.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <ECOG: 1 74.27% 70.59% 70.46%> (from previous page)",
        "start_page": 225,
        "end_page": 225,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 24.40.29% Row 2: 3·23.30% Row 3: Prior PD-(L)1 immunotherapy: Yes ~73.30% Row 4: Prior platinum-based chemotherapy: Yes ~84.47% Row 5: Albumin (g/L) ~37.26",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <ECOG: 1 74.27% 70.59% 70.46%> (from previous page, column 1)",
        "start_page": 225,
        "end_page": 225,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Baseline characteristics Row 2: •Control Row 3: ECOG: 1 •70.59% Row 4: Brain metastasis: Yes •30.59% Row 5: Metastatic: Yes •90.59% Row 6: Presence of EGFR/ALK/BRAF/ROS-1 mutation •8.24%",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <ECOG: 1 74.27% 70.59% 70.46%> (from previous page, column 1)",
        "start_page": 225,
        "end_page": 225,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 18 to 64 years 41.18% Row 2: 65 to 74 years 35.29% Row 3: ≥ 75 years 23.53% Row 4: BMI (kg/m2) 26.25",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <ECOG: 1 74.27% 70.59% 70.46%> (from previous page, column 1)",
        "start_page": 225,
        "end_page": 225,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: 1°34.12% Row 2: 2°40.00% Row 3: 3°25.88% Row 4: Liver metastasis: Yes·14.12% Row 5: Prior PD-(L)1 immunotherapy: Yes·65.88% Row 6: Prior Platinum-based chemotherapy: Yes·87.06% Row 7: Albumin (g/L) 37.57",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <ECOG: 1 74.27% 70.59% 70.46%> (from previous page, column 1)",
        "start_page": 225,
        "end_page": 225,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "21,2 7,2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2R2Rwaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywaywayway",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <(N = 85) (N = 133.11)>",
        "start_page": 226,
        "end_page": 226,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Regimen· Unweighted copyright Row 2: \"n· % of copyright\"",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <(N = 85) (N = 133.11)> (column 1)",
        "start_page": 226,
        "end_page": 226,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •(N = 206) • Row 2: Platinum-based chemotherapy • 64 • 31.07% • 27.78 Row 3: Chemotherapy monotherapy (excludes the clerks) • 61 • 29.61% • 32.48 Row 4: Docetaxel plus ramucirumab • 45 • 21.84% • 41.24 Row 5: Docetaxel monotherapy • 21 • 10.19% • 12.16 Row 6: Other chemotherapy-based regimenns • 15 • 7.28% • 6.91 Row 7: •",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <(N = 85) (N = 133.11)> (column 1)",
        "start_page": 226,
        "end_page": 226,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: •(N = 85) • Row 2: Platinum-based chemotherapy • 25 • 29.41% • 23.83 Row 3: Chemotherapy monotherapy (excludes the clerks) • 24 • 28.24% • 30.42 Row 4: Docetaxel plus ramucirumab • 18.18% • 64.17 Row 5: Docetaxel monotherapy • 11.94% • 8.56 Row 6: Other chemotherapy-based regimenns • 7 • 8.24% • 6.13",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <(N = 85) (N = 133.11)> (column 1)",
        "start_page": 226,
        "end_page": 226,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X Row 2: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <12.3.2.3 Overall survival>",
        "start_page": 227,
        "end_page": 227,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X° Row 2: X° X° Row 3: X° X° X° Row 4: X° X° X° Row 5: X° X° X° Row 6: X° X° X°",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <12.3.2.3 Overall survival>",
        "start_page": 227,
        "end_page": 227,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "See also Article 4 of Regulation (EU) No 182/2011 of the European Parliament and of the Council of 16 February 2011 laying down the rules and general principles concerning mechanisms for control by Member States of the Commission's exercise of implementing powers (OJ L 55, 28.2.2011, p. 13).",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X>",
        "start_page": 228,
        "end_page": 228,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X Row 2: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X>",
        "start_page": 228,
        "end_page": 228,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X Row 2: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X>",
        "start_page": 228,
        "end_page": 228,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Model/Unrestricted Row 2: ...AIC...BIC...AIC...BIC...BIC...AIC...BIC...BIC...BIC...BIC...AIC Row 3: Exponential...479.1...481.9...605.1....6081.4....1084.2 Row 4: Gompertz...481.0...486.5...612.4...181.8....1085.5 Row 5: Weibull....778.5.....................48.6...................................................................1................................................................................................................................................................................................................................................................................................",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X> (column 1)",
        "start_page": 228,
        "end_page": 228,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Rows 1 and 2 have been issued by the competent authority of the Member State in which the person concerned is established.",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <12.3.2.4 Progression-free survival>",
        "start_page": 230,
        "end_page": 230,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: Distribution:Independent fit • sotorasib • Independent fit - chemo • Joint fit (unrestricted) • Row 2: • AIC • AIC • AIC • AIC • AIC • AIC Row 3: Exponential • 564.5 • 567.3 • 604.8 • 1166.0 • 11166.0 • 11166.0 Row 4: Gompertz • 562.8 • 568.4 • 603.0 • 1169.7 • 1180.9 1167.7 • 667.7 • 607 • 1154.4 • 1177.11152.3 Row 7: Loglogistic • 558.8 • 564.4 • 564.5 • 568.7 • 565.7 • 595.7 • 597.7 • 607 • 1177 • 1152.3 Row 7: Loglogistic • 558.8 • 564.4 • 595.4 • 555.7 • 555.7 • 81.5 • 57.55 • 71.55 • 7",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <12.3.2.4 Progression-free survival> (column 1)",
        "start_page": 230,
        "end_page": 230,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X Row 2: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X>",
        "start_page": 231,
        "end_page": 231,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "Row 1: X Row 2: X",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "table under heading <X>",
        "start_page": 231,
        "end_page": 231,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "21,2p2Right rightwaywaywaywayway right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right 5: \"Numberber' right right right right right right right right 5: \"Number' right right right right right right right right right right right right right right right 5: \"Number' right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right right:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "metadata": {
        "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
        "heading": "Table 69. EQ-5D-5L Collection rates by assessment time points",
        "start_page": 243,
        "end_page": 243,
        "created_date": "unknown_year",
        "country": "DK",
        "original_file_path": "nsclc_kras_g12c 2/HTA submissions/DK/bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx_cleaned.json",
        "split_index": 0
      }
    }
  ]
}